0001628280-23-041717 | POS AM | XBRL Viewer

Print Document View Excel Document

Investments - Held to Maturity Securities Cost (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023
Equity Method Investments and Joint Ventures [Abstract]
Amortized cost, net of accrued interest		$ 49,611	$ 49,103
Accrued interest		93	30
Total		49,704	49,133
Aggregate Fair Value	$ 44,763	49,593	49,098
Gross unrealized gains	8	5	1
Gross unrealized losses	$ (36)	$ (23)	$ (6)

Fair Value

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Mar. 31, 2023

Jun. 30, 2023

Sep. 30, 2023

Dec. 31, 2022

Fair Value Disclosures [Abstract]

Fair Value

Fair Value (Restated)

The following table presents the Company’s fair value hierarchy for its assets and liabilities measured at fair value as of March 31, 2023 and December 31, 2022 (in thousands):


	Fair Value Measurement as of
	March 31, 2023
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	31,397	$	—	$	—	$	31,397
Total assets	$	31,397	$	—	$	—	$	31,397

Liabilities:
FPA Put Option liability	$	—	$	—	$	44,593	$	44,593
Fixed Maturity Consideration	—		—		6,967		6,967
Shortfall Warrants	—		—		5,104		5,104
Brookfield SAFE liability	—		—		19,400		19,400
Private placement warrants	—		—		2,626		2,626
Public warrants	2,189		—		—		2,189
Total liabilities	$	2,189	$	—	$	78,690	$	80,879


	Fair Value Measurement as of
	December 31, 2022
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	523	$	—	$	—	$	523

Liabilities:
Warrants on preferred shares	—		—		2,119		2,119
Brookfield SAFE liability	—		—		50,000		50,000
AM SAFE warrant	—		—		1,989		1,989
AM SAFE liability	—		—		28,986		28,986
Total Liabilities	$	—	$	—	$	83,094	$	83,094

Forward Purchase Agreement

The fair value upon issuance of the FPA (both the FPA Put Option liability and Fixed Maturity Consideration) and the change in fair value from issuance to March 31, 2023, is included in other expense, net in the condensed consolidated statements of operations and comprehensive loss. The fair value of the FPA was estimated using a Monte-Carlo Simulation in a risk-neutral framework. Specifically, the future stock price is simulated assuming a Geometric Brownian Motion (“GBM”). For each simulated path, the forward purchase value is calculated based on the contractual terms and then discounted back to present. Finally, the value of the forward is calculated as the average present value over all simulated paths. The Fixed Maturity Consideration was also valued as part of this model as the timing of the payment of the Fixed Maturity Consideration may be accelerated if the Maturity Date is accelerated.

The following table represents the weighted average inputs used in calculating the fair value of the prepaid forward contract and the Fixed Maturity Consideration as of March 31, 2023:


	March 31, 2023
Stock price	$	3.88
Term (in years)	2.86
Expected volatility	55.0		%
Risk-free interest rate	3.81		%
Expected dividend yield	—		%

Warrants on preferred shares

The fair value of the warrants on preferred shares was estimated using a Black-Scholes option pricing model. Since the warrants were exercised on February 8, 2023 (see Note 8 - Warrants, for a description of the valuation on that date), the following table represents the weighted average inputs used in calculating the fair value of the preferred share warrants outstanding as of December 31, 2022:


	December 31, 2022
Stock price	$	5.21
Weighted average exercise price	$	3.96
Term (in years)	1.1
Expected volatility	73.4		%
Risk-free interest rate	4.47		%
Expected dividend yield	—		%

Shortfall Warrants


	March 31, 2023
Stock price	$	3.88
Weighted average exercise price	$	10.00
Term (in years)	5.0
Expected volatility	68.0		%
Risk-free interest rate	3.59		%
Expected dividend yield	—		%

SAFE Liabilities and AM SAFE Warrant

The change in fair value between reporting periods for the Brookfield SAFE liability is included in other expense, net in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2023. The change in fair value between December 31, 2022 and the Closing Date for the AM SAFE liability is included in other expense, net in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2023. See Note 7 - AM SAFE for more details. See Note 8 - Warrants for further details on the AM SAFE warrant.

approach which allowed the Company to estimate the implied value of the business based on the terms of the SAFE. Significant unobservable inputs included probability and expected term. Probability was based upon the likelihood of the Company closing a transaction with a special purpose acquisition company. The expected term was based on the anticipated time until the SAFE investments would have a conversion event.

At conversion, the AM SAFE liability was valued as described in Note 7 - AM SAFE. Significant inputs for Level 3 AM SAFE liability fair value measurement at December 31, 2022 are as follows:


	Near Term		Long-Term
Key assumptions:
Probability weighting	61	%	39	%
Time to conversion (in years)	0.1		0.8
Liquidity price	100	%	90	%
Discount rate	24.7	%	24.7	%

At conversion to equity classification on February 8, 2023, the AM SAFE warrant was valued using a Black-Scholes option pricing model as the warrant became exercisable for a fixed number of shares at a fixed price as described in Note 8 - Warrants. The following table represents the weighted average inputs used in calculating the fair value of the preferred share warrants outstanding at conversion to equity on February 8, 2023:


	February 8, 2023
Stock price	$	9.91
Term (in years)	5.00
Expected volatility	70.0		%
Risk-free interest rate	3.82		%
Expected dividend yield	—		%

Significant inputs for Level 3 AM SAFE warrant fair value measurement at December 31, 2022 are as follows:


	Near Term		Long-Term
Key assumptions:
Probability weighting	61	%	39	%
Remaining life (in years)	5.0		5.0
Volatility	75	%	75	%
Interest rate	3.99	%	3.99	%
Time to conversion (in years)	0.1		0.8
Risk-free interest rate	4.12	%	4.75	%
Dividend yield	—	%	—	%

Significant inputs for Level 3 Brookfield SAFE liability fair value measurement at December 31, 2022 are the timing and likelihood of project financings under the Brookfield Framework Agreement. The Brookfield SAFE is legal form debt that the Company has elected to measure using the FVO under ASC 825. As of March 31, 2023, no part of the Brookfield SAFE has converted to Company common shares as a qualifying financing had not yet occurred and no project investments were presented. There were no cash flows associated with the Brookfield SAFE in the three months ended March 31, 2023.

sufficient projects meeting the agreed-upon investment criteria pursuant to the Brookfield Framework Agreement are maintained. As such the Brookfield SAFE’s fair value is estimated to be $50,000, as of December 31, 2022.

As of March 31, 2023, the Company expects to present sufficient projects to Brookfield to result in the Brookfield SAFE being automatically converted into shares. Since the liquidity price is not expected to change during the life of the Brookfield SAFE, the number of shares that Brookfield receives is fixed. Based on this expectation, the value of the Brookfield SAFE is equal to the Brookfield SAFE's as-converted value, which is the initial purchase amount, divided by the liquidity price, times the stock price, resulting in an estimated fair value of $19,400 recorded on the condensed consolidated balance sheet.

Significant inputs for Level 3 Brookfield SAFE measurement at March 31, 2023 are as follows:


	March 31, 2023
Initial purchase amount	$	50,000
Liquidity price	10.00
Stock price	3.88

Public Warrants and Private Placement Warrants

For the Public Warrants, the Company uses inputs such as actual trade data, quoted market prices from dealers or brokers, and other similar sources to determine the fair value and recognized a decrease in the fair value of the liability of approximately $286 on the condensed consolidated statements of operations and comprehensive loss within other expense, net representing the change in fair value from the Closing Date to March 31, 2023.

The fair value of the Private Placement Warrants was estimated using a Black-Scholes option pricing model. For the three months ended March 31, 2023, the Company recognized an increase in the fair value of liabilities of approximately $477 on the condensed consolidated statements of operations and comprehensive loss within other expense, net representing the change in fair value from the Closing Date to March 31, 2023.

The following table represents the weighted average inputs used in calculating the fair value of the Private Placement Warrants outstanding as of March 31, 2023 and at the time of the Business Combination:


	March 31, 2023			February 8, 2023
Stock price	$	3.88		$	9.91
Exercise price	$	11.50		$	11.50
Term (in years)	4.86			5.00
Expected volatility	45.0		%	2.0		%
Risk-free interest rate	3.60		%	3.82		%
Expected dividend yield	—		%	—		%

The following tables represent reconciliations of the fair value measurements of the assets and liabilities using significant unobservable inputs (Level 3) (in thousands):


	FPA Put Option liability		Fixed Maturity Consideration		Shortfall Warrants		Warrants on Preferred Shares		AM SAFE liability		AM SAFE warrant		Brookfield SAFE		Private placement warrants
Balance as of January 1, 2023	$	—	$	—	$	—	$	(2,119)	$	(28,986)	$	(1,989)	$	(50,000)	$	—
Recognized as a result of the Business Combination	—		—		—		—		—		—		—		(2,148)
(Loss) gain recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss	(44,593)		(6,967)		(5,104)		(3,770)		(744)		189		30,600		(477)
Conversion of warrants to preferred shares	—		—		—		5,889		—		—		—		—
Conversion of SAFE liability	—		—		—		—		29,730		—		—		—
Conversion of AM SAFE warrant to equity classification	—		—		—		—		—		1,800		—		—

Balance as of March 31, 2023	$	(44,593)	$	(6,967)	$	(5,104)	$	—	$	—	$	—	$	(19,400)	$	(2,626)


	Warrants on Preferred Shares		AM SAFE liability		AM SAFE warrant


Balance as of January 1, 2022	$	(1,145)	$	(28,271)	$	(1,729)
Gain (loss) recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss	41		148		(129)
Balance as of March 31, 2022	$	(1,104)	$	(28,123)	$	(1,858)

Fair Value (Restated)

The following table presents the Company’s fair value hierarchy for its assets and liabilities measured at fair value as of June 30, 2023 and December 31, 2022 (in thousands):


	Fair Value Measurement as of
	June 30, 2023
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	31,665	$	—	$	—	$	31,665
Total assets	$	31,665	$	—	$	—	$	31,665

Liabilities:
FPA Put Option liability	$	—	$	—	$	26,743	$	26,743
Fixed Maturity Consideration	—		—		6,737		6,737
Brookfield SAFE liability	—		—		34,150		34,150
Private placement warrants	—		—		5,347		5,347
Public warrants	3,075		—		—		3,075
Total liabilities	$	3,075	$	—	$	72,977	$	76,052


	Fair Value Measurement as of
	December 31, 2022
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	523	$	—	$	—	$	523

Liabilities:
Warrants on preferred shares	—		—		2,119		2,119
Brookfield SAFE liability	—		—		50,000		50,000
AM SAFE warrant	—		—		1,989		1,989
AM SAFE liability	—		—		28,986		28,986
Total Liabilities	$	—	$	—	$	83,094	$	83,094

Forward Purchase Agreement

The fair value upon issuance of the FPA (both the FPA Put Option liability and Fixed Maturity Consideration) and the change in fair value from issuance to June 30, 2023, is included in other expense, net in the condensed consolidated statements of operations and comprehensive loss. The fair value of the FPA was estimated using a Monte-Carlo Simulation in a risk-neutral framework. Specifically, the future stock price is simulated assuming a Geometric Brownian Motion (“GBM”). For each simulated path, the forward purchase value is calculated based on the contractual terms and then discounted back to present. Finally, the value of the forward is calculated as the average present value over all simulated paths. The Fixed Maturity Consideration was also valued as part of this model as the timing of the payment of the Fixed Maturity Consideration may be accelerated if the Maturity Date is accelerated.

The following table represents the weighted average inputs used in calculating the fair value of the prepaid forward contract and the Fixed Maturity Consideration as of June 30, 2023:


	June 30, 2023
Stock price	$	6.83
Term (in years)	2.61
Expected volatility	50.0		%
Risk-free interest rate	4.59		%
Expected dividend yield	—		%

Warrants on preferred shares

The fair value of the warrants on preferred shares was estimated using a Black-Scholes option pricing model. Since the warrants were exercised on February 8, 2023 (see Note 7 - Warrants, for a description of the valuation on that date), the following table represents the weighted average inputs used in calculating the fair value of the preferred share warrants outstanding as of December 31, 2022:


	December 31, 2022
Stock price	$	5.21
Weighted average exercise price	$	3.96
Term (in years)	1.1
Expected volatility	73.4		%
Risk-free interest rate	4.47		%
Expected dividend yield	—		%

Shortfall Warrants

The fair value of the Shortfall Warrants was estimated using a Black-Scholes option pricing model. The following table represents the weighted average inputs used in calculating the fair value of the Shortfall Warrants as of May 13, 2023 when the Shortfall Warrant Agreement was amended and the Shortfall Warrants were marked-to-market and reclassified to additional paid-in capital on the condensed consolidated balance sheet:


	May 13, 2023
Stock price	$	3.42
Weighted average exercise price	$	10.00
Term (in years)	4.87
Expected volatility	54.0		%
Risk-free interest rate	3.46		%
Expected dividend yield	—		%

SAFE Liabilities and AM SAFE Warrant

The change in fair value between reporting periods for the Brookfield SAFE liability is included in other expense, net in the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2023. The change in fair value between December 31, 2022 and the Closing Date for the AM SAFE liability is included in other expense, net in the condensed consolidated statements of operations and comprehensive loss for the six months ended June 30, 2023. See below for further details on the AM SAFE liability and see Note 7 - Warrants for further details on the AM SAFE warrant.

The Company’s AM SAFE liability (until conversion to shares on the Closing Date), AM SAFE warrant (until conversion to an equity classified warrant on the Closing Date) and Brookfield SAFE liability are mark-to-market liabilities and are classified within Level 3 of the fair value hierarchy as the Company is using a scenario-based approach which allowed the Company to estimate the implied value of the business based on the terms of the SAFE. Significant unobservable inputs included probability and expected term. Probability was based upon the likelihood of the Company closing a transaction with a special purpose acquisition company. The expected term was based on the anticipated time until the SAFE investments would have a conversion event.

At conversion on the Closing Date, the AM SAFE liability converted into 3,000,000 shares of common stock. As of the Closing Date, the AM SAFE had a fair value of $29,730, which equals the closing price of approximately $9.91 on the Closing Date, multiplied by the number of shares issued. The AM SAFE was adjusted to its fair value on the Closing Date prior to settlement.

As of December 31, 2022, the AM SAFE had a fair value of $28,986 and was recorded within current liabilities on the condensed consolidated balance sheet. Significant inputs for Level 3 AM SAFE liability fair value measurement at December 31, 2022 are as follows:


	Near Term		Long-Term
Key assumptions:
Probability weighting	61	%	39	%
Time to conversion (in years)	0.1		0.8
Liquidity price	100	%	90	%
Discount rate	24.7	%	24.7	%

described in Note 7 - Warrants. The following table represents the weighted average inputs used in calculating the fair value of the preferred share warrants outstanding at conversion to equity on February 8, 2023:


	February 8, 2023
Stock price	$	9.91
Term (in years)	5.00
Expected volatility	70.0		%
Risk-free interest rate	3.82		%
Expected dividend yield	—		%

Significant inputs for Level 3 AM SAFE warrant fair value measurement at December 31, 2022 are as follows:


	Near Term		Long-Term
Key assumptions:
Probability weighting	61	%	39	%
Remaining life (in years)	5.0		5.0
Volatility	75	%	75	%
Interest rate	3.99	%	3.99	%
Time to conversion (in years)	0.1		0.8
Risk-free interest rate	4.12	%	4.75	%
Dividend yield	—	%	—	%

Significant inputs for Level 3 Brookfield SAFE liability fair value measurement at December 31, 2022 are the timing and likelihood of project financings under the Brookfield Framework Agreement. The Brookfield SAFE is legal form debt that the Company has elected to measure using the FVO under ASC 825. As of June 30, 2023, no part of the Brookfield SAFE has converted to Company common shares as a qualifying financing had not yet occurred and no project investments were presented. There were no cash flows associated with the Brookfield SAFE in the six months ended June 30, 2023.

As of its issuance date, the fair value of the Brookfield SAFE is equal to the investment amount of $50,000 based on the orderly nature of the transaction. The value as of December 31, 2022 remains the same due to the proximity of the valuation date to the issuance date (i.e., less than two months) and the absence of events which would indicate a change in expected payoffs to the investor. As of December 31, 2022 the same expectations about sufficient projects meeting the agreed-upon investment criteria pursuant to the Brookfield Framework Agreement are maintained. As such the Brookfield SAFE’s fair value is estimated to be $50,000, as of December 31, 2022.

As of June 30, 2023, the Company expects to present sufficient projects to Brookfield to result in the Brookfield SAFE being automatically converted into shares. Since the liquidity price is not expected to change during the life of the Brookfield SAFE, the number of shares that Brookfield receives is fixed. Based on this expectation, the value of the Brookfield SAFE is equal to the Brookfield SAFE's as-converted value, which is the initial purchase amount, divided by the liquidity price, times the stock price, resulting in an estimated fair value of $34,150 recorded on the condensed consolidated balance sheet.

Significant inputs for Level 3 Brookfield SAFE measurement at June 30, 2023 are as follows:


	June 30, 2023
Initial purchase amount	$	50,000
Liquidity price	$	10.00
Stock price	$	6.83

Public Warrants and Private Placement Warrants

For the Public Warrants, the Company uses inputs such as actual trade data, quoted market prices from dealers or brokers, and other similar sources to determine the fair value and recognized an increase in the fair value of the liability of approximately $600 on the condensed consolidated statements of operations and comprehensive loss within other expense, net representing the change in fair value from the Closing Date to June 30, 2023.

The fair value of the Private Placement Warrants was estimated using a Black-Scholes option pricing model. For the six months ended June 30, 2023, the Company recognized an increase in the fair value of liabilities of approximately $3,199 on the condensed consolidated statements of operations and comprehensive loss within other expense, net representing the change in fair value from the Closing Date to June 30, 2023.

The following table represents the weighted average inputs used in calculating the fair value of the Private Placement Warrants outstanding as of June 30, 2023 and at the time of the Business Combination:


	June 30, 2023
Stock price	$	6.83
Exercise price	$	11.50
Term (in years)	4.61
Expected volatility	32.5		%
Risk-free interest rate	4.13		%
Expected dividend yield	—		%

The following tables represent reconciliations of the fair value measurements of the assets and liabilities using significant unobservable inputs (Level 3) (in thousands):


	FPA Put Option liability		Fixed Maturity Consideration		Shortfall Warrants		Warrants on Preferred Shares		AM SAFE liability		AM SAFE warrant		Brookfield SAFE		Private placement warrants
Balance as of January 1, 2023	$	—	$	—	$	—	$	(2,119)	$	(28,986)	$	(1,989)	$	(50,000)	$	—
Recognized as a result of the Business Combination	—		—		—		—		—		—		—		(2,148)
(Loss) gain recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss	(26,743)		(6,737)		(3,063)		(3,770)		(744)		189		15,850		(3,199)
Conversion of warrants to preferred shares	—		—		—		5,889		—		—		—		—
Conversion of SAFE liability	—		—		—		—		29,730		—		—		—
Conversion of warrant to equity classification	—		—		3,063		—		—		1,800		—		—

Balance as of June 30, 2023	$	(26,743)	$	(6,737)	$	—	$	—	$	—	$	—	$	(34,150)	$	(5,347)


	Warrants on Preferred Shares		AM SAFE liability		AM SAFE warrant


Balance as of January 1, 2022	$	(1,145)	$	(28,271)	$	(1,729)
Gain (loss) recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss	(78)		1,062		(218)
Balance as of June 30, 2022	$	(1,223)	$	(27,209)	$	(1,947)

Fair Value

The following table presents the Company’s fair value hierarchy for its assets and liabilities measured at fair value as of September 30, 2023 and December 31, 2022 (in thousands):


	Fair Value Measurement as of
	September 30, 2023
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	37,370	$	—	$	—	$	37,370
Total assets	$	37,370	$	—	$	—	$	37,370

Liabilities:
FPA Put Option liability	$	—	$	—	$	38,092	$	38,092
Fixed Maturity Consideration	—		—		7,020		7,020
Brookfield SAFE liability	—		—		23,350		23,350
Private placement warrants	—		—		5,060		5,060
Public warrants	4,575		—		—		4,575
Total liabilities	$	4,575	$	—	$	73,522	$	78,097


	Fair Value Measurement as of
	December 31, 2022
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	523	$	—	$	—	$	523

Liabilities:
Warrants on preferred shares	—		—		2,119		2,119
Brookfield SAFE liability	—		—		50,000		50,000
AM SAFE warrant	—		—		1,989		1,989
AM SAFE liability	—		—		28,986		28,986
Total Liabilities	$	—	$	—	$	83,094	$	83,094

Forward Purchase Agreement

The fair value upon issuance of the FPA (both the FPA Put Option liability and Fixed Maturity Consideration) and the change in fair value from issuance to September 30, 2023 net of the Prepayment Amount, is included in other expense, net in the condensed consolidated statements of operations and comprehensive loss. The fair value of the FPA was estimated using a Monte-Carlo Simulation in a risk-neutral framework. Specifically, the future stock price is simulated assuming a Geometric Brownian Motion (“GBM”). For each simulated path, the forward purchase value is calculated based on the contractual terms and then discounted back to present. Finally, the value of the forward is calculated as the average present value over all simulated paths. The Fixed Maturity Consideration was also valued as part of this model as the timing of the payment of the Fixed Maturity Consideration may be accelerated if the Maturity Date is accelerated.

The following table represents the weighted average inputs used in calculating the fair value of the prepaid forward contract and the Fixed Maturity Consideration as of September 30, 2023:


	September 30, 2023
Stock price	$	4.67
Term (in years)	2.36
Expected volatility	50.0		%
Risk-free interest rate	4.89		%
Expected dividend yield	—		%

Warrants on preferred shares


	December 31, 2022
Stock price	$	5.21
Weighted average exercise price	$	3.96
Term (in years)	1.1
Expected volatility	73.4		%
Risk-free interest rate	4.47		%
Expected dividend yield	—		%

Shortfall Warrants


	May 13, 2023
Stock price	$	3.42
Weighted average exercise price	$	10.00
Term (in years)	4.87
Expected volatility	54.0		%
Risk-free interest rate	3.46		%
Expected dividend yield	—		%

SAFE Liabilities and AM SAFE Warrant

The change in fair value between reporting periods for the Brookfield SAFE liability is included in other expense, net in the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2023. The change in fair value between December 31, 2022 and the Closing Date for the AM SAFE liability is included in other expense, net in the condensed consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2023. See below for further details on the AM SAFE liability and see Note 7 - Warrants for further details on the AM SAFE warrant.


	Near Term		Long-Term
Key assumptions:
Probability weighting	61	%	39	%
Time to conversion (in years)	0.1		0.8
Liquidity price	100	%	90	%
Discount rate	24.7	%	24.7	%


	February 8, 2023
Stock price	$	9.91
Term (in years)	5.00
Expected volatility	70.0		%
Risk-free interest rate	3.82		%
Expected dividend yield	—		%

Significant inputs for Level 3 AM SAFE warrant fair value measurement at December 31, 2022 are as follows (in thousands):


	Near Term		Long-Term
Key assumptions:
Probability weighting	61	%	39	%
Remaining life (in years)	5.0		5.0
Volatility	75	%	75	%
Interest rate	3.99	%	3.99	%
Time to conversion (in years)	0.1		0.8
Risk-free interest rate	4.12	%	4.75	%
Dividend yield	—	%	—	%

Significant inputs for Level 3 Brookfield SAFE liability fair value measurement at December 31, 2022 are the timing and likelihood of project financings under the Brookfield Framework Agreement. The Brookfield SAFE is legal form debt that the Company has elected to measure using the FVO under ASC 825. As of September 30, 2023, no part of the Brookfield SAFE has converted to Company common shares as a qualifying financing had not yet occurred and no project investments were presented. There were no cash flows associated with the Brookfield SAFE in the nine months ended September 30, 2023.

As of September 30, 2023, the Company expects to present sufficient projects to Brookfield to result in the Brookfield SAFE being automatically converted into shares. Since the liquidity price is not expected to change during the life of the Brookfield SAFE, the number of shares that Brookfield receives is fixed. Based on this expectation, the value of the Brookfield SAFE is equal to the Brookfield SAFE's as-converted value, which is the initial purchase amount, divided by the liquidity price, times the stock price, resulting in an estimated fair value of $23,350 recorded on the condensed consolidated balance sheet.

Significant inputs for Level 3 Brookfield SAFE measurement at September 30, 2023 are as follows:


	September 30, 2023
Initial purchase amount	$	50,000
Liquidity price	$	10.00
Stock price	$	4.67

Public Warrants and Private Placement Warrants

For the Public Warrants, the Company uses inputs such as actual trade data, quoted market prices from dealers or brokers, and other similar sources to determine the fair value and recognized an increase in the fair value of the liability of approximately $2,100 on the condensed consolidated statements of operations and comprehensive loss within other expense, net representing the change in fair value from the Closing Date to September 30, 2023.

The fair value of the Private Placement Warrants was estimated using a Black-Scholes option pricing model. For the nine months ended September 30, 2023, the Company recognized an increase in the fair value of liabilities of approximately $2,912 on the condensed consolidated statements of operations and comprehensive loss within other expense, net representing the change in fair value from the Closing Date to September 30, 2023.

The following table represents the weighted average inputs used in calculating the fair value of the Private Placement Warrants outstanding as of September 30, 2023 and at the time of the Business Combination:


	September 30, 2023
Stock price	$	4.67
Exercise price	$	11.50
Term (in years)	4.36
Expected volatility	52.5		%
Risk-free interest rate	4.66		%
Expected dividend yield	—		%

The following tables represent reconciliations of the fair value measurements of the assets and liabilities using significant unobservable inputs (Level 3) (in thousands):


	Fixed Maturity Consideration		Shortfall Warrants		Warrants on Preferred Shares		AM SAFE liability		AM SAFE warrant		Brookfield SAFE		Private placement warrants
Balance as of January 1, 2023	$	—	$	—	$	(2,119)	$	(28,986)	$	(1,989)	$	(50,000)	$	—
Recognized as a result of the Business Combination	—		—		—		—		—		—		(2,148)

(Loss) gain recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss	(7,020)		(3,063)		(3,770)		(744)		189		26,650		(2,912)
Conversion of warrants to preferred shares	—		—		5,889		—		—		—		—
Conversion of SAFE liability to equity classification	—		—		—		29,730		—		—		—
Conversion of warrant to equity classification	—		3,063		—		—		1,800		—		—

Balance as of September 30, 2023	$	(7,020)	$	—	$	—	$	—	$	—	$	(23,350)	$	(5,060)


	Warrants on Preferred Shares		AM SAFE liability		AM SAFE warrant


Balance as of January 1, 2022	$	(1,145)	$	(28,271)	$	(1,729)
Gain (loss) recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss	(427)		1,050		(293)
Balance as of September 30, 2022	$	(1,572)	$	(27,221)	$	(2,022)

Fair Value

The following table presents the Company’s fair value hierarchy for its assets and liabilities measured at fair value as of December 31, 2022 and December 31, 2021 (in thousands):


	Fair Value Measurement as of
	December 31, 2022
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	523	$	—	$	—	$	523

Liabilities:
Warrants on preferred shares	$	—	$	—	$	2,119	$	2,119
Brookfield SAFE liability	—		—		50,000		50,000
AM SAFE warrant	—		—		1,989		1,989
AM SAFE liability	—		—		28,986		28,986
Total liabilities	$	—	$	—	$	83,094	$	83,094


	Fair Value Measurement as of
	December 31, 2021
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	516	$	—	$	—	$	516

Liabilities:
Warrants	—		—		1,145		$	1,145
AM SAFE warrant	—		—		1,729		1,729
AM SAFE liability	—		—		28,271		28,271
Total Liabilities	$	—	$	—	$	31,145	$	31,145

Warrants

The Company has warrants to purchase preferred shares outstanding as of December 31, 2022 and December 31, 2021 representing 985,278 preferred shares, for each period respectively, which warrants expire at various dates through December 31, 2027. The exercise prices of the warrants range from $3.36 to $4.56 as of each of December 31, 2022 and December 31, 2021.

The warrants are accounted for as liabilities in accordance with ASC 480, and are presented within other accrued liabilities on the consolidated balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within the consolidated statements of operations and comprehensive loss.

The fair value of the warrants was calculated using the Black-Scholes Option Pricing Model. For the years ended December 31, 2022 and 2021, the Company recognized a change in the fair value of liabilities of approximately $(974) and $(563), respectively, on the consolidated statements of operations and comprehensive loss within other expense, net.

The estimated fair value of the warrants is determined using Level 3 inputs. Inherent in the Black-Scholes Option Pricing Model are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its warrants based on implied volatility from the Company’s warrants and from historical volatility of select peer companies that match the expected remaining life of

the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.

The following table represents the weighted average inputs used in calculating the fair value of the preferred share warrants outstanding as of December 31, 2022 and December 31, 2021:


	December 31, 2022			December 31, 2021
Stock price	$	5.21		$	3.15
Weighted average exercise price	3.96			3.96
Term (in years)	1.1			2.8
Expected volatility	73.4		%	70.6		%
Risk-free interest rate	4.5		%	0.8		%
Expected dividend yield	—		%	—		%

SAFE Liabilities and AM SAFE Warrant

The change in fair value between reporting periods for both the SAFE liabilities and SAFE warrant is included in other expense, net in the consolidated statements of operations and comprehensive loss.

The Company’s AM SAFE liability, Brookfield SAFE liability and AM SAFE warrant are mark-to-market liabilities and are classified within Level 3 of the fair value hierarchy as the Company is using a scenario-based approach which allowed the Company to estimate the implied value of the business based on the terms of the SAFE. Significant unobservable inputs included probability and expected term. Probability is based upon the likelihood of the Company closing a transaction with a special purpose acquisition company. The expected term was based on the anticipated time until the SAFE investments would have a conversion event.

Significant inputs for Level 3 AM SAFE liability fair value measurement at December 31, 2022 are as follows:


	Near Term		Long-Term
Key assumptions:
Probability weighting	61	%	39	%
Time to conversion (in years)	0.1		0.8
Liquidity price	100	%	90	%
Discount rate	24.7	%	24.7	%

Significant inputs for Level 3 SAFE warrant fair value measurement at December 31, 2022 are as follows:


	Near Term		Long-Term
Key assumptions:
Probability weighting	61	%	39	%
Remaining life (in years)	5.0		5.0
Volatility	75	%	75	%
Interest rate	3.99	%	3.99	%
Time to conversion (in years)	0.1		0.8
Risk-free interest rate	4.12	%	4.75	%
Dividend yield	—	%	—	%

fair value of the Brookfield SAFE is equal to the investment amount of $50,000 based on the orderly nature of the transaction. The value as of December 31, 2022 remains the same due to the proximity of the valuation date to the issuance date (i.e., less than two months) and the absence of events which would indicate a change in expected payoffs to the investor. As of December 31, 2022 the same expectations about sufficient projects meeting the agreed-upon investment criteria pursuant to the Brookfield Framework Agreement are maintained. As such the Brookfield SAFE’s fair value is estimated to be $50,000, as of December 31, 2022.

The following tables represent reconciliations of the fair value measurements of the liabilities associated with our SAFE and warrant obligations using significant unobservable inputs (Level 3) (in thousands):


	Warrants		AM SAFE liability		AM SAFE warrant		Brookfield SAFE
Balance as of January 1, 2022	$	1,145	$	28,271	$	1,729	$	—
Issuance of Brookfield SAFE liability	—		—		—		50,000
Loss recognized in consolidated statement of operations and comprehensive loss	974		715		260		$	—
Balance as of December 31, 2022	$	2,119	$	28,986	$	1,989	$	50,000


	Warrants		AM SAFE liability		AM SAFE warrant		Brookfield SAFE


Balance as of January 1, 2021	$	582	$	—	$	—	$	—
Issuance of SAFE liability and warrant	—		28,271		1,729		—
Loss recognized in consolidated statement of operations and comprehensive loss	563		—		—		—
Balance as of December 31, 2021	$	1,145	$	28,271	$	1,729	$	—

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Investments - Summarized Financial Information (Details) - USD ($) $ in Thousands	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2023
Schedule of Equity Method Investments [Line Items]
Revenues	$ 19,605	$ 12,917	$ 9,646	$ 8,072	$ 9,852	$ 7,857	$ 22,563	$ 17,709	$ 42,168	$ 25,781	$ 37,343	$ 25,461
Net income (loss)	(25,326)	(26,786)	(63,312)	$ (22,267)	(15,929)	$ (16,778)	(90,098)	(32,707)	(115,424)	(54,974)	(76,356)	(46,689)
Net loss attributable to the Company		130			$ 3,095		(478)	$ 2,813	(941)	$ 2,346	(1,422)	(1,606)
Current assets	177,483	208,917	240,647				208,917		177,483		123,897	148,675	$ 123,897
Current liabilities	$ 33,743	$ 32,615	$ 34,077				$ 32,615		$ 33,743		55,981	49,290
Equity Method Investment, Nonconsolidated Investee or Group of Investees
Schedule of Equity Method Investments [Line Items]
Revenues											40,985	40,244
Gross profit											7,319	(5,703)
Net income (loss)											(6,221)	(9,695)
Current assets											72,711	56,204
Non-current assets											114,736	270,454
Current liabilities											15,534	64,499
Non-current liabilities											$ 114,934	$ 58,802

Investments - Narrative (Details) $ / shares in Units, ¥ in Thousands				2 Months Ended	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	May 13, 2020 USD ($)	Sep. 28, 2011 USD ($)	Sep. 28, 2011 CNY (¥)	Apr. 04, 2021 USD ($) investment_round shares	Sep. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2021 USD ($) $ / shares	Feb. 08, 2023 $ / shares	Nov. 09, 2022 $ / shares
Schedule of Equity Method Investments [Line Items]
Profit amortization period							15 years								15 years
Number of rounds of investments \| investment_round				2
Equity method investments cost											$ 288,000	$ 0	$ 288,000	$ 0
Transfer from Foreign Currency Translation to Equity Security Investment															$ 928,000
Impairment on equity method investments							$ 0				0		0		0	$ 0
Dividends from equity investments					$ 0		0	$ 0		$ 0	0	0	0	0	0	0
Revenues					19,605,000	$ 12,917,000	9,646,000	8,072,000	$ 9,852,000	7,857,000	22,563,000	17,709,000	42,168,000	25,781,000	$ 37,343,000	$ 25,461,000
Class of warrant or right, exercise price of warrants or rights (in dollars per share) \| $ / shares															$ 3.36	$ 4.56	$ 9.91	$ 0.01
Debt Securities, Held-to-Maturity, Allowance for Credit Loss					0								0
Debt Securities, Unrealized Gain (Loss)							0
Related Party
Schedule of Equity Method Investments [Line Items]
Revenues							973,000			654,000
Licensing
Schedule of Equity Method Investments [Line Items]
Revenues					1,515,000	815,000	553,000	540,000	540,000	540,000	1,369,000	1,080,000	2,902,000	1,620,000	$ 2,160,000	$ 2,025,000
Licensing \| Related Party
Schedule of Equity Method Investments [Line Items]
Revenues					$ 1,515,000	$ 815,000		540,000	540,000		$ 1,369,000	1,080,000	$ 2,902,000	1,620,000
LanzaJet
Schedule of Equity Method Investments [Line Items]
Contribution of intellectual property	$ 15,000,000
Ownership percentage	37.50%			25.00%	23.15%	23.15%					23.15%		23.15%
Revenue from Contract with Customer, Excluding Assessed Tax					$ 565,000	$ 565,000	553,000	540,000	540,000	540,000	$ 1,119,000		$ 1,701,000		2,160,000	2,025,000
Deferred revenue					6,047,000	6,719,000	7,390,000			8,062,000	$ 6,719,000		$ 6,047,000		8,062,000	10,746,000
Profit amortization period											15 years		15 years
Gain on dilution				$ 503,000
Contingent right to receive additional interest \| shares				45,000,000
Equity method investments cost				$ 0
Carrying value less than proportionate share of book value					$ 2,200,000	$ 2,100,000	3,800,000				$ 2,100,000		$ 2,200,000		3,700,000	3,100,000
Equity Method Investment, Realized Gain (Loss) on Disposal											$ 502,000		$ 502,000
Equity Method Investment, Ownership Percentage, Diluted					22.38%	22.38%					22.38%		22.38%
LanzaJet \| Intra-entity
Schedule of Equity Method Investments [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax					$ 107,000	$ 89,000	$ 118,000	$ 132,000	$ 132,000	$ 132,000	$ 206,000	$ 263,000	$ 313,000	$ 395,000	$ 527,000	$ 662,000
SGLT
Schedule of Equity Method Investments [Line Items]
Ownership percentage		30.00%	30.00%												9.31%	10.01%
Gain on dilution															$ 3,368,000	$ 3,048,000
Equity securities loss															$ 76,000
SGLT \| Intellectual Property
Schedule of Equity Method Investments [Line Items]
Contribution of intellectual property		$ 4,000,000	¥ 25,800

Redeemable, Convertible Preferred Stock - Changes (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($) shares
Increase (Decrease) in Temporary Equity [Roll Forward]
Beginning balance, Redeemable Convertible Preferred Stock (in shares) \| shares	112,558,444
Beginning balance, temporary equity \| $	$ 394,408
Issuance of Series F Preferred Stock, net of issuance cost (in shares) \| shares	15,898,496
Issuance of Series F Preferred Stock, net of issuance cost of $0 \| $	$ 83,073
Ending balance, Redeemable Convertible Preferred Stock (in shares) \| shares	129,148,393
Ending balance, temporary equity \| $	$ 480,631

- Definition

Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.E.Q2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

+ Details

Summary of Significant Accounting Policies - Segment Information (Details) - segment	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2023	Jun. 30, 2023	Sep. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Number of operating segments	1	1	1	1

Income Taxes - Components of (Loss) Income (Details) - USD ($) $ in Thousands	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Domestic											$ (73,271)	$ (39,860)
Foreign											(3,085)	(6,829)
Net income (loss)	$ (25,326)	$ (26,786)	$ (63,312)	$ (22,267)	$ (15,929)	$ (16,778)	$ (90,098)	$ (32,707)	$ (115,424)	$ (54,974)	$ (76,356)	$ (46,689)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Materials and supplies				$ 4,164	$ 2,900
Prepaid assets				2,833	1,503
Other				4,160	1,376
Other Assets, Current	$ 16,677	$ 18,952	$ 18,689	$ 11,157	$ 5,779

Leases - Lessor, Operating Lease, Payments to be Received (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Leases [Abstract]
2023	$ 34
2024	155
2025	155
2026	155
2027	155
Thereafter	1,240
Total	$ 1,894

Description of the Business (Details) $ / shares in Units, $ in Thousands	Mar. 08, 2022 USD ($)	Sep. 30, 2023 USD ($) plant	Jun. 30, 2023 USD ($) plant	Mar. 31, 2023 USD ($) plant	Dec. 31, 2022 USD ($)	Dec. 07, 2022 USD ($) $ / shares	Sep. 30, 2022 plant	Jun. 30, 2022 plant	Mar. 31, 2022 plant
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Purchase price	$ 1,800,000
Minimum closing cash condition	$ 250,000					$ 230,000
Sale of stock price (usd per share) \| $ / shares						$ 10.00
Commercial plants operated \| plant			3	3				2	2
Other accrued liabilities		$ (6,049)	$ (3,639)	$ (4,143)	$ (4,502)
Warrants		$ 9,636	$ 8,422	$ 9,919	4,108
CHINA
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Commercial plants operated \| plant		4					3
INDIA
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Commercial plants operated \| plant		1
Reclassification Of Warrants On Preferred Shares
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Other accrued liabilities					2,119
Warrants					$ 2,119

Summary of Significant Accounting Policies - Concentration of Credit Risk and Other Risks and Uncertainties (Details)	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Revenue Benchmark \| Geographic Concentration Risk \| Non-US
Concentration Risk [Line Items]
Concentration risk, percentage	75.00%	84.00%	62.00%	54.00%	65.00%		75.00%	64.00%	75.00%	61.00%	61.00%	38.00%
Revenue Benchmark \| Customer Concentration Risk \| Customer A
Concentration Risk [Line Items]
Concentration risk, percentage	36.00%	51.00%	30.00%	0.00%	10.00%	19.00%	42.00%	14.00%	39.00%	10.00%	22.00%	27.00%
Revenue Benchmark \| Customer Concentration Risk \| Customer B
Concentration Risk [Line Items]
Concentration risk, percentage	7.00%	5.00%	13.00%	27.00%	22.00%	22.00%	9.00%	22.00%	8.00%	24.00%	10.00%	15.00%
Revenue Benchmark \| Customer Concentration Risk \| Customer C
Concentration Risk [Line Items]
Concentration risk, percentage	0.00%		10.00%	21.00%		8.00%			0.00%	10.00%	7.00%	12.00%
Accounts Receivable \| Geographic Concentration Risk \| Non-US
Concentration Risk [Line Items]
Concentration risk, percentage			41.00%				50.00%		49.00%		35.00%	35.00%

Stock-Based Compensation

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Mar. 31, 2023

Jun. 30, 2023

Sep. 30, 2023

Dec. 31, 2022

Share-Based Payment Arrangement [Abstract]

Stock-Based Compensation

Share-Based Compensation

The Company offers equity incentive plans to employees, directors, and others providing similar employee-related services, which meet the definition of an equity-classified share-based payment.

Stock Options

The Company has five ownership-based participation rights plans for employees, directors, and certain third-party providers. In accordance with the provisions of the plans, as approved by the directors and shareholders, grantees have been granted options to purchase common shares at exercise prices based on the fair value price of the Company’s common shares on the date of grant as approved by the directors. The stock options generally have a service condition of two to five years and vest over time as the service condition is being satisfied. Upon termination of employment, unvested stock options are evaluated for forfeiture or modifications, subject to the terms of the awards and Company's policies. The below table reflects the pre-combination shares under option multiplied by the exchange ratio and the weighted average exercise price divided by the exchange ratio.

Stock option awards outstanding as of March 31, 2023 and changes during the period ended March 31, 2023 were as follows:


	Shares under option (thousands)	Weighted average exercise price		Weighted average remaining contractual term (years)	Aggregate intrinsic value (thousands)
Outstanding at January 1, 2023	14,661	$	1.48	5.80	$	58,565
Vested and expecting to vest at January 1, 2023	14,661	1.48		5.80	58,565
Exercisable at January 1, 2023	11,203	$	1.44	5.15	$	45,204
Granted	259	9.97		—	34
Exercised	(472)	1.59		—	1,827
Cancelled/forfeited	(93)	1.18		—	673
Outstanding at March 31, 2023	14,355	$	1.63	5.81	$	33,903
Vested and expecting to vest at March 31, 2023	14,355	1.63		5.81	33,903
Exercisable at March 31, 2023	11,303	$	1.44	5.25	$	27,650

The Company recorded compensation expense related to the options of $764 and $738 for the three months ended March 31, 2023 and March 31, 2022, respectively. Unrecognized compensation costs as of March 31, 2023 was $4,321 and will be recognized over a weighted average of 2.37 years.

Restricted Stock Awards (“RSAs”)

RSAs become eligible to vest upon the satisfaction of a time-based service condition. However, in order to vest, a liquidity event, defined as acquisition, asset transfer, or initial listing, must occur within 10 years from the grant date. Upon a liquidity event, if the participant’s service has not terminated, the entire RSA award vests in full, whether or not previously eligible for vesting. If the participant’s service has terminated and they have satisfied the time-based service condition, the RSAs that are outstanding and eligible for vesting immediately vest in full upon liquidity event. The time-based service requirements of the RSAs have a maximum term of three years from the date of grant.

As of December 31, 2022, there were 2,535,825 outstanding unvested shares for a weighted average grant date fair value of $1.08. This is also the number of RSAs that vested as a result of the Business Combination on the Closing Date. The vesting of the RSAs resulted in compensation expense of $2,741. Subsequent to the vesting of these shares, the holders of the RSAs surrendered 771,141 common shares to fund the payment of payroll tax on

their behalf by the Company. This resulted in a total cash payment of $7,650 by the Company for employee payroll taxes associated with this vesting event.

Share-Based Compensation

The Company adopted the LanzaTech 2023 Long-Term Incentive Plan (the “LTIP”) in conjunction with the closing of the Business Combination. The LTIP provides for grants of a variety of awards to employees, directors, and other service providers to the Company, including, but not limited to stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards and other stock-based awards or cash incentives. Prior to the effective date of the closing of the Business Combination, the Company granted awards under the LanzaTech NZ Inc. 2013 Stock Plan, the LanzaTech NZ Inc. 2015 Stock Plan, and the LanzaTech NZ, Inc. 2019 Stock Plan, (collectively, the “Prior Stock Plans”).

Equity Classified Awards:

RSUs

Under the LTIP, the Company has granted two types of RSUs: time-based RSUs, and market-based. Time-based RSUs granted to employees and other service providers (other than directors) are generally subject to a three-year annual pro-rata vesting schedule whereby the awards generally vest in 3 equal tranches on the first, second, and third anniversaries of the vesting commencement date, subject to grantee’s continued service through each vesting date. However, vesting will accelerate in certain circumstances (e.g., retirement, death, disability, or a qualified termination in connection with a change in control). Time-based RSUs granted to directors are subject to a one-year vesting schedule and the full award vests on the first anniversary of the vesting commencement date, subject to the director’s continued service through the vesting date. However, vesting will accelerate in certain circumstances (e.g., removal in connection with a change in control).

The market-based RSUs have both a time-based and a market-based vesting component. Both components must be met for the award to vest. The market-based RSUs are subject to the same three-year annual pro-rata vesting schedule as the employee time-based RSUs. The market-based vesting component is satisfied if on any date during the period beginning on the 151st date following the vesting commencement date and ending on the fifth anniversary of the vesting commencement date, the average closing price of a share of the Company’s common stock, equals or exceeds $11.50, determined using the closing share price from the 20 trading days preceding such determination date.

A summary of the unvested time-based and market-based equity-classified RSUs are presented in the following table:


	Number of RSUs (thousands)		Weighted Average Grant Date Fair Value
	Time-based	Market-based
January 1, 2023	—	—	$	—
Granted	3,082	3,830	2.43
Vested	—	—	—
Cancelled/forfeited	(11)	—	3.45
June 30, 2023	3,071	3,830	$	2.43

The Company recorded compensation expense related to the RSUs of $2,677 for the three and six months ended June 30, 2023. Unrecognized compensation costs as of June 30, 2023 was $14,068 and will be recognized over a weighted average of 2.33 years.

Stock Options

In accordance with the LTIP and Prior Stock Plans, grantees have also been granted stock options to purchase common shares. The exercise prices of each stock option was no less than the fair market value price of the Company’s common shares determined as of the date of grant. The stock options generally vest over the course of two to five years, subject to the service provider’s continued service through each vesting date. Upon termination of service, unvested stock options are forfeited in accordance with their terms unless the award agreement provides for accelerated vesting (e.g., due to retirement). The below table reflects the stock options granted prior to the Business Combination multiplied by the exchange ratio and the weighted average exercise price divided by the exchange ratio.

Stock option awards outstanding as of June 30, 2023 and changes during the period ended June 30, 2023 were as follows:


	Shares under option (thousands)	Weighted average exercise price		Weighted average remaining contractual term (years)	Aggregate intrinsic value (thousands)
Outstanding at January 1, 2023	14,661	$	1.48	5.80	$	58,565
Vested and expecting to vest at January 1, 2023	14,661	1.48		5.80	58,565
Exercisable at January 1, 2023	11,203	$	1.44	5.15	$	45,204
Granted	3,556	3.77		—	594
Exercised	(699)	1.55		—	2,337
Cancelled/forfeited	(100)	1.30		—	693
Outstanding at June 30, 2023	17,418	$	1.94	6.41	$	85,948
Vested and expecting to vest at June 30, 2023	17,418	1.94		6.41	85,948
Exercisable at June 30, 2023	11,240	$	1.48	5.11	$	60,321

The Company recorded compensation expense related to the options of $2,445 and $676 for the three months ended June 30, 2023 and 2022, respectively, and $3,209 and $1,414 for the six months ended June 30, 2023 and 2022. Unrecognized compensation costs as of June 30, 2023 was $10,801 and will be recognized over a weighted average of 2.51 years.

Restricted Stock Awards (“RSAs”)

Under the Prior Stock Plans, the Company granted RSAs which become eligible to vest upon the satisfaction of a time-based service condition. However, in order to vest, a liquidity event, defined as acquisition, asset transfer, or initial listing, must occur within 10 years from the grant date. Upon a liquidity event, if the participant’s service has

not terminated, the entire RSA award vests in full, whether or not previously eligible for vesting. If the participant’s service has terminated and they have satisfied the time-based service condition, the RSAs that are outstanding and eligible for vesting immediately vest in full upon liquidity event. The time-based service requirements of the RSAs have a maximum term of three years from the date of grant.

As of December 31, 2022, there were 2,535,825 outstanding unvested RSAs with a weighted average grant date fair value of $1.08. The Business Combination constituted a “liquidity event” which caused the vesting of all such outstanding, unvested RSAs. The vesting of the RSAs resulted in compensation expense of $0 and $2,741 for the three and six months ended June 30, 2023, respectively. There was no compensation expense recorded in the comparable periods in 2022, because the Company concluded that the liquidity event performance condition was not probable of being satisfied at the time. In connection with the vesting of these RSAs, certain holders of the RSAs surrendered 771,141 shares in a withhold to cover transaction to fund the payment of applicable tax withholding on their behalf by the Company. This resulted in a total cash payment of $7,650 by the Company to the Internal Revenue Service for the applicable tax withholding associated with this vesting event.

Liability-Classified Awards

Phantom RSUs

Under a phantom equity sub-plan of the LTIP, certain non-US employees of the Company were provided with Phantom RSUs that can only be settled in cash and are therefore recorded as a liability. The Phantom RSUs have a graded vesting schedule and vest in 3 equal tranches on the first, second, and third anniversaries of the vesting commencement date, subject to the employee meeting the requisite service requirements. Grantees are entitled to receive a cash payment equal to the fair market value of a share multiplied by the number of vested RSUs as of the applicable vesting date.

Phantom SARs

Under a phantom equity sub-plan of the LTIP, certain non-US employees of the company were provided with Phantom SARs that can only be settled in cash and are therefore recorded as a liability. The Phantom SARs have a graded vesting schedule and vest in three equal tranches on the first, second, and third anniversaries of the vesting commencement date, subject to the employee meeting the requisite service requirements. Phantom SARs expire 10 years after the grant date and entitle the grantee to receive a cash payment upon exercise of the award equal to the excess of the fair market value of a share on the date of exercise over the exercise price multiplied by the number of SARs exercised.

Share-Based Compensation

Equity Classified Awards:

RSUs

Under the LTIP, the Company has granted two types of RSUs: time-based RSUs, and market-based RSUs. Time-based RSUs granted to employees and other service providers (other than directors) are generally subject to a three-year annual pro-rata vesting schedule whereby the awards generally vest in 3 equal tranches on the first, second, and third anniversaries of the vesting commencement date, subject to grantee’s continued service through each vesting date. However, vesting will accelerate in certain circumstances (e.g., retirement, death, disability, or a qualified termination in connection with a change in control). Time-based RSUs granted to directors are subject to a one-year vesting schedule and the full award vests on the first anniversary of the vesting commencement date, subject to the director’s continued service through the vesting date. However, vesting will accelerate in certain circumstances (e.g., removal in connection with a change in control).

A summary of the unvested time-based and market-based equity-classified RSUs are presented in the following table:


	Number of RSUs (thousands)		Weighted Average Grant Date Fair Value
	Time-based	Market-based
January 1, 2023	—	—	$	—
Granted	3,143	3,930	2.49
Vested	(2)	—	3.45
Cancelled/forfeited	(28)	—	3.43
September 30, 2023	3,113	3,930	$	2.49

The Company recorded compensation expense related to the RSUs of $1,895 and $4,594 for the three and nine months ended September 30, 2023. Unrecognized compensation costs as of September 30, 2023 was $12,936 and will be recognized over a weighted average of 1.98 years.

Stock Options

Stock option awards outstanding as of September 30, 2023 and changes during the period ended September 30, 2023 were as follows:


	Shares subject to option (thousands)	Weighted average exercise price		Weighted average remaining contractual term (years)	Aggregate intrinsic value (thousands)
Outstanding at January 1, 2023	14,661	$	1.48	5.80
Vested and expecting to vest at January 1, 2023	14,661	1.48		5.80
Exercisable at January 1, 2023	11,203	$	1.44	5.15
Granted	3,556	3.77		—
Exercised	(1,075)	1.53		—
Cancelled/forfeited	(120)	1.76		—
Outstanding at September 30, 2023	17,022	$	1.95	6.21	$	47,653
Vested and expecting to vest at September 30, 2023	17,022	1.95		6.21	47,653
Exercisable at September 30, 2023	11,208	$	1.48	4.98	$	36,026

The Company recorded compensation expense related to the options of $1,234 and $653 for the three months ended September 30, 2023 and 2022, respectively, and $4,443 and $2,067 for the nine months ended September 30, 2023 and 2022. Unrecognized compensation costs as of September 30, 2023 was $9,550 and will be recognized over a weighted average of 2.29 years.

Restricted Stock Awards (“RSAs”)

initial listing, must occur within 10 years from the grant date. Upon a liquidity event, if the participant’s service has not terminated, the entire RSA award vests in full, whether or not previously eligible for vesting. If the participant’s service has terminated and they have satisfied the time-based service condition, the RSAs that are outstanding and eligible for vesting immediately vest in full upon liquidity event. The time-based service requirements of the RSAs have a maximum term of three years from the date of grant.

As of December 31, 2022, there were 2,535,825 outstanding unvested RSAs with a weighted average grant date fair value of $1.08. The Business Combination constituted a “liquidity event” which caused the vesting of all such outstanding, unvested RSAs. The vesting of the RSAs resulted in compensation expense of $0 and $2,741 for the three and nine months ended September 30, 2023, respectively. There was no compensation expense recorded in the comparable periods in 2022, because the Company concluded that the liquidity event performance condition was not probable of being satisfied at the time. In connection with the vesting of these RSAs, certain holders of the RSAs surrendered 771,141 shares in a withhold to cover transaction to fund the payment of applicable tax withholding on their behalf by the Company. This resulted in a total cash payment of $7,650 by the Company to the Internal Revenue Service for the applicable tax withholding associated with this vesting event.

Liability-Classified Awards

Phantom RSUs

Phantom SARs

Share-Based Compensation

The Company offers share option plans to employees, directors, and others providing similar employee-related services, which meet the definition of an equity-classified share-based payment.

Stock Options

service condition of two to five years and vest over time as the service condition is being satisfied. Upon termination of employment, unvested stock options are evaluated for forfeiture or modifications, subject to the terms of the awards and Company's policies. The below table reflects the pre-combination shares under option multiplied by the exchange ratio and the weighted average exercise price divided by the exchange ratio.

Stock option awards outstanding as of December 31, 2022 and changes during the period ended December 31, 2022 were as follows:


	Shares under option (thousands)	Weighted average exercise price		Weighted average remaining contractual term (years)	Aggregate intrinsic value (thousands)
Outstanding at January 1, 2022	16,822	$	1.50	6.16	$	27,796
Vested and expecting to vest at January 1, 2022	16,822	1.50		6.16	27,796
Exercisable at January 1, 2022	10,845	$	1.44	4.85	$	18,499

Exercised	(1,968)	1.60		—	3,520
Cancelled/forfeited	(191)	2.20		—	218
Expired	(2)	1.52		—	4
Outstanding at December 31, 2022	14,661	$	1.48	5.80	$	58,565
Vested and expecting to vest at December 31, 2022	14,661	1.48		5.80	58,565
Exercisable at December 31, 2022	11,203	$	1.44	5.15	$	45,204

The Company recorded compensation expense of $2,527 and $2,531 for the years ended December 31, 2022 and December 31, 2021, respectively. Unrecognized compensation costs as of December 31, 2022 was $3,354 and will be recognized over a weighted average of 2.07 years .

Restricted Stock Awards (“RSAs”)

RSAs become eligible to vest upon the satisfaction of a time-based service condition. However, in order to vest, a liquidity event, defined as acquisition, asset transfer, or initial listing, must occur within 10 years from the grant date. Upon a liquidity event, if the participant’s service has not terminated, the entire RSA award vests in full, whether or not previously eligible for vesting. If the participant’s service has terminated and they have satisfied the time-based service condition, the RSAs that are outstanding and eligible for vesting shall immediately vest in full upon liquidity event. The time-based service requirements of the RSAs have a maximum term of three years from the date of grant.

As of December 31, 2022, there were 2,535,825 outstanding unvested shares for a weighted average fair value of $1.08. There were no changes during the year ended December 31, 2022.

As of December 31, 2022, and December 31, 2021 the Company concluded that the liquidity event performance condition described above for the RSAs was not probable of being satisfied at such time. As a result, the Company did not recognize any compensation expense during the years ended December 31, 2022 and December 31, 2021 for these RSAs.

Forward Purchase Agreement - Narrative (Details) - USD ($) $ in Thousands		6 Months Ended	9 Months Ended
	Feb. 03, 2023	Jun. 30, 2023	Sep. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Derivative [Line Items]
Additional paid-in capital		$ 936,157	$ 939,868	$ 927,641	$ 24,782	$ 21,710
FPA Put Option liability		26,743	38,092	44,593	0
Fixed Maturity Consideration		6,737	7,020	6,967	$ 0
Adjustments
Derivative [Line Items]
Additional paid-in capital		(60,547)		(60,547)
FPA Put Option liability		26,743		$ 44,593
Forward Contracts
Derivative [Line Items]
Derivative transaction costs	$ 451	$ 451	$ 451

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Temporary equity par value (usd per share)	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Temporary equity, shares authorized (in shares)	20,000,000	20,000,000	20,000,000	130,133,670	130,133,670
Temporary equity, shares issued (in shares)	0	0	0	129,148,393	129,148,393
Temporary equity, shares outstanding (in shares)	0	0	0	129,148,393	129,148,393
Common shares, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Common shares, shares authorized (in shares)	400,000,000	400,000,000	400,000,000	158,918,093	158,918,093
Common shares, shares issued (in shares)	196,055,228	195,674,502	195,451,596	10,422,051	9,217,160
Common shares, shares outstanding (in shares)	196,055,228	195,674,502	195,451,596	10,422,051	9,217,160

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Revenues [Abstract]
Revenue from collaborative arrangements	$ 1,566,000	$ 462,000	$ 1,088,000	$ 760,000	$ 973,000	$ 0	$ 1,550,000	$ 973,000	$ 3,116,000	$ 1,733,000	$ 2,575,000	$ 3,337,000
Revenues	19,605,000	12,917,000	9,646,000	8,072,000	9,852,000	7,857,000	22,563,000	17,709,000	42,168,000	25,781,000	37,343,000	25,461,000
Costs and Expenses [Abstract]
Cost of revenue from collaborative arrangements (exclusive of depreciation shown below)	(678,000)	(419,000)	(407,000)	(256,000)	(471,000)	0	(826,000)	(471,000)	(1,504,000)	(727,000)	(1,250,000)	(1,254,000)
Cost of revenue from related party transactions (exclusive of depreciation shown below)	(59,000)	(50,000)	(41,000)	(46,000)	(227,000)	(69,000)	(91,000)	(296,000)	(150,000)	(342,000)	(477,000)	(808,000)
Research and development expense	(16,645,000)	(18,908,000)	(16,286,000)	(14,260,000)	(13,237,000)	(12,361,000)	(35,194,000)	(25,598,000)	(51,839,000)	(39,858,000)	(53,191,000)	(44,229,000)
Depreciation expense	(1,376,000)	(1,348,000)	(1,257,000)	(1,211,000)	(1,163,000)	(1,059,000)	(2,605,000)	(2,222,000)	(3,981,000)	(3,433,000)	(4,660,000)	(3,806,000)
Selling, general and administrative expense	(11,808,000)	(12,452,000)	(16,835,000)	(7,258,000)	(7,146,000)	(5,078,000)	(29,287,000)	(12,224,000)	(41,095,000)	(19,482,000)	(26,804,000)	(13,216,000)
Total cost and operating expenses	(44,200,000)	(43,535,000)	(42,168,000)	(28,704,000)	(28,973,000)	(24,327,000)	(85,703,000)	(53,300,000)	(129,903,000)	(82,004,000)	(112,942,000)	(76,480,000)
Loss from operations	(24,595,000)	(30,618,000)	(32,522,000)	(20,632,000)	(19,121,000)	(16,470,000)	(63,140,000)	(35,591,000)	(87,735,000)	(56,223,000)	(75,599,000)	(51,019,000)
Nonoperating Income (Expense) [Abstract]
Interest income, net	1,249,000	1,701,000	214,000	8,000	(5,000)	0	1,915,000	(5,000)	3,164,000	3,000	8,000	(7,000)
Gain on extinguishment of debt											0	3,065,000
Other expense, net	(1,517,000)	2,001,000	(30,396,000)	(1,176,000)	102,000	(26,000)	(28,395,000)	76,000	(29,912,000)	(1,100,000)	(2,757,000)	(673,000)
Total other expense, net	(268,000)	3,702,000	(30,182,000)	(1,168,000)	97,000	(26,000)	(26,480,000)	71,000	(26,748,000)	(1,097,000)	(2,749,000)	2,385,000
Loss before income taxes	(24,863,000)	(26,916,000)	(62,704,000)	(21,800,000)	(19,024,000)	(16,496,000)	(89,620,000)	(35,520,000)	(114,483,000)	(57,320,000)	(78,348,000)	(48,634,000)
Income tax expense	0	0	0	0	0	0	0	0	0	0	0	0
Loss from equity method investees, net	(463,000)		(608,000)	(467,000)		(282,000)			(941,000)	2,346,000	1,992,000	1,945,000
Net income (loss)	(25,326,000)	(26,786,000)	(63,312,000)	(22,267,000)	(15,929,000)	(16,778,000)	(90,098,000)	(32,707,000)	(115,424,000)	(54,974,000)	(76,356,000)	(46,689,000)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]
Loss from equity method investees, net	(1,001,000)	96,000	(49,000)	(384,000)	(355,000)	(28,000)	47,000	(383,000)	(954,000)	(767,000)	(1,449,000)	95,000
Comprehensive loss	(26,327,000)	(26,690,000)	(63,361,000)	(22,651,000)	(16,284,000)	(16,806,000)	(90,051,000)	(33,090,000)	(116,378,000)	(55,741,000)	(77,805,000)	(46,594,000)
Unpaid cumulative dividends on preferred stock	0	0	(4,117,000)	(9,748,000)	(9,654,000)	(9,523,000)	(4,117,000)	(19,177,000)	(4,117,000)	(28,925,000)	(38,672,000)	(36,758,000)
Net loss allocated to common shareholders	$ (25,326,000)	$ (26,786,000)	$ (67,429,000)	$ (32,015,000)	$ (25,583,000)	$ (26,301,000)	$ (94,215,000)	$ (51,884,000)	$ (119,541,000)	$ (83,899,000)	$ (115,028,000)	$ (83,447,000)
Basic and diluted net income (loss) per share - basic (in dollars per share)	$ (0.13)	$ (0.14)	$ (0.58)	$ (3.47)	$ (2.77)	$ (2.85)	$ (0.60)	$ (5.63)	$ (0.70)	$ (9.10)	$ (12.37)	$ (9.72)
Basic and diluted net income (loss) per share - diluted (in dollars per share)	$ (0.13)	$ (0.14)	$ (0.58)	$ (3.47)	$ (2.77)	$ (2.85)	$ (0.60)	$ (5.63)	$ (0.70)	$ (9.10)	$ (12.37)	$ (9.72)
Weighted average shares outstanding of common stock - basic (in shares)	195,869,537	195,537,601	116,530,963	9,229,781	9,222,214	9,219,499	156,472,730	9,222,870	169,797,443	9,223,884	9,302,080,000	8,585,999,000
Weighted-average number of common shares outstanding - diluted (in shares)	195,869,537	195,537,601	116,530,963	9,229,781	9,222,214	9,219,499	156,472,730	9,222,870	169,797,443	9,223,884	9,302,080,000	8,585,999,000
Related Party
Revenues [Abstract]
Revenue from contracts with customers			$ 973,000			$ 654,000
Revenues			973,000			654,000
Service
Costs and Expenses [Abstract]
Cost of revenue from contracts with customers	$ (11,862,000)	$ (9,631,000)	(7,342,000)	$ (3,694,000)	$ (6,417,000)	(5,196,000)	$ (16,973,000)	$ (11,613,000)	$ (28,835,000)	$ (15,307,000)	$ (22,912,000)	$ (13,167,000)
Service \| Nonrelated Party
Revenues [Abstract]
Revenue from contracts with customers	14,162,000	10,372,000	7,585,000	4,917,000	7,139,000	6,463,000	17,957,000	13,602,000	32,119,000	18,519,000	27,798,000	18,871,000
Service \| Related Party
Revenues [Abstract]
Revenue from contracts with customers	1,619,000	1,076,000		704,000	758,000		2,049,000	1,412,000	3,668,000	2,116,000	2,970,000	3,253,000
Tangible Products
Costs and Expenses [Abstract]
Cost of revenue from contracts with customers	(1,772,000)	(727,000)	0	(1,979,000)	(312,000)	(564,000)	(727,000)	(876,000)	(2,499,000)	(2,855,000)	(3,648,000)	0
Tangible Products \| Nonrelated Party
Revenues [Abstract]
Revenue from contracts with customers	$ 2,258,000	$ 1,007,000	$ 0	$ 1,691,000	$ 982,000	$ 740,000	$ 1,007,000	$ 1,722,000	$ 3,265,000	$ 3,413,000	$ 4,000,000	$ 0

Revenues - Contract Balances (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2023	Jun. 30, 2023	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Contract with Customer, Asset, after Allowance for Credit Loss, Current [Abstract]
Beginning balance	$ 18,000	$ 18,000	$ 18,000	$ 11,700	$ 6,186
Additions to unbilled accounts receivable	11,241	23,684	43,901	30,308	8,516
Unbilled accounts receivable recognized in trade receivables	(10,833)	(20,016)	(37,413)	(24,062)	(3,002)
Unbilled accounts receivable recognized in trade receivables	52	108	(175)	54
Ending balance	18,460	21,776	24,313	18,000	11,700
Contract With Customer, Liability, Current [Abstract]
Beginning balance	3,101	3,101	3,101	3,476	5,480
Contract With Customer, Liability, Current, Amounts Collected		515	4,486	996	20
Reclassification from long-term to short-term	672	1,344	2,016	2,837	3,080
Reclassification to revenue as a result of performance obligations satisfied	(731)	(2,008)	(6,471)	(4,208)	(5,104)
Ending balance	3,042	2,952	3,132	3,101	3,476
Contract With Customer, Liability, Noncurrent [Abstract]
Beginning balance	10,760	10,760	10,760	13,901	11,291
Contract With Customer, Liability, Noncurrent, Amounts Collected				37	5,690
Contract With Customer, Liability, Noncurrent, Foreign Currency Translation Adjustment	(83)	(64)	73	(341)
Reclassification from long-term to short-term	(672)	(1,344)	(2,016)	(2,837)	(3,080)
Ending balance	$ 10,171	$ 9,480	$ 8,671	$ 10,760	$ 13,901

SAFE	3 Months Ended	12 Months Ended
SAFE	Mar. 31, 2023	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
SAFE	AM SAFEIn December 2021, the Company issued the AM SAFE that allows an investor to participate in future equity financings through a share-settled redemption of the invested amount. On the Closing Date of the Business Combination, the AM SAFE converted into 3,000,000 shares of common stock. As of the Closing Date, the AM SAFE had a fair value of $29,730, which equals the closing price of approximately $9.91 on the Closing Date, multiplied by the number of shares issued. The AM SAFE was adjusted to its fair value on the Closing Date prior to settlement. As of December 31, 2022, the AM SAFE had a fair value of $28,986. The AM SAFE was recorded within current liabilities on the condensed consolidated balance sheet as of December 31, 2022.	SAFE AM SAFE In December 2021, the Company issued the AM SAFE that allows an investor to participate in future equity financings through a share-settled redemption of the invested amount. Upon the occurrence of a change of control, the investor has the right to receive the greater of (i) a cash payment equal to the invested amount under the AM SAFE, or (ii) the consideration payable in such change of control in respect of the number of common shares equal to the invested amount divided by the liquidity price set forth in the AM SAFE. Upon an initial public offering or a business combination with a special purpose acquisition company, the investor has the right to receive a number of common shares equal to the invested amount divided by the liquidity price set forth in the AM SAFE, except that if a business combination with a special purpose acquisition company involves a private placement of newly issued shares, the invested amount will be treated as participating in such private placement and exchanged for a number of common shares equal to the invested amount divided by the price per share applicable in such private placement (subject to a discount upon certain circumstances). The AM SAFE also contains change of control and initial public offering settlement alternatives described above, that settle differently upon a next round financing such that it allows the investor to participate in future equity financings through a share-settled redemption at a discounted price to the price paid by other investors. That is, upon a future equity financing involving preferred shares, the AM SAFE would be settled into a number of preferred shares equal to the invested amount of the AM SAFE divided by a percentage of the discounted price investors paid to purchase preferred shares in the financing, with such discounted price calculated as a percentage of the price investors paid to purchase preferred shares in the financing. The AM SAFE had not yet converted as a qualifying financing had not yet occurred as of December 31, 2022. As of December 31, 2022 and December 31, 2021, the AM SAFE had a fair value of $28,986 and $28,271, respectively. The AM SAFE was recorded within current liabilities on the consolidated balance sheet. Brookfield SAFE On October 2, 2022, LanzaTech entered into the Brookfield SAFE and received a cash payment of $50,000 as the Initial Purchase Amount. In exchange, the Company granted to Brookfield the right to certain shares of the Company's capital stock upon a Liquidity Event. If no Liquidity Event occurs prior to the fifth anniversary of the Brookfield SAFE, LanzaTech will repay in cash any remaining unconverted portion of the Initial Purchase Amount less any Non-Repayable Amount (i.e. the Remaining Amount), plus interest on such Remaining Amount in the high single digits, compounded annually. Brookfield has the option to extend the repayment date to the tenth anniversary of the date of the Brookfield SAFE if certain events do not occur Following the first of either (a) a transaction with the principal purpose of raising capital, pursuant to which the Company issues and sells preferred stock at a fixed valuation (an “Equity Financing”), or (b) the completion of an initial public offering, a direct listing, or a merger of LanzaTech with a special purpose acquisition company, which includes the Business Combination (such a merger, a “de-SPAC Transaction” and such event described in (b), a “Liquidity Event”), Brookfield may, at any time at its option, convert all or a portion of the Initial Purchase Amount less any amount that has already been converted or repaid into shares of LanzaTech capital stock or, in the case of a de-SPAC Transaction, shares of common stock of the surviving public company in such de-SPAC Transaction (including, in the case of the Business Combination, New LanzaTech Common Stock) at Liquidity Event or Equity Financing’s share price. For each $50,000 of aggregate equity funding required for qualifying projects acquired by Brookfield in accordance with the Brookfield Framework Agreement (discussed below), the Remaining Amount will be reduced by $5,000 (such cumulative reductions the “Non-Repayable Amount”) and converted into shares of LanzaTech. Upon and after the first Equity Financing or Liquidity Event, the Non-Repayable Amount would convert automatically into shares of LanzaTech capital stock or, in the case of a de-SPAC Transaction, shares of common stock of the surviving public company in such de-SPAC Transaction (including, in the case of the Business Combination, New LanzaTech Common Stock), at the Liquidity Event or Equity Financing's share price. The Remaining Amount may convert into LanzaTech or New LanzaTech capital stock, in the case of a de-SPAC Transaction, at any time at the sole option of Brookfield. The Brookfield SAFE had not yet converted as a qualifying financing had not yet occurred and no project investments were presented to Brookfield as of December 31, 2022. As of December 31, 2022, the Brookfield SAFE had a fair value of $50,000 and was recorded within non-current liabilities on the consolidated balance sheet. Brookfield Framework Agreement On October 2, 2022, LanzaTech entered into a framework agreement with Brookfield (the “Brookfield Framework Agreement”). Under such agreement, LanzaTech agreed to exclusively offer Brookfield the opportunity to acquire or invest in certain projects to construct commercial production facilities employing carbon capture and transformation technology in the U.S., the European Union, the United Kingdom, Canada or Mexico for which LanzaTech is solely or jointly responsible for obtaining or providing equity financing, subject to certain exceptions. LanzaTech agreed to present Brookfield with projects that over the term of the agreement require equity funding of at least $500,000 in the aggregate. With respect to projects acquired by Brookfield, LanzaTech is entitled to a percentage of free cash flow generated by such projects determined in accordance with a hurdle-based return waterfall. Brookfield has no obligation under the Brookfield Framework Agreement to invest in any of the projects. There have been no investments in projects as of December 31, 2022.

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Assets, Current [Abstract]
Cash and cash equivalents	$ 91,397	$ 110,719	$ 145,118	$ 83,045	$ 128,318
Debt security investments		49,704	49,103	0
Held-to-maturity investment securities	35,011			0
Trade and other receivables, net of allowance	10,085	7,766	9,277	11,695	2,878
Contract assets	24,313	21,776	18,460	18,000	11,700
Other current assets	16,677	18,952	18,689	11,157	5,779
Total current assets	177,483	208,917	240,647	123,897	148,675
Property, plant and equipment, net	22,818	22,280	19,794	19,689	14,148
Non-current held-to-maturity investment securities	9,780			0
Right-of-use assets	6,023	6,582	6,437	6,969	4,686
Equity method investment	9,594	10,164	9,835	10,561	24,752
Equity security investment	14,990	14,990	14,990	14,990	0
Other non-current assets	5,659	5,600	300	750	750
Total assets	246,347	268,533	292,003	176,856	193,011
Liabilities, Current [Abstract]
Accounts payable	5,779	11,153	11,522	7,455	2,444
Other accrued liabilities				6,621	7,059
Other accrued liabilities	6,049	3,639	4,143	4,502
AM SAFE liability	0	0	0	28,986	28,271
AM SAFE warrant				1,989	1,729
Warrants	9,636	8,422	9,919	4,108
Contract liabilities	3,132	2,952	3,042	3,101	3,476
Accrued salaries and wages	7,196	5,093	4,644	7,031	4,261
Current lease liabilities	1,951	1,356	807	798	2,050
Total current liabilities	33,743	32,615	34,077	55,981	49,290
Non-current lease liabilities	5,250	6,038	5,939	6,615	3,283
Non-current contract liabilities	8,671	9,480	10,171	10,760	13,901
Fixed Maturity Consideration	7,020	6,737	6,967	0
FPA Put Option liability	38,092	26,743	44,593	0
Brookfield SAFE liability	23,350	34,150	19,400	50,000	0
Other long-term liabilities	1,746	1,679	1,591	1,591	823
Total liabilities	117,872	117,442	122,738	124,947	67,297
Commitments and Contingencies (see note 15)
Redeemable convertible preferred stock,	0	0	0	480,631	480,631
Stockholders' Equity Attributable to Parent [Abstract]
Common stock	19	19	19	1	1
Additional paid-in capital	939,868	936,157	927,641	24,782	21,710
Accumulated other comprehensive income	1,786	2,787	2,691	2,740	3,261
Accumulated deficit	(813,198)	(787,872)	(761,086)	(456,245)	(379,889)
Total shareholders’ equity (deficit)	128,475	151,091	169,265	(428,722)	(354,917)
Total liabilities, contingently redeemable preferred stock, and shareholders' equity	$ 246,347	$ 268,533	$ 292,003	$ 176,856	$ 193,011

Reverse Recapitalization (Tables)

3 Months Ended

6 Months Ended

12 Months Ended

Mar. 31, 2023

Jun. 30, 2023

Dec. 31, 2023

Reverse Recapitalization [Abstract]

Schedule of reverse recapitalization

The number of shares of Class A common stock issued and outstanding immediately following the consummation of the Business Combination and PIPE financing were:


	Shares	Percentage
Legacy LanzaTech shares	167,324,363	85.3	%
Public stockholders	10,398,374	5.3	%
PIPE shares	18,500,000	9.4	%
Total	196,222,737	100	%

The following table reconciles the elements of the Business Combination and PIPE financing to the condensed consolidated statement of cash flows for the three months ended March 31, 2023:


	Recapitalization
Cash - AMCI trust account1	$	64,090
Cash - PIPE financing	155,000
Less: Transaction costs allocated to equity and paid in the three months ended March 31, 2023	(5,709)
Effect of the Business Combination and PIPE financing	$	213,381

__________________

(1)The cash from the AMCI trust account is net of redemptions and the payment of pre-combination AMCI expenses.

The following table reconciles the elements of the Business Combination and PIPE financing to the change in additional paid-in capital on the condensed consolidated statement of changes in redeemable convertible preferred stock and shareholders’ equity / deficit for the three months ended March 31, 2023:


	Recapitalization
Cash - AMCI trust account	$	64,090
Public Warrants and Private Placement Warrants recorded on the Closing Date	(4,624)
Cash - PIPE financing	155,000
Conversion of the AM SAFE	29,730
Transaction costs allocated to equity	(7,223)
	$	236,973
Less: par value of shares held by PIPE investors and public stockholders	(3)
Total additional paid-in capital from recapitalization	$	236,970

The number of shares of Class A common stock issued and outstanding immediately following the consummation of the Business Combination and PIPE financing were:


	Shares	Percentage
Legacy LanzaTech shares	167,324,363	85.3	%
Public stockholders	10,398,374	5.3	%
PIPE shares	18,500,000	9.4	%
Total	196,222,737	100	%

The following table reconciles the elements of the Business Combination and PIPE financing to the condensed consolidated statement of cash flows:


	Recapitalization
Cash - AMCI trust account1	$	64,090
Cash - PIPE financing	155,000
Less: Transaction costs allocated to equity	(5,709)
Effect of the Business Combination and PIPE financing	$	213,381

__________________

(1)The cash from the AMCI trust account is net of redemptions and the payment of pre-combination AMCI expenses.


	Recapitalization
Cash - AMCI trust account	$	64,090
Public Warrants and Private Placement Warrants recorded on the Closing Date	(4,624)
Cash - PIPE financing	155,000
Conversion of the AM SAFE	29,730
Transaction costs allocated to equity	(7,223)
	$	236,973
Less: par value of shares held by PIPE investors and public stockholders	(3)
Total additional paid-in capital from recapitalization	$	236,970

The number of shares of Class A common stock issued and outstanding immediately following the consummation of the Business Combination and PIPE financing were:


	Shares	Percentage
Legacy LanzaTech shares	167,324,363	85.3	%
Public stockholders	10,398,374	5.3	%
PIPE shares	18,500,000	9.4	%
Total	196,222,737	100	%

The following table reconciles the elements of the Business Combination and PIPE financing to the condensed consolidated statement of cash flows:


	Recapitalization
Cash - AMCI trust account1	$	64,090
Cash - PIPE financing	155,000
Less: Transaction costs allocated to equity	(5,709)
Effect of the Business Combination and PIPE financing	$	213,381

__________________

(1)The cash from the AMCI trust account is net of redemptions and the payment of pre-combination AMCI expenses.


	Recapitalization
Cash - AMCI trust account	$	64,090
Public Warrants and Private Placement Warrants recorded on the Closing Date	(4,624)
Cash - PIPE financing	155,000
Conversion of the AM SAFE	29,730
Transaction costs allocated to equity	(7,223)
	$	236,973
Less: par value of shares held by PIPE investors and public stockholders	(3)
Total additional paid-in capital from recapitalization	$	236,970

Summary of Significant Accounting Policies - Benefit Plans (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Contributions to plan	$ 987	$ 720

Description of the Business	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
Description of the Business	Mar. 31, 2023	Jun. 30, 2023	Sep. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of the Business	Description of the Business LanzaTech Global, Inc., formerly known as AMCI Acquisition Corp. II (“AMCI”) prior to February 8, 2023 (the “Closing Date”) was incorporated as a Delaware Corporation on January 28, 2021. On March 8, 2022, LanzaTech NZ, Inc. ("Legacy LanzaTech") entered into an Agreement and Plan of Merger (the “Merger Agreement”) with AMCI and AMCI Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of AMCI (“Merger Sub”). On February 8, 2023, Legacy LanzaTech completed its business combination with AMCI by which the Merger Sub merged with and into Legacy LanzaTech, with Legacy LanzaTech continuing as the surviving corporation and as a wholly owned subsidiary of AMCI (the “Business Combination”). The reporting entity is LanzaTech Global, Inc. and its subsidiaries (collectively referred to herein as “the Company” or "LanzaTech"). The Company is headquartered in Skokie, Illinois. The Company is a nature-based carbon refining company that transforms waste carbon into the chemical building blocks for consumer goods such as sustainable fuels, fabrics, and packaging that people use in their daily lives. The Company’s customers leverage its proven proprietary gas fermentation technology platform to convert certain feedstock, including waste carbon gases, into sustainable fuels and chemicals such as ethanol. The Company performs related services such as feasibility studies, engineering services, and research and development ("R&D") in biotechnology for commercial and government customers. The Company also purchases the low carbon chemicals produced at customer facilities employing the Company’s technology and sells it under the brand name CarbonSmart. As of March 31, 2023, the Company’s partners operate three commercial scale waste-to-gas ethanol plants in China, with others currently in development in various countries compared to two commercial scale waste-to-gas ethanol plants in China as of March 31, 2022. The Company has reclassified its warrants on preferred shares as of December 31, 2022 from other accrued liabilities to warrants on the condensed consolidated balance sheet to conform with current period presentation. This reclassification resulted in a decrease to other accrued liabilities and corresponding increase to warrants of $2,119 as of December 31, 2022. As a result of the Business Combination, the Company’s common stock trades under the ticker symbol “LNZA” and its Public Warrants trade under the ticker symbol “LNZAW” on the Nasdaq Stock Market. Prior to the consummation of the Business Combination, the Company’s common shares were listed on Nasdaq Stock Market under the symbol “AMCI.”	Description of the Business LanzaTech Global, Inc., formerly known as AMCI Acquisition Corp. II (“AMCI”) prior to February 8, 2023 (the “Closing Date”) was incorporated as a Delaware corporation on January 28, 2021. On March 8, 2022, LanzaTech NZ, Inc. ("Legacy LanzaTech") entered into an Agreement and Plan of Merger (the “Merger Agreement”) with AMCI and AMCI Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of AMCI (“Merger Sub”). On February 8, 2023, Legacy LanzaTech completed its business combination with AMCI by which the Merger Sub merged with and into Legacy LanzaTech, with Legacy LanzaTech continuing as the surviving corporation and as a wholly owned subsidiary of AMCI (the “Business Combination”). The reporting entity is LanzaTech Global, Inc. and its subsidiaries (collectively referred to herein as “the Company” or "LanzaTech"). The Company is headquartered in Skokie, Illinois. The Company is a nature-based carbon refining company that transforms waste carbon into the chemical building blocks for consumer goods such as sustainable fuels, fabrics, and packaging that people use in their daily lives. The Company’s customers leverage its proven proprietary gas fermentation technology platform to convert certain feedstock, including waste carbon gases, into sustainable fuels and chemicals such as ethanol. The Company performs related services such as feasibility studies, engineering services, and research and development ("R&D") in biotechnology for commercial and government customers. The Company also purchases low carbon chemicals produced at customer facilities employing the Company’s technology and sells it under the brand name CarbonSmart. As of June 30, 2023, the Company’s partners operate three commercial-scale waste-to-gas ethanol plants in China, with others currently in development in various countries, compared to two commercial scale waste-to-gas ethanol plants in China as of June 30, 2022. The Company has reclassified its warrants on preferred shares as of December 31, 2022 from other accrued liabilities to warrants on the condensed consolidated balance sheet to conform with current period presentation. This reclassification resulted in a decrease to other accrued liabilities and corresponding increase to warrants of $2,119 as of December 31, 2022. As a result of the Business Combination, the Company’s common stock trades under the ticker symbol “LNZA” and its Public Warrants trade under the ticker symbol “LNZAW” on the Nasdaq Stock Market. Prior to the consummation of the Business Combination, the Company’s common shares were listed on Nasdaq Stock Market under the symbol “AMCI.”	Description of the Business LanzaTech Global, Inc., formerly known as AMCI Acquisition Corp. II (“AMCI”) prior to February 8, 2023 (the “Closing Date”) was incorporated as a Delaware corporation on January 28, 2021. On March 8, 2022, LanzaTech NZ, Inc. ("Legacy LanzaTech") entered into an Agreement and Plan of Merger (the “Merger Agreement”) with AMCI and AMCI Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of AMCI (“Merger Sub”). On February 8, 2023, Legacy LanzaTech completed its business combination with AMCI by which the Merger Sub merged with and into Legacy LanzaTech, with Legacy LanzaTech continuing as the surviving corporation and as a wholly owned subsidiary of AMCI (the “Business Combination”). The reporting entity is LanzaTech Global, Inc. and its subsidiaries (collectively referred to herein as “the Company” or "LanzaTech"). The Company is headquartered in Skokie, Illinois. The Company is a nature-based carbon refining company that transforms waste carbon into the chemical building blocks for consumer goods such as sustainable fuels, fabrics, and packaging that people use in their daily lives. The Company’s customers leverage its proven proprietary gas fermentation technology platform to convert certain feedstock, including waste carbon gases, into sustainable fuels and chemicals such as ethanol. The Company performs related services such as feasibility studies, engineering services, and research and development ("R&D") in biotechnology for commercial and government customers. The Company also purchases low carbon chemicals produced at customer facilities employing the Company’s technology and sells it under the brand name CarbonSmart. We have also been developing the capabilities to produce single cell protein as a primary product from our gas fermentation platform. As of September 30, 2023, licensees of the Company’s technology operate four commercial-scale waste-to-gas ethanol plants in China and started operations of another one in India, with others currently in development in various countries, compared to three commercial scale waste-to-gas ethanol plants in China as of September 30, 2022. The Company has reclassified its warrants on preferred shares as of December 31, 2022 from other accrued liabilities to warrants on the condensed consolidated balance sheet to conform with current period presentation. This reclassification resulted in a decrease to other accrued liabilities and corresponding increase to warrants of $2,119 as of December 31, 2022. As a result of the Business Combination, the Company’s common stock trades under the ticker symbol “LNZA” and its Public Warrants trade under the ticker symbol “LNZAW” on the Nasdaq Stock Market. Prior to the consummation of the Business Combination, the Company’s common shares were listed on Nasdaq Stock Market under the symbol “AMCI” and the Public Warrants were listed on the Nasdaq Stock Market under the symbol “AMCI-W”. Unless otherwise indicated, amounts in these financial statements are presented in thousands, except for share and per share amounts.	Description of the Business Effective October 28, 2021, LanzaTech New Zealand Limited filed a Certificate of Incorporation to form a new entity in Delaware, LanzaTech NZ, Inc. and migrated the country of domicile of its global headquarters from New Zealand to Delaware. The reporting entity is LanzaTech NZ, Inc. and its subsidiaries (collectively, “the Company” or "LanzaTech"). LanzaTech NZ, Inc. is a profit-oriented entity previously incorporated in New Zealand. The amendment of the Article of Incorporation was approved by the Board of Directors of LanzaTech and was effected by the filing of a Certificate of Incorporation with the Delaware Secretary of State. By using the Company’s proprietary fermentation technology, the Company’s customers can convert certain carbon-rich waste gases into fuels and chemicals.The Company licenses its technology to customers and sells biocatalysts used in the fermentation process. It also performs related services such as feasibility studies, engineering services, and research and development ("R&D") in biotechnology for commercial and government customers. The Company also purchases the low carbon ethanol produced at customer facilities employing the Company’s technology and sells it under the brand name CarbonSmart. As of December 31, 2022, the Company’s partners operate three commercial scale waste-to-gas ethanol plants in China, with others currently in development in various countries compared to two commercial scale waste-to-gas ethanol plants in Chain as of December 31, 2021. Proposed Merger On March 8, 2022, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with AMCI Acquisition Corp. II, a Delaware corporation (“AMCI”) and AMCI Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of AMCI (“Merger Sub”). Under the Merger Agreement, Merger Sub will merge with and into LanzaTech, with LanzaTech surviving the Merger as a wholly-owned subsidiary of AMCI (“the Business Combination”). In connection with the Business Combination, AMCI will be renamed LanzaTech Global, Inc. (“New LanzaTech”). AMCI has agreed to acquire all of the outstanding equity interests of LanzaTech at a valuation of approximately $1.8 billion. Completion of the transaction is subject to certain customary regulatory consents and approval by stockholders of AMCI and the Company. The Merger Agreement was amended on December 7, 2022, to provide for, among other things, (i) the inclusion of the aggregate net proceeds from each of the ArcelorMittal ("AM") Simple Agreement for Future Equity ("SAFE") Note and Brookfield SAFE in the Acquiror Closing Cash Amount, (ii) the reduction of the Minimum Closing Cash Condition from $250,000 to $230,000, (iii) the clarification that, to the extent that the Brookfield SAFE remains unexercised at Closing, it will be assumed by AMCI, remain in effect on the same terms and conditions as are in effect prior to the Closing and thereafter entitle the holder thereof to be issued shares of common stock in AMCI after the Closing, (iv) the clarification that, in the event that it becomes reasonably apparent to the parties that the Acquiror Closing Cash Amount will be less than the Minimum Closing Cash Condition, AMCI will use commercially reasonable efforts to enter into non-redemption agreements, or similar agreements, as may be necessary to satisfy the Minimum Closing Cash Condition, (v) the extension of the outside date applicable to the Closing from December 7, 2022 to February 28, 2023 and (vi) the elimination of LanzaTech's right to terminate the agreement in the event that we fail to, on or prior to July 7, 2022, enter into one or more additional subscription agreements or non-redemption agreements as a result of which the sum of the PIPE Investment Amount (including net proceeds under the AM SAFE Note to LanzaTech) and the aggregate number of shares of Class A common stock subject to non-redemption agreements multiplied by $10.00, minus certain transaction expenses and other liabilities at Closing, would be equal to at least the Minimum Closing Cash Condition. In connection with the Merger Agreement, AMCI entered into subscription agreements with certain investors pursuant to which AMCI agreed to issue and sell a private placement to close immediately prior to the Business Combination.The transaction closed on February 8, 2023. Please refer to Note 16, Subsequent Events. Reported shares and earnings per share available to common stockholders, prior to the Business Combination, have been retroactively restated to reflect the exchange ratio established in the Merger Agreement. The number of shares of preferred stock was also retroactively restated based on the exchange ratio.

Net Loss Per Share (Tables)

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Mar. 31, 2023

Jun. 30, 2023

Sep. 30, 2023

Dec. 31, 2022

Earnings Per Share [Abstract]

Schedule of calculation of basic and diluted net loss per share

The following table presents the calculation of basic and diluted net loss per share for the Company’s common stock (in thousands, except shares and per share amounts):


	Three Months Ended March 31,
	2023		2022
Numerator:
Net loss for basic and diluted earnings per common share	$	(63,312)	$	(16,778)
Unpaid cumulative dividends on preferred stock	(4,117)		(9,523)
Net loss allocated to common shareholders	$	(67,429)	$	(26,301)
Denominator:
Weighted-average shares used in calculating net loss per share, basic and diluted	116,530,963		9,219,499
Net loss per common share, basic and diluted(1)	$	(0.58)	$	(2.85)

__________________

(1)In periods in which the Company reports a net loss, all potential common shares are excluded from the calculation of diluted weighted average shares outstanding because of their anti-dilutive effect on loss per share.

The following table presents the calculation of basic and diluted net loss per share for the Company’s common stock (in thousands, except shares and per share amounts):


	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Numerator:
Net loss for basic and diluted earnings per common share	$	(26,786)	$	(15,929)	$	(90,098)	$	(32,707)
Unpaid cumulative dividends on preferred stock	—		(9,654)		(4,117)		(19,177)
Net loss allocated to common shareholders	$	(26,786)	$	(25,583)	$	(94,215)	$	(51,884)
Denominator:
Weighted-average shares used in calculating net loss per share, basic and diluted	195,537,601		9,222,214		156,472,730		9,222,870
Net loss per common share, basic and diluted(1)	$	(0.14)	$	(2.77)	$	(0.60)	$	(5.63)

__________________

The following table presents the calculation of basic and diluted net loss per share for the Company’s common stock (in thousands, except shares and per share amounts):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Numerator:
Net loss for basic and diluted earnings per common share	$	(25,326)	$	(22,267)	$	(115,424)	$	(54,974)
Unpaid cumulative dividends on preferred stock	—		(9,748)		(4,117)		(28,925)
Net loss allocated to common shareholders	$	(25,326)	$	(32,015)	$	(119,541)	(83,899)
Denominator:
Weighted-average shares used in calculating net loss per share, basic and diluted	195,869,537		9,229,781		169,797,443		9,223,884
Net loss per common share, basic and diluted(1)	$	(0.13)	$	(3.47)	$	(0.70)	$	(9.10)

__________________

(1)In periods in which the Company reports a net loss, all common stock equivalents are excluded from the calculation of diluted weighted average shares outstanding because of their anti-dilutive effect on loss per share.

The following table presents the calculation of basic and diluted net loss per share for the Company’s common stock (in thousands, except shares and per share amounts):


	Year Ended December 31,
	2022		2021
Numerator:
Net loss for basic and diluted earnings per common share	$	(76,356)	$	(46,689)
Unpaid cumulative dividends on preferred stock	(38,672)		(36,758)
Net loss allocated to common shareholders	$	(115,028)	$	(83,447)
Denominator:
Weighted-average shares used in calculating net loss per share, basic and diluted	9,302,080		8,585,999
Net loss per common share, basic and diluted(1)	$	(12.37)	$	(9.72)

__________________

(1)In periods in which the Company reports a net loss, all stock-based compensation awards are excluded from the calculation of diluted weighted average shares outstanding because of their anti-dilutive effect on earnings (loss) per share.

Schedule of antidilutive securities excluded from computation of earnings per share

As of March 31, 2023 and 2022, potential shares of common stock not included in the computation of loss per share because their effect would be antidilutive include the following:


	Three Months Ended March 31,
	2023	2022
Redeemable convertible preferred stock (if converted)	—	129,148,393
Options	14,355,066	16,790,437
RSAs	—	2,535,825
Brookfield SAFE	5,000,000	—
Warrants	16,657,686	985,278
Total	36,012,752	149,459,933

As of June 30, 2023 and 2022, potential shares of common stock not included in the computation of loss per share because their effect would be antidilutive include the following:


	June 30,
	2023	2022
Redeemable convertible preferred stock (if converted)	—	129,148,393
Options	17,423,238	16,633,612
RSUs	6,901,360	—
RSAs	—	2,535,825
Brookfield SAFE	5,000,000	—
Warrants	16,657,686	985,278
Total	45,982,284	149,303,108

As of September 30, 2023 and 2022, common stock equivalents not included in the computation of loss per share because their effect would be antidilutive include the following:


	September 30,
	2023	2022
Redeemable convertible preferred stock (if converted)	—	129,148,393
Options	17,021,827	16,584,305
RSUs	7,042,901	—
RSAs	—	2,535,825
Brookfield SAFE	5,000,000	—
Warrants	16,657,686	985,278
Total	45,722,414	149,253,801

As of December 31, 2022 and 2021, potential shares of common stock not included in the computation of loss per share because their effect would be antidilutive include the following:


	Year Ended December 31,
	2022	2021
Redeemable convertible preferred stock (if converted)	129,148,393	129,148,393
Options	14,661,253	16,821,596
RSAs	2,535,825	2,535,825
Warrants	985,278	985,278
Total	147,330,749	149,491,092

Revenues (Tables)

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Mar. 31, 2023

Jun. 30, 2023

Sep. 30, 2023

Dec. 31, 2022

Revenue from Contract with Customer [Abstract]

Disaggregated revenue

The following table presents disaggregated revenue in the following categories (in thousands):


	Three Months Ended March 31,
	2023		2022
Contract Types:
Licensing	$	553	$	540
Engineering and other services	5,801		4,308
Biorefining: carbon capture and transformation revenue	$	6,354	$	4,848

Joint development agreements	2,036		1,027
Contract research	1,256		1,242
Joint development and Contract research revenue	$	3,292	$	2,269

CarbonSmart (tangible product)	—		740

Total Revenue	$	9,646	$	7,857

The following table presents disaggregation of the Company’s revenues by customer location for the three months ended March 31, 2023 and 2022 (in thousands):


	Three Months Ended March 31,
	2023		2022
North America	$	4,232	$	4,039
Europe, Middle East, Africa (EMEA)	4,711		2,823
Asia	50		410
Australia	653		585
Total Revenue	$	9,646	$	7,857

The following table presents disaggregated revenue in the following categories:


	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Contract Types:
Licensing	$	815	$	540	$	1,369	$	1,080
Engineering and other services	8,878		5,367		14,678		9,675
Biorefining revenue	$	9,693	$	5,907	$	16,047	$	10,755

Joint development agreements	1,080		1,420		3,116		2,447
Contract research	1,137		1,543		2,393		2,785
Joint development and contract research revenue	$	2,217	$	2,963	$	5,509	$	5,232

CarbonSmart (tangible product)	1,007		982		1,007		1,722

Total Revenue	$	12,917	$	9,852	$	22,563	$	17,709

The following table presents revenue from partners in collaborative arrangements, which is included in the table above within Joint development agreements.


	Three Months Ended June 30,			Six Months Ended June 30,
	2023	2022		2023	2022
Revenue from partners in collaborative agreements	462	$	973	1,550	973

The following table presents revenue from related parties, which is included in the table above within both Licensing and Engineering and other services.


	Three Months Ended June 30,		Six Months Ended June 30,
	2023	2022	2023	2022
Revenue from related parties, included within Licensing	815	540	1,369	1,080
Revenue from related parties, included within Engineering and other services	261	218	680	332

The following table presents disaggregation of the Company’s revenues by customer location for the three and six months ended June 30, 2023 and 2022 (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
North America	$	2,314	$	3,910	$	6,547	$	7,949
Europe, Middle East, Africa (EMEA)	9,646		3,784		14,356		6,607
Asia	418		1,853		468		2,263
Australia	539		305		1,192		890
Total Revenue	$	12,917	$	9,852	$	22,563	$	17,709

The following table presents disaggregated revenue in the following categories (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Contract Types:
Licensing	$	1,515	$	540	$	2,902	$	1,620
Engineering and other services	10,912		2,955		25,572		12,630
Biorefining revenue	$	12,427	$	3,495	$	28,474	$	14,250

Joint development agreements	1,933		1,571		5,049		4,018
Contract research	2,987		1,315		5,380		4,100
Joint development and contract research revenue	$	4,920	$	2,886	$	10,429	$	8,118

CarbonSmart (tangible product)	2,258		1,691		3,265		3,413

Total Revenue	$	19,605	$	8,072	$	42,168	$	25,781

The following table presents revenue from partners in collaborative arrangements, which is included in the table above within Joint development agreements (in thousands).


	Three Months Ended September 30,			Nine Months Ended September 30,
	2023	2022		2023	2022
Revenue from partners in collaborative agreements	1,566	$	760	3,116	1,733

The following table presents disaggregation of the Company’s revenues by customer location for the three and nine months ended September 30, 2023 and 2022 (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
North America	$	4,847	$	4,412	$	11,309	$	12,361
Europe, Middle East, Africa (EMEA)	10,732		1,287		25,088		7,894
Asia	2,137		1,888		2,690		4,151
Australia	1,889		485		3,081		1,375
Total Revenue	$	19,605	$	8,072	$	42,168	$	25,781

The following table presents disaggregated revenue in the following categories (in thousands):


	Year Ended December 31,
	2022		2021
Contract Types:
Licensing	2,160		2,025
Engineering and other services	19,061		9,539
Carbon capture and utilization revenue	21,221		11,564

Joint development agreements	6,021		11,700
Other contract research	6,101		2,197
Research and development revenue	12,122		13,897

CarbonSmart (tangible product)	4,000		—

Total Revenue	$	37,343	$	25,461

The following table presents disaggregation of the Company’s revenues by customer location for the years ended December 31, 2022 and 2021 (in thousands):


	Year Ended December 31,
	2022		2021
North America	$	17,149	$	15,825
Europe, Middle East, Africa (EMEA)	11,500		7,522
Asia	5,752		1,477
Australia	2,942		637
Total Revenue	$	37,343	$	25,461

Changes in contract assets and liabilities

The following table provides changes in contract assets and liabilities (in thousands):


	Current Contract Assets		Current Contract Liabilities		Non-current Contract Liabilities
Balance as of January 1, 2023	$	18,000	$	3,101	$	10,760
Additions to unbilled accounts receivable	11,241		—		—

Unbilled accounts receivable recognized in trade receivables	(10,833)		—		—
Increase on revaluation on currency	52		—		83
Reclassification from long-term to short-term	—		672		(672)
Reclassification to revenue as a result of performance obligations satisfied	—		(731)		—
Balance as of March 31, 2023	$	18,460	$	3,042	$	10,171

The following table provides changes in contract assets and liabilities (in thousands):


	Current Contract Assets		Current Contract Liabilities		Non-current Contract Liabilities
Balance as of January 1, 2023	$	18,000	$	3,101	$	10,760
Additions to unbilled accounts receivable	23,684		—		—
Increases due to cash received	—		515		—
Unbilled accounts receivable recognized in trade receivables	(20,016)		—		—
Increase on revaluation on currency	108		—		64
Reclassification from long-term to short-term	—		1,344		(1,344)
Reclassification to revenue as a result of performance obligations satisfied	—		(2,008)		—
Balance as of June 30, 2023	$	21,776	$	2,952	$	9,480

The following table provides changes in contract assets and liabilities (in thousands):


	Current Contract Assets		Current Contract Liabilities		Non-current Contract Liabilities
Balance as of January 1, 2023	$	18,000	$	3,101	$	10,760
Additions to unbilled accounts receivable	43,901		—		—
Increases due to cash received	—		4,486		—
Unbilled accounts receivable recognized in trade receivables	(37,413)		—		—
Decrease on revaluation on currency	(175)		—		(73)
Reclassification from long-term to short-term	—		2,016		(2,016)
Reclassification to revenue as a result of performance obligations satisfied	—		(6,471)		—
Balance as of September 30, 2023	$	24,313	$	3,132	$	8,671

The following table provides changes in contract assets and liabilities (in thousands):


	Current Contract Assets		Current Contract Liabilities		Non-current Contract Liabilities
Balance as of January 1, 2021	$	6,186	$	5,480	$	11,291
Additions to unbilled accounts receivable	8,516		—		—
Increases due to cash received	—		20		5,690
Unbilled accounts receivable recognized in trade receivables	(3,002)		—		—
Reclassification from long-term to short-term	—		3,080		(3,080)
Reclassification to revenue as a result of performance obligations satisfied	—		(5,104)		—
Balance as of December 31, 2021	11,700		3,476		13,901
Additions to unbilled accounts receivable	30,308		—		—
Increases due to cash received	—		996		37
Unbilled accounts receivable recognized in trade receivables	(24,062)		—		—
Change on revaluation of currency	54		—		(341)
Reclassification from non-current to current contract liabilities	—		2,837		(2,837)
Reclassification to revenue as a result of performance obligations satisfied	—		(4,208)		—
Balance as of December 31, 2022	$	18,000	$	3,101	$	10,760

Remaining performance obligations

Remaining performance obligations consisted of the following (in thousands):


	As of
	March 31, 2023		December 31, 2022
Current	$	3,042	$	3,101
Non-current	10,171		10,760
Total	$	13,213	$	13,861

Remaining performance obligations consisted of the following (in thousands):


	As of
	June 30, 2023		December 31, 2022
Current	$	2,952	$	3,101
Non-current	9,480		10,760
Total	$	12,432	$	13,861

Remaining performance obligations consisted of the following (in thousands):


	As of
	September 30, 2023		December 31, 2022
Current	$	3,132	$	3,101
Non-current	8,671		10,760
Total	$	11,803	$	13,861

Remaining performance obligations consisted of the following (in thousands):


	As of
	December 31, 2022		December 31, 2021
Current	$	3,101	$	3,476
Non-current	10,760		13,901
Total	$	13,861	$	17,377

Reverse Recapitalization

3 Months Ended

6 Months Ended

9 Months Ended

Mar. 31, 2023

Jun. 30, 2023

Sep. 30, 2023

Reverse Recapitalization [Abstract]

Reverse Recapitalization

On February 8, 2023, Legacy LanzaTech and AMCI consummated the merger contemplated by the Merger Agreement (see Note 1 - Description of the Business).

Immediately following the Business Combination, there were 196,222,737 shares of common stock outstanding with a par value of $0.0001. Additionally, there were outstanding warrants to purchase 12,574,200 shares of common stock.

The Business Combination was accounted for as a reverse recapitalization in accordance with US GAAP. Under this method, while AMCI was the legal acquirer, it has been treated as the “acquired” company for financial reporting purposes. Accordingly, the Business Combination was treated as the equivalent of pre-combination Legacy LanzaTech issuing stock for the net assets of AMCI, accompanied by a recapitalization. The net assets of AMCI were stated at historical cost, with no goodwill or other intangible assets recorded. Operations prior to the Business Combination are those of pre-combination Legacy LanzaTech. Reported shares and earnings per share available to holders of the Company’s common stock and preferred shares, prior to the Business Combination, have been retroactively restated to reflect the exchange ratio established in the Business Combination (approximately one pre-combination Legacy LanzaTech share to 4.3747 of the Company’s shares).

Upon closing of the Business Combination, the shareholders of AMCI, including AMCI founders, were issued 10,398,374 shares of common stock of the Company. In connection with the closing, holders of 8,351,626 shares of common stock of AMCI were redeemed at a price per share of approximately $10.16. In connection with the Closing, 18,500,000 shares of common stock of the Company were issued to PIPE investors. 15,500,000 of those shares were issued at a price per share of $10.00. The remaining 3,000,000 shares were issued upon conversion of the AM SAFE liability. The Company incurred $7,223 in transaction costs relating to the Business Combination and recorded those costs against additional paid-in capital in the condensed consolidated balance sheet.

The number of shares of Class A common stock issued and outstanding immediately following the consummation of the Business Combination and PIPE financing were:


	Shares	Percentage
Legacy LanzaTech shares	167,324,363	85.3	%
Public stockholders	10,398,374	5.3	%
PIPE shares	18,500,000	9.4	%
Total	196,222,737	100	%

The following table reconciles the elements of the Business Combination and PIPE financing to the condensed consolidated statement of cash flows for the three months ended March 31, 2023:


	Recapitalization
Cash - AMCI trust account1	$	64,090
Cash - PIPE financing	155,000
Less: Transaction costs allocated to equity and paid in the three months ended March 31, 2023	(5,709)
Effect of the Business Combination and PIPE financing	$	213,381

__________________

(1)The cash from the AMCI trust account is net of redemptions and the payment of pre-combination AMCI expenses.


	Recapitalization
Cash - AMCI trust account	$	64,090
Public Warrants and Private Placement Warrants recorded on the Closing Date	(4,624)
Cash - PIPE financing	155,000
Conversion of the AM SAFE	29,730
Transaction costs allocated to equity	(7,223)
	$	236,973
Less: par value of shares held by PIPE investors and public stockholders	(3)
Total additional paid-in capital from recapitalization	$	236,970

Reverse Recapitalization

On February 8, 2023, Legacy LanzaTech and AMCI consummated the merger contemplated by the Merger Agreement (see Note 1 - Description of the Business).

The number of shares of Class A common stock issued and outstanding immediately following the consummation of the Business Combination and PIPE financing were:


	Shares	Percentage
Legacy LanzaTech shares	167,324,363	85.3	%
Public stockholders	10,398,374	5.3	%
PIPE shares	18,500,000	9.4	%
Total	196,222,737	100	%

The following table reconciles the elements of the Business Combination and PIPE financing to the condensed consolidated statement of cash flows:


	Recapitalization
Cash - AMCI trust account1	$	64,090
Cash - PIPE financing	155,000
Less: Transaction costs allocated to equity	(5,709)
Effect of the Business Combination and PIPE financing	$	213,381

__________________

(1)The cash from the AMCI trust account is net of redemptions and the payment of pre-combination AMCI expenses.


	Recapitalization
Cash - AMCI trust account	$	64,090
Public Warrants and Private Placement Warrants recorded on the Closing Date	(4,624)
Cash - PIPE financing	155,000
Conversion of the AM SAFE	29,730
Transaction costs allocated to equity	(7,223)
	$	236,973
Less: par value of shares held by PIPE investors and public stockholders	(3)
Total additional paid-in capital from recapitalization	$	236,970

Reverse Recapitalization

On February 8, 2023, Legacy LanzaTech and AMCI consummated the merger contemplated by the Merger Agreement (see Note 1 - Description of the Business).

The number of shares of Class A common stock issued and outstanding immediately following the consummation of the Business Combination and PIPE financing were:


	Shares	Percentage
Legacy LanzaTech shares	167,324,363	85.3	%
Public stockholders	10,398,374	5.3	%
PIPE shares	18,500,000	9.4	%
Total	196,222,737	100	%

The following table reconciles the elements of the Business Combination and PIPE financing to the condensed consolidated statement of cash flows:


	Recapitalization
Cash - AMCI trust account1	$	64,090
Cash - PIPE financing	155,000
Less: Transaction costs allocated to equity	(5,709)
Effect of the Business Combination and PIPE financing	$	213,381

__________________

(1)The cash from the AMCI trust account is net of redemptions and the payment of pre-combination AMCI expenses.


	Recapitalization
Cash - AMCI trust account	$	64,090
Public Warrants and Private Placement Warrants recorded on the Closing Date	(4,624)
Cash - PIPE financing	155,000
Conversion of the AM SAFE	29,730
Transaction costs allocated to equity	(7,223)
	$	236,973
Less: par value of shares held by PIPE investors and public stockholders	(3)
Total additional paid-in capital from recapitalization	$	236,970

Reverse Recapitalization - Narrative (Details) $ / shares in Units, $ in Thousands	Feb. 08, 2023 USD ($) $ / shares shares	Sep. 30, 2023 $ / shares shares	Jun. 30, 2023 $ / shares shares	Mar. 31, 2023 $ / shares shares	Dec. 31, 2022 $ / shares shares	Dec. 31, 2021 $ / shares shares
Schedule Of Reverse Recapitalization [Line Items]
Common shares, shares authorized (in shares)	196,222,737	400,000,000	400,000,000	400,000,000	158,918,093	158,918,093
Common shares, par value (in dollars per share) \| $ / shares	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Warrants outstanding (in shares)	12,574,200
Recapitalization exchange ratio	4.3747
Shares issued in transaction (in shares)	196,222,737
Recapitalization costs \| $	$ 7,223
Priced At $10.00 Per Share
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	15,500,000
Stock repurchased (usd per share) \| $ / shares	$ 10.00
AMCI
Schedule Of Reverse Recapitalization [Line Items]
Stock repurchased (in shares)	8,351,626
Stock repurchased (usd per share) \| $ / shares	$ 10.16
Public Stockholders
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	10,398,374
PIPE Shares
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	18,500,000
AM SAFE Liability
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	3,000,000

Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2022

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Other Current Assets

As of December 31, 2022 and 2021 other current assets consisted of the following (in thousands):


	As of
	December 31, 2022		December 31, 2021
Materials and supplies	$	4,164	$	2,900
Prepaid assets	2,833		1,503
Other	4,160		1,376
	$	11,157	$	5,779

Commitments and Contingencies

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Mar. 31, 2023

Jun. 30, 2023

Sep. 30, 2023

Dec. 31, 2022

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Litigation

The Company may be involved in legal proceedings and exposed to potential claims in the normal course of business. As of March 31, 2023 and December 31, 2022, the Company does not have any reasonably possible or probable losses from such claims.

Commitments

In November 2022, the Company entered into a Note Purchase Agreement. Refer to Note 13 - Related Party Transactions, for more information.

In November 2022, the Company entered into a lease for real estate to expand its headquarters in Skokie, Illinois, commencing on May 1, 2024. As the lease has not commenced, it is not recorded on the condensed consolidated balance sheet. Total lease payments in 2024, 2025 and 2026 for this lease are expected to be $3,287.

Commitments and Contingencies

Litigation

The Company may be involved in legal proceedings and exposed to potential claims in the normal course of business. As of June 30, 2023 and December 31, 2022, the Company does not have any reasonably possible or probable losses from such claims.

Commitments

Commitments and Contingencies

Litigation

The Company may be involved in legal proceedings and exposed to potential claims in the normal course of business. As of September 30, 2023 and December 31, 2022, the Company does not have any reasonably possible or probable losses from such claims.

Commitments

Commitments and Contingencies

Litigation

The Company may be involved in legal proceedings and exposed to potential claims in the normal course of business. As of December 31, 2022 and December 31, 2021, the Company does not have any reasonably possible or probable losses from such claims.

Commitments

In November 2022, the Company entered into a Note Purchase Agreement. Refer to Note 12, Related Party Transactions, for more information.

In November 2022, the Company entered into a lease for real estate to expand its headquarters in Skokie, Illinois, commencing on May 1, 2024. As the lease has not commenced, it is not part of the disclosures in Note 15, Leases. The following table represents the future lease payments for this lease (in thousands):


Year ending December 31,
2023						—
2024						642
2025						1,303
2026						1,342
2027						—
Thereafter						—
Total cash payments						3,287

Stock-Based Compensation - Stock Option Award Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2023	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Beginning balance (in shares)	17,418,000	14,355,000	14,661,000	14,661,000	14,661,000	16,822,000
Exercised (in shares)			(472,000)	(699,000)	(1,075,000)	(1,968,000)
Granted (in shares)			259,000	3,556,000	3,556,000
Cancelled/forfeited (in shares)			(93,000)	(100,000)	(120,000)	(191,000)
Expired (in shares)						(2,000)
Ending balance (in shares)	17,022,000	17,418,000	14,355,000	17,418,000	17,022,000	14,661,000	16,822,000
Vested and expected to vest (in shares)	17,022,000	17,418,000	14,355,000	17,418,000	17,022,000	14,661,000	16,822,000
Exercisable (in shares)	11,208,000	11,240,000	11,303,000	11,240,000	11,208,000	11,203,000	10,845,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Beginning balance (usd per share)	$ 1.94	$ 1.63	$ 1.48	$ 1.48	$ 1.48	$ 1.50
Exercised (usd per share)			1.59	1.55	1.53	1.60
Granted (usd per share)			9.97	3.77	3.77
Cancelled/forfeited (usd per share)			1,180	1,300	1.76	2,200
Expired (usd per share)						1.52
Ending balance (usd per share)	1.95	1.94	1.63	1.94	1.95	1.48	$ 1.50
Vested and expecting to vest (usd per share)	1.95	1.94	1.63	1.94	1.95	1.48	1.50
Exercisable (usd per share)	$ 1.48	$ 1.48	$ 1.44	$ 1.48	$ 1.48	$ 1.44	$ 1.44
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding, Weighted average remaining contractual term			5 years 9 months 21 days	6 years 4 months 28 days	6 years 2 months 15 days	5 years 9 months 18 days	6 years 1 month 28 days
Vested and expecting, Weighted average remaining contractual term			5 years 9 months 21 days	6 years 4 months 28 days	6 years 2 months 15 days	5 years 9 months 18 days	6 years 1 month 28 days
Exercisable, Weighted average remaining contractual term			5 years 3 months	5 years 1 month 9 days	4 years 11 months 23 days	5 years 1 month 24 days	4 years 10 months 6 days
Outstanding, Aggregate intrinsic value	$ 47,653	$ 85,948	$ 33,903	$ 85,948	$ 47,653	$ 58,565	$ 27,796
Vested and expecting to vest, Aggregate intrinsic value	47,653	85,948	33,903	85,948	47,653	58,565	27,796
Exercisable, Aggregate intrinsic value	$ 36,026	$ 60,321	27,650	60,321	$ 36,026	45,204	$ 18,499
Granted, Aggregate intrinsic value			34	594
Exercised, Aggregate intrinsic value			1,827	2,337		3,520
Cancelled/forfeited, Aggregate intrinsic value			$ 673	$ 693		218
Expired, Aggregate intrinsic value						$ 4
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term			0 years	0 years	0 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercised, Weighted Average Remaining Contractual Term			0 years	0 years	0 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Canceled And Forfeited, Weighted Average Remaining Contractual Term			0 years	0 years	0 years

Summary of Significant Accounting Policies - Going Concern (Details)				3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Feb. 08, 2023 USD ($) shares	Feb. 03, 2023 tradingDay consecutiveTradingDay financial_instrument $ / shares	Mar. 08, 2022 USD ($)	Sep. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 07, 2022 $ / shares
Accounting Policies [Abstract]
Voting rights stock	85.30%
Cash and cash equivalents				$ 91,397,000	$ 110,719,000	$ 145,118,000				$ 110,719,000		$ 91,397,000		$ 83,045,000	$ 128,318,000
Accumulated deficit				(813,198,000)	(787,872,000)	(761,086,000)				(787,872,000)		(813,198,000)		(456,245,000)	(379,889,000)
Net cash used in operating activities						(33,810,000)			$ (18,118,000)	(59,116,000)	$ (42,505,000)	(81,565,000)	$ (71,336,000)	(84,703,000)	(42,591,000)
Net income (loss)				(25,326,000)	(26,786,000)	(63,312,000)	$ (22,267,000)	$ (15,929,000)	$ (16,778,000)	(90,098,000)	$ (32,707,000)	(115,424,000)	$ (54,974,000)	(76,356,000)	(46,689,000)
Subsequent Event [Line Items]
Proceeds from divestiture of businesses, net of cash divested	$ 153,285,000					153,285,000
Shares issued in transaction (in shares) \| shares	196,222,737
Sale of stock price (usd per share) \| $ / shares																$ 10.00
Purchase price			$ 1,800,000,000
Trigger share price (usd per share) \| $ / shares		$ 3.00
Maturity Date Acceleration, Trading Days \| tradingDay		50
Maturity Date Acceleration, Consecutive Trading Days \| consecutiveTradingDay		60
Number of Freestanding Financial Instruments \| financial_instrument		3
Additional paid-in capital				939,868,000	936,157,000	927,641,000				936,157,000		939,868,000		24,782,000	$ 21,710,000
FPA Put Option liability				$ 38,092,000	$ 26,743,000	$ 44,593,000				$ 26,743,000		$ 38,092,000		$ 0
Subsequent Event
Subsequent Event [Line Items]
Proceeds from divestiture of businesses, net of cash divested	$ 153,042,000

Revenues - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Revenue from collaborative arrangements	$ 1,566	$ 462	$ 1,088	$ 760	$ 973	$ 0	$ 1,550	$ 973	$ 3,116	$ 1,733	$ 2,575	$ 3,337
Revenues	19,605	12,917	9,646	8,072	9,852	7,857	22,563	17,709	42,168	25,781	37,343	25,461
Billed accounts receivable, net of allowance	10,085	7,766	9,277				7,766		10,085		11,695	2,878
Related Party
Disaggregation of Revenue [Line Items]
Revenues			973			654
Licensing
Disaggregation of Revenue [Line Items]
Revenues	1,515	815	553	540	540	540	1,369	1,080	2,902	1,620	2,160	2,025
Licensing \| Related Party
Disaggregation of Revenue [Line Items]
Revenues	1,515	815		540	540		1,369	1,080	2,902	1,620
Engineering and other services
Disaggregation of Revenue [Line Items]
Revenues	10,912	8,878	5,801	2,955	5,367	4,308	14,678	9,675	25,572	12,630	19,061	9,539
Engineering and other services \| Related Party
Disaggregation of Revenue [Line Items]
Revenues	$ 104	$ 261	$ 420	$ 164	$ 218	$ 114	$ 680	$ 332	$ 766	$ 496	$ 810	$ 1,228

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

+ Details

Related Party Transactions (Details) - USD ($)	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
Related Party Transactions (Details) - USD ($)	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Feb. 08, 2023	Feb. 03, 2023	Nov. 09, 2022
Related Party Transaction [Line Items]
Investments	$ 24,584,000	$ 25,154,000	$ 24,825,000				$ 25,154,000		$ 24,584,000		$ 25,551,000	$ 24,752,000
Revenues	19,605,000	12,917,000	9,646,000	$ 8,072,000	$ 9,852,000	$ 7,857,000	22,563,000	$ 17,709,000	42,168,000	$ 25,781,000	$ 37,343,000	$ 25,461,000
Notes receivable, commitment to purchase															$ 5,500,000
Sale of private placement warrants (in shares)											985,278	985,278	985,278	10,000,000	316,250
Class of warrant or right, exercise price of warrants or rights (in dollars per share)											$ 3.36	$ 4.56	$ 9.91		$ 0.01
Senior Secured Notes Receivable
Related Party Transaction [Line Items]
Approval of note holders to amend agreement															66.66%
One Tranche Of Notes
Related Party Transaction [Line Items]
Amount of Notes purchased															$ 10,000,000
Sale of private placement warrants (in shares)															575,000
Class of warrant or right, exercise price of warrants or rights (in dollars per share)															$ 0.0575
Warrants term															3 years
LanzaJet Freedom Pines Fuels LLC
Related Party Transaction [Line Items]
Notes receivable, aggregate principal amount															$ 147,000,000
LanzaJet Freedom Pines Fuels LLC \| Senior Secured Notes Receivable
Related Party Transaction [Line Items]
Notes receivable, aggregate principal amount															$ 113,500,000
Line of credit facility, interest rate															6.00%
LanzaJet Freedom Pines Fuels LLC \| Subordinated Secured Notes Receivable
Related Party Transaction [Line Items]
Notes receivable, aggregate principal amount															$ 33,500,000
Line of credit facility, interest rate															6.00%
Related Party Transition Services Agreement \| Equity Method Investee
Related Party Transaction [Line Items]
Revenues	97,000	67,000	45,000	23,000	58,000	67,000	112,000	125,000	209,000	148,000	$ 185,000	$ 495,000
Related Party Investment Agreement \| Equity Method Investee
Related Party Transaction [Line Items]
Revenues	6,000	102,000	338,000	39,000	108,000	23,000	440,000	131,000	446,000	170,000		428,000
Related Party Supply Agreement \| Equity Method Investee
Related Party Transaction [Line Items]
Revenues	0	75,000	0	87,000	46,000	18,000	75,000	64,000	75,000	151,000	289,000	282,000
Related party transaction	199,000	164,000	$ 126,000	630,000	137,000	$ 249,000	414,000	263,000	612,000	893,000	$ 645,000	$ 1,223,000
Related Party Licensing Agreement \| Equity Method Investee
Related Party Transaction [Line Items]
Revenues	$ 951,000	$ 249,000		$ 0	$ 0		$ 249,000	$ 0	$ 1,200,000	$ 0

Commitment and Contingencies (Tables)

12 Months Ended

Dec. 31, 2022

Commitments and Contingencies Disclosure [Abstract]

Lessee, Operating Lease, Liability, Maturity

As the lease has not commenced, it is not part of the disclosures in Note 15, Leases. The following table represents the future lease payments for this lease (in thousands):


Year ending December 31,
2023						—
2024						642
2025						1,303
2026						1,342
2027						—
Thereafter						—
Total cash payments						3,287

As of December 31, 2022, lease payments for operating leases for the Company’s office facility and laboratories are shown below (in thousands):


Year ending December 31,
2023	$	1,302
2024	2,602
2025	2,347
2026	2,418
2027	—
Thereafter	—
Total lease payments	$	8,669
Less: imputed interest	1,256
Total lease liabilities	$	7,413

Investments

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Mar. 31, 2023

Jun. 30, 2023

Sep. 30, 2023

Dec. 31, 2022

Equity Method Investments and Joint Ventures [Abstract]

Investments

Debt securities

The Company has held-to-maturity securities consisting of U.S. Treasury securities. As these investments were purchased on March 31, 2023, the amortized cost equals the estimated fair value. There are no unrealized gains and losses. All held-to-maturity securities have contractual maturities due in one year or less. The Company regularly reviews held-to-maturity securities for declines in fair values that are determined to be credit related. As of March 31, 2023, the Company did not have an allowance for credit losses related to held-to-maturity securities as they are guaranteed by the U.S. government.

Equity investments

The Company’s equity investments consisted of the following (in thousands):


	As of
	March 31, 2023		December 31, 2022
Equity Method Investment in LanzaJet	$	9,835	$	10,561
Equity Security Investment in SGLT	$	14,990	14,990
Total Investment	$	24,825	$	25,551

LanzaJet

On May 13, 2020, the Company contributed $15,000 in intellectual property in exchange for a 37.5% interest (“Original Interest”) of LanzaJet, Inc. (“LanzaJet”) in connection with an investment agreement (“Investment Agreement”). The Company accounts for the transaction as a revenue transaction with a customer under ASC 606. The licensing and technical support services provided are recognized as a single combined performance obligation satisfied over the expected period of those services, beginning May 2020 through December 2025. During the three months ended March 31, 2023 and 2022, the Company has recognized revenue from this arrangement of $553 and $540 respectively, net of intra-entity profit elimination, and has recorded deferred revenue of $7,390 and $8,062, as of March 31, 2023 and December 31, 2022, respectively. Intra-entity profits related to revenue contracts with LanzaJet are $118 and $132 as of March 31, 2023, and 2022, respectively. Intra-entity profit is amortized over the 15-year amortization period through 2034.

Between February 1, 2021 and April 4, 2021, LanzaJet closed two additional rounds of investment which reduced the Company's Original Interest to approximately 25%. The Company retained its contingent right to receive additional interest in LanzaJet of up to 45 million shares for no additional consideration.

The carrying value of our equity method investment in LanzaJet as of March 31, 2023 and December 31, 2022 was approximately $3,800 and $3,700 less than our proportionate share of our equity method investees’ book values, respectively. The basis differences are largely the result of a difference in the timing of recognition of variable consideration to which we may become entitled in exchange for our contribution of intellectual property to LanzaJet. The variable consideration we may receive will be in the form of additional ownership interests and the majority of the basis difference will reverse in connection with recognition of that variable consideration.

In connection with a sublicense agreement to LanzaJet under our license agreement with Battelle Memorial Institute (“Battelle”), LanzaTech remains responsible for any failure by LanzaJet to pay royalties due to Battelle. The fair value of LanzaTech’s obligation under this guarantee was immaterial as of March 31, 2023 and December 31, 2022.

SGLT

On September 28, 2011, the Company contributed RMB 25,800 (approx. $4,000) in intellectual property in exchange for 30% of the registered capital of Beijing Shougang LanzaTech Technology Co., LTD (“SGLT”).

As of December 31, 2022, the Company’s interest in SGLT’s registered capital is approximately 9.31% as a result of the admittance of new investors during the year. As of September 30, 2022, the Company no longer had significant influence over the operating and financial policies of SGLT due to the significant and sustained decrease in SGLT's technological dependence on LanzaTech. As such, the Company ceased applying the equity method and from October 1, 2022 and forward, the Company accounts for its investment in equity security of SGLT using the alternative measurement principals as permitted under ASC 321, Investments - Equity Securities, because SGLT's fair value is not readily determinable. For the three months ended March 31, 2023, there was no change in the value of the investment in SGLT.

As of March 31, 2023 and December 31, 2022, there were no impairments of equity method investees. During the three months ended March 31, 2023 and 2022, the Company received no dividends from equity method

investments. See Note 13 - Related Party Transactions, for information on revenues, accounts receivable, contract assets and purchases and open accounts payable with equity method investment.

Investments

Debt securities

The Company has held-to-maturity securities consisting of U.S. Treasury securities. All held-to-maturity securities have contractual maturities due in one year or less.


	As of
	June 30, 2023		March 31, 2023
Amortized cost, net of accrued interest	$	49,611	$	49,103
Accrued interest	93		30
Total	$	49,704	$	49,133

Aggregate Fair Value	49,593		49,098
Gross unrealized gains	5		1
Gross unrealized losses	(23)		(6)

The Company regularly reviews held-to-maturity securities for declines in fair values that are determined to be credit related. As of June 30, 2023, the Company did not have an allowance for credit losses related to held-to-maturity securities as they are guaranteed by the U.S. government.

Equity investments

The Company’s equity investments consisted of the following (in thousands):


	As of
	June 30, 2023		December 31, 2022
Equity Method Investment in LanzaJet	$	10,164	$	10,561
Equity Security Investment in SGLT	14,990		14,990
Total Investment	$	25,154	$	25,551

LanzaJet

On May 13, 2020, the Company contributed $15,000 in intellectual property in exchange for a 37.5% interest (“Original Interest”) of LanzaJet, Inc. (“LanzaJet”) in connection with an investment agreement (“Investment Agreement”). The Company accounts for the transaction as a revenue transaction with a customer under ASC 606. The licensing and technical support services provided are recognized as a single combined performance obligation satisfied over the expected period of those services, beginning May 2020 through December 2025. During the three months ended June 30, 2023 and 2022, the Company recognized revenue from this arrangement of $565 and $540 respectively, net of intra-entity profit elimination. During the six months ended June 30, 2023 and June 30, 2022, the Company recognized revenue from this arrangement of $1,119 and $1,080 respectively, net of intra-entity profit elimination and has associated deferred revenue of $6,719 and $8,062, as of June 30, 2023 and December 31, 2022, respectively. Intra-entity profits related to revenue contracts with LanzaJet are $89 and $132 for the three months ended June 30, 2023, and 2022, respectively. Intra-entity profits related to revenue contracts with LanzaJet are $206 and $263 for the six months ended June 30, 2023 and 2022, respectively. Intra-entity profits are amortized over a 15-year period through 2034.

Between February 1, 2021 and April 4, 2021, LanzaJet closed two additional rounds of investment which reduced the Company's Original Interest to approximately 25%. In connection with the LanzaJet Note Purchase Agreement as described in Note 12 - Related Party Transactions, LanzaJet issued warrants that are exercisable for $0.01 by the holder when the related funds are drawn by LanzaJet. The warrants held by LanzaTech and other lenders meet the accounting criteria for in-substance common stock at the time the related note commitment is drawn by LanzaJet and the warrants become exercisable. As of June 30, 2023, LanzaTech’s ownership was diluted

to approximately 23.15% because LanzaTech received proportionally fewer warrants than the other investors. The Company recorded a gain on dilution of $502. LanzaTech’s ownership is subject to further dilution to approximately 22.38% if LanzaJet draws additional funds committed in the LanzaJet Note Purchase Agreement and the remaining warrants become exercisable by the holders. The Company retained its contingent right to receive additional interest in LanzaJet of up to 45 million shares for no additional consideration.

The carrying value of our equity method investment in LanzaJet as of June 30, 2023 and December 31, 2022 was approximately $2,100 and $3,700 less than our proportionate share of our equity method investees’ book values, respectively. The basis differences are largely the result of a difference in the timing of recognition of variable consideration to which we may become entitled in exchange for our contribution of intellectual property to LanzaJet. The variable consideration we may receive will be in the form of additional ownership interests and the majority of the basis difference will reverse in connection with recognition of that variable consideration.

SGLT

As of December 31, 2022, the Company’s interest in SGLT’s registered capital is approximately 9.31% as a result of the admittance of new investors during the year. As of September 30, 2022, the Company no longer had significant influence over the operating and financial policies of SGLT due to the significant and sustained decrease in SGLT's technological dependence on LanzaTech. As such, the Company ceased applying the equity method and from October 1, 2022 and forward, the Company accounts for its investment in equity security of SGLT using the alternative measurement principals as permitted under ASC 321, Investments - Equity Securities, because SGLT's fair value is not readily determinable. For the three and six months ended June 30, 2023, there was no change in the value of the investment in SGLT.

As of June 30, 2023 and December 31, 2022, there were no impairments of equity investments. During the three months and six months ended June 30, 2023 and 2022, the Company received no dividends from equity investments. See Note 12 - Related Party Transactions, for information on revenues, accounts receivable, contract assets and purchases and open accounts payable with its equity investments.

Investments

HTM Debt Securities

HTM debt securities are comprised of U.S. Treasury bills and notes, Yankee debt securities, and corporate debt securities. HTM debt securities are classified as short-term or long-term based upon the contractual maturity of the underlying investment.


	September 30, 2023
(in thousands)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value		Accrued Interest
Short-term
US Treasury bills and notes	$	20,178	$	—	$	(7)	$	20,171	$	45
Corporate debt securities	14,833		3		(26)		14,810		109
Total debt securities due within a year	$	35,011	$	3	$	(33)	$	34,981	$	154

After 1 year through 5 years
Corporate debt	6,780		3		(3)		6,780		24
Yankee debt securities	3,000		2		—		3,002		—
Total debt securities due after 1 year through 5 years	$	9,780	$	5	$	(3)	$	9,782	$	24

Total HTM Debt Securities	44,791		8		(36)		44,763		178

The Company regularly reviews held-to-maturity securities for declines in fair values that are determined to be credit related. As of September 30, 2023, the Company did not have an allowance for credit losses related to held-to-maturity securities.

Equity investments

The Company’s equity investments consisted of the following (in thousands):


	As of
	September 30, 2023		December 31, 2022
Equity Method Investment in LanzaJet	$	9,594	$	10,561
Equity Security Investment in SGLT	14,990		14,990
Total Investment	$	24,584	$	25,551

LanzaJet

On May 13, 2020, the Company contributed $15,000 in intellectual property in exchange for a 37.5% interest (“Original Interest”) of LanzaJet, Inc. (“LanzaJet”) in connection with an investment agreement (“Investment Agreement”). The Company accounts for the transaction as a revenue transaction with a customer under ASC 606. The licensing and technical support services provided are recognized as a single combined performance obligation satisfied over the expected period of those services, beginning May 2020 through December 2025. During the three months ended September 30, 2023 and 2022, the Company recognized revenue from this arrangement of $565 and $540 respectively, net of intra-entity profit elimination. During the nine months ended September 30, 2023 and September 30, 2022, the Company recognized revenue from this arrangement of $1,701 and $1,620 respectively, net of intra-entity profit elimination and has associated deferred revenue of $6,047 and $8,062, as of September 30, 2023 and December 31, 2022, respectively. Intra-entity profits related to revenue contracts with LanzaJet are $107 and $132 for the three months ended September 30, 2023, and 2022, respectively. Intra-entity profits related to revenue contracts with LanzaJet are $313 and $395 for the nine months ended September 30, 2023 and 2022, respectively. Intra-entity profits are amortized over a 15-year period through 2034.

Agreement as described in Note 12 - Related Party Transactions, LanzaJet issued warrants that are exercisable for $0.01 by the holder when the related funds are drawn by LanzaJet. The warrants held by LanzaTech and other lenders meet the accounting criteria for in-substance common stock at the time the related note commitment is drawn by LanzaJet and the warrants become exercisable. As of September 30, 2023, LanzaTech’s ownership was diluted to approximately 23.15% because LanzaTech received proportionally fewer warrants than the other investors. The Company recorded a gain on dilution of $502. LanzaTech’s ownership is subject to further dilution to approximately 22.38% if LanzaJet draws additional funds committed in the LanzaJet Note Purchase Agreement and the remaining warrants are exercisable by the holders. The Company retained its contingent right to receive additional interest in LanzaJet of up to 45 million shares for no additional consideration.

The carrying value of our equity method investment in LanzaJet as of September 30, 2023 and December 31, 2022 was approximately $2,200 and $3,700 less than our proportionate share of our equity method investees’ book values, respectively. The basis differences are largely the result of a difference in the timing of recognition of variable consideration to which we may become entitled in exchange for our contribution of intellectual property to LanzaJet. The variable consideration we may receive will be in the form of additional ownership interests and the majority of the basis difference will reverse in connection with recognition of that variable consideration.

SGLT

As of December 31, 2022, the Company’s interest in SGLT’s registered capital is approximately 9.31% as a result of the admittance of new investors during the year. As of September 30, 2022, the Company no longer had significant influence over the operating and financial policies of SGLT due to the significant and sustained decrease in SGLT's technological dependence on LanzaTech. As such, the Company ceased applying the equity method and from October 1, 2022 and forward, the Company accounts for its investment in equity security of SGLT using the alternative measurement principals as permitted under ASC 321, Investments - Equity Securities, because SGLT's fair value is not readily determinable. For the three and nine months ended September 30, 2023, there was no change in the value of the investment in SGLT.

As of September 30, 2023 and December 31, 2022, there were no impairments of equity investments. During the three months and nine months ended September 30, 2023 and 2022, the Company received no dividends from equity investments. See Note 12 - Related Party Transactions, for information on revenues, accounts receivable, contract assets and purchases and open accounts payable with its equity investments.

Investments

The Company’s investments consisted of the following (in thousands):


	As of
	December 31, 2022		December 31, 2021
Equity Method Investment in LanzaJet	$	10,561	$	12,433
Equity Method Investment in SGLT	—		12,319
Equity Security Investment in SGLT	14,990		—
Total Investment	$	25,551	$	24,752

LanzaJet

On May 13, 2020, the Company contributed $15,000 in intellectual property in exchange for a 37.5% interest (“Original Interest”) of LanzaJet, Inc. (“LanzaJet”) in connection with an investment agreement (“Investment Agreement”). The Company accounts for the transaction as a revenue transaction with a customer under ASC 606. The licensing and technical support services provided are recognized as a single combined performance obligation satisfied over the expected period of those services, beginning May 2020 through December 2025. During the years ended December 31, 2022 and 2021, the Company has recognized revenue from this arrangement of $2,160 and $2,025 respectively, net of intra-entity profit elimination, and has recorded deferred revenue of $8,062 and $10,746, as of December 31, 2022 and December 31, 2021, respectively. Intra-entity profits related to revenue contracts with LanzaJet are $527 and $662 as of December 31, 2022, and December 31, 2021, respectively. Intra-entity profit is amortized over the 15-year amortization period through 2034.

Between February 1, 2021 and April 4, 2021, LanzaJet closed two additional rounds of investment which reduced the Company's Original Interest to approximately 25%. As a result, the Company recognized a gain on dilution of $503. The Company retained its contingent right to receive additional interest in LanzaJet of up to 45 million shares for no additional consideration.

The carrying value of our equity method investment in LanzaJet as of December 31, 2022 and December 31, 2021 was approximately $3,700 and $3,100 less than our proportionate share of our equity method investees’ book values, respectively. The basis differences are largely the result of a difference in the timing of recognition of variable consideration to which we may become entitled in exchange for our contribution of intellectual property to LanzaJet. The variable consideration we may receive will be in the form of additional ownership interests and the majority of the basis difference will reverse in connection with recognition of that variable consideration.

SGLT

As of December 31, 2021, the Company’s interest in SGLT’s registered capital is approximately 10.01%. As the result of the admittance of new investors, the Company recognized a gain from dilution of $3,048 during the year ended December 31, 2021. On April 29, 2022, SGLT closed a round of financing which reduced the Company's ownership to 9.31% and resulted in the recognition of gain from dilution of $3,368. As of September 30, 2022, the Company no longer had significant influence over the operating and financial policies of SGLT due to the significant and sustained decrease in SGLT's technological dependence on LanzaTech. As such, the Company ceased applying the equity method and reclassified cumulative currency translation adjustments associated with its investment in SGLT of $928 to include those adjustments in the carrying value of its investment, which is included

as a non-cash adjustment in the consolidated statement of cash flows. From October 1, 2022 and forward, the Company accounts for its investment in equity security of SGLT using the alternative measurement principals as permitted under ASC 321, Investments - Equity Securities, because SGLT's fair value is not readily determinable. As the change was effective on September 30, 2022, the Company recorded SGLT's attributable net loss of $76, for the first nine months of the year, on the consolidated statements of operations and comprehensive loss.

The following table presents summarized aggregated financial information of the equity method investments:


	Year Ended December 31,
	2022		2021
Selected Statement of Operations Information(1):
Revenues	$	40,985	$	40,244
Gross profit	7,319		(5,703)
Net loss	(6,221)		(9,695)
Net loss attributable to the Company	(1,422)		(1,606)

	Year Ended December 31,
	2022		2021
Selected Balance Sheet Information(2):
Current assets	$	72,711	$	56,204
Non-current assets	114,736		270,454
Current liabilities	15,534		64,499
Non-current liabilities	114,934		58,802

__________________

(1)As of September 30, 2022 the Company no longer accounts for the investment in SGLT under the equity method. As such, the income statement balances reflect SGLT activity for the nine months ended September 30, 2022 and LanzaJet activity for the year ended December 31, 2022.

(2)The balance sheet information reflects only LanzaJet as of December 31, 2022.

As of December 31, 2022 and 2021, there were no impairments of equity method investees. During 2022 and 2021, the Company received no dividends from equity method investments. See Note 12 - Related Party Transactions, for information on sales, accounts receivable, contract assets and purchases and open accounts payable with equity method investees.

Revenues - Remaining Performance Obligations (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Current	$ 3,132	$ 2,952	$ 3,042	$ 3,101	$ 3,476
Non-current	8,671	9,480	10,171	10,760	13,901
Total	$ 11,803	$ 12,432	$ 13,213	$ 13,861	$ 17,377

Summary of Significant Accounting Policies - Restatement (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Additional paid-in capital	$ 939,868	$ 936,157	$ 927,641	$ 24,782	$ 21,710
Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Additional paid-in capital		$ (60,547)	$ (60,547)

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Reverse Recapitalization - Schedule of Shares (Details)	Feb. 08, 2023 shares
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	196,222,737
Percentage	100.00%
Legacy LanzaTech
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	167,324,363
Percentage	85.30%
Public Stockholders
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	10,398,374
Percentage	5.30%
PIPE Shares
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	18,500,000
Percentage	9.40%

Summary of Significant Accounting Policies - Trade and Other Receivables (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Allowance for doubtful accounts	$ 1,751	$ 1,851	$ 1,851	$ 1,051	$ 1,235

Summary of Significant Accounting Policies

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Mar. 31, 2023

Jun. 30, 2023

Sep. 30, 2023

Dec. 31, 2022

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies (Restated)

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles for interim financial information, and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America ("US GAAP"), the accounting principles, standards, and procedures adopted by the U.S. Securities and Exchange Commission, for complete financial statements. However, in the opinion of management, all adjustments (consisting of normal recurring accruals) have been made that are necessary for a fair presentation of the condensed consolidated financial statements for the interim periods. For further information refer to the Consolidated Financial Statements and Footnotes thereto included in Legacy LanzaTech's Annual Report for the year ended December 31, 2022 included in the Company’s second amended S-1 registration statement filed with the SEC on May 5, 2023.

The Business Combination is accounted for as a reverse recapitalization as Legacy LanzaTech was determined to be the accounting acquirer under Accounting Standards Codification (“ASC”) 805, Business Combinations (“ASC 805”) based on the evaluation of the following facts and circumstances:

•Legacy LanzaTech stockholders have the largest portion of voting rights (85.3% at the closing of the Business Combination) in the Company;

•Legacy LanzaTech’s existing senior management team comprise senior management of the Company;

•The operations of the Company primarily represent operations of Legacy LanzaTech; and

•In comparison with AMCI, Legacy LanzaTech has significantly more revenue and total assets.

Accordingly, for accounting purposes, the financial statements of the Company represent a continuation of the financial statements of Legacy LanzaTech with the acquisition being treated as the equivalent of Legacy LanzaTech issuing stock for the net assets of AMCI, accompanied by a recapitalization. The net assets of AMCI were stated at historical cost, with no goodwill or other intangible assets recorded. Legacy LanzaTech was deemed to be the predecessor, and the consolidated assets and liabilities and results of operations prior to February 8, 2023 are those of Legacy LanzaTech. Reported shares and earnings per share available to common stockholders, prior to the Business Combination, have been retroactively restated to reflect the exchange ratio established in the Merger Agreement. The number of shares of preferred stock was also retroactively restated based on the exchange ratio.

Restatement

Prior to filing our financial statements for the quarter ended September 30, 2023, which were filed with the U.S. Securities and Exchange Commission (“SEC”) on Form 10-Q, the Company reviewed its prior interpretation of the accounting guidance applicable to certain elements of the Forward Purchase Agreement (“FPA”) and determined the prepayment amount of $60.5 million, previously recorded as part of a net non-current derivative asset in the condensed consolidated balance sheet, should be reclassified to the equity section of the condensed consolidated balance sheet, and the remaining liability balance associated with the FPA, including the in-substance written put option, the Maturity Consideration and the Share Consideration, should be reflected as non-current liabilities in our condensed consolidated balance sheet.

In accordance with ASC 250, Accounting Changes and Error Corrections, LanzaTech also evaluated the materiality of the errors to the Company’s previously filed financial statements for the first and second quarters of 2023. Considering both quantitative and qualitative factors, the Company determined that the related impact was material to the previously filed condensed consolidated financial statements as of and for the periods ended March 31, 2023 and June 30, 2023, and restated and reissued these financial statements.

Description of Error Corrected:

The previously reported FPA Prepayment Amount, as described in Note 2, Summary of Significant Accounting Policies and Note 9, Forward Purchase Agreement, was incorrectly classified as an asset instead of as an equity transaction. Additionally, the FPA Put Option liability was incorrectly netted with the Prepayment Amount and presented as a net asset, instead of being separately presented as a liability. These errors impacted the prepaid forward contract derivative, the FPA Put Option liability, and additional paid-in capital in the Condensed Consolidated Balances Sheet as of March 31, 2023, as well as the related disclosure within Note 10, Fair Value.

The effect of the correction of the error noted above on the relevant financial statement line items is as follows:


	As of March 31, 2023
	As Previously Reported		Adjustments		As Restated
Condensed Consolidated Balance Sheet
Prepaid forward contract derivative	15,954		(15,954)		—
Total assets	$	307,957	$	(15,954)	$	292,003
FPA Put Option liability	—		44,593		44,593
Total liabilities	$	78,145	$	44,593	$	122,738
Additional paid-in capital	988,188		(60,547)		927,641
Total shareholders’ equity (deficit)	$	229,812	$	(60,547)	$	169,265
Total liabilities, contingently redeemable preferred stock, and shareholders' equity	$	307,957	$	(15,954)	$	292,003


	Period Ended March 31, 2023
	As Previously Reported		Adjustments		As Restated
Condensed Consolidated Statement of Changes in Redeemable Convertible Preferred Stock and Shareholders’ Equity/ Deficit
Forward Purchase Agreement prepayment	—		(60,547)		(60,547)
Additional Paid-in Capital - balance at March 31, 2023	988,188		(60,547)		927,641
Total shareholders’ deficit - balance at March 31, 2023	$	229,812	$	(60,547)	$	169,265

The change in accounting and related restatement for the FPA did not have any impact on the condensed consolidated statements of operations and comprehensive loss, the condensed consolidated statements of cash flows for the quarter ended March 31, 2023, or earnings per share calculation for the quarter ended March 31, 2023.

Variable Interest Entity (“VIE”)

The Company makes judgments in determining whether an entity is a VIE and, if so, whether it is the primary beneficiary of the VIE and is thus required to consolidate the entity. A VIE is a legal entity that has a total equity investment that is insufficient to finance its activities without additional subordinated financial support or whose equity investors lack the characteristics of a controlling financial interest. The Company’s variable interest arises from contractual, ownership or other monetary interests in the entity, which changes with fluctuations in the fair value of the entity’s net assets. A VIE is consolidated by its primary beneficiary, the party that has both the power to direct the activities that most significantly impact the VIE’s economic performance, and the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. The Company consolidates a VIE when the Company is deemed to be the primary beneficiary. The Company assesses whether or not the Company is the primary beneficiary of a VIE on an ongoing basis. If the Company is not deemed to be the primary beneficiary in a VIE, the Company accounts for the investment or other variable interests in a VIE in accordance with applicable US GAAP.

The Company holds interests in certain VIEs for which it has been determined the Company is not the primary beneficiary. The Company's variable interests primarily relate to entities in which the Company has a non-controlling equity interest. Although these financial arrangements resulted in holding variable interests in these entities, they do not empower the Company to direct the activities of the VIEs that most significantly impact the VIEs' economic performance. The Company's interests in the VIEs are, therefore, accounted for under the equity method of accounting or at fair value (including, when applicable, the practicability exception to fair value under ASC 321-10-35). Refer to Note 6 - Investments, for further information. The Company is exposed to the VIEs’ losses and other impairment indicators up to the carrying value of each investment and any amounts receivable from the VIE, less amounts payable. Refer to Note 13, Related Party Transactions, for further details on the transactions with VIEs.

Going Concern

The accompanying condensed consolidated financial statements of the Company have been prepared in accordance with US GAAP and assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. The Company had cash and cash equivalents of $145,118, short-term held-to-maturity debt investments of $49,103 and an accumulated deficit of $(761,086) as of March 31, 2023 and cash outflows from operations of $(33,810) and a net loss of $(63,312) for the three months ended March 31, 2023. As a result of the Business Combination described in Note 1 closing on February 8, 2023, the Company received $153,285, which represents the proceeds from the Business Combination received net of (1) transaction expenses paid in the three months ended March 31, 2023, (2) the PIPE investment and (3) the amount paid to ACM ARRT H LLC (“ACM”) and Vellar Opportunity Fund SPV LLC - Series 10 (“Vellar”) in relation to the Forward Purchase Agreement.

issued, the Company projects that it will be able to cover its liquidity needs for the next twelve months with cash on hand.

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include fair value of equity awards granted to both employees and non-employees, revenue recognized over time, AM SAFE, Brookfield SAFE, AM SAFE warrants, the Forward Purchase Agreement and the Private Placement Warrants.

The Company uses the percentage of completion for both input and output methods to recognize revenue over time for certain contracts with customers. Under the output method, the Company exercises judgment and estimation when determining the percentage of completion against the total transaction price initially estimated. Under the input method, the Company exercises judgment and estimation when selecting the most indicative measure of such performance.

Most of our arrangements provide fixed consideration, however, when there are variable consideration elements, the Company estimates the transaction price and whether revenue should be constrained. Significant estimates and judgments are also used when a material right is provided to the customer. In these instances, the Company estimates the stand-alone selling price and apportions the total transaction price to this material right. Refer to the Revenue Recognition section in Note 2 hereunder.

Changes in facts and circumstances or additional information may result in revised estimates, and actual results may differ from these estimates.

Segment Information

The Company operates as one operating segment. Operating segments are defined as components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision maker (“CODM”), in deciding how to allocate resources and assess performance.

While the Company offers a variety of services and operates in multiple countries, the Company’s business operates in one operating segment because most of the Company’s service offerings are delivered and supported on a global basis, most of the Company’s service offerings are deployed in a similar way, and the Company’s CODM evaluates the Company’s financial information and resources and assesses the performance of these resources on a consolidated basis. There are no segment managers who are held accountable by the CODM, or anyone else, for operations, operating results, and planning for components below the consolidated level. Accordingly, the Company has determined that it has a single reportable and operating segment. See Note 5 - Revenues, for disaggregation of the Company’s revenues by customer location and contract type.

Foreign Currencies

The Company’s reporting currency is the U.S. Dollar. The Company has certain foreign subsidiaries where the functional currency is the local currency. All of the assets and liabilities of these subsidiaries are translated to U.S. dollars at the exchange rate in effect at the balance sheet date, income and expense accounts are translated at average rates for the period, and shareholders’ equity accounts are translated at historical rates. The effects of translating financial statements of foreign operations into the Company’s reporting currency are recognized in accumulated other comprehensive income (loss).

The Company also has foreign subsidiaries that have a functional currency of the U.S. dollar. Purchases and sales of assets and income and expense items denominated in foreign currencies are remeasured into U.S. dollar amounts on the respective dates of such transactions. Net realized and unrealized foreign currency gains or losses relating to the differences between these recorded amounts and the U.S. dollar equivalent actually received or paid

are included within other expense, net in the condensed consolidated statements of operations and comprehensive loss.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. As of March 31, 2023 and December 31, 2022, the Company had $145,118 and $83,045 of cash and cash equivalents, respectively.

Restricted Cash

The Company is required to maintain a cash deposit with a bank which consists of collateral on certain travel and expense programs maintained by the bank. The following represents a reconciliation of cash and cash equivalents in the condensed consolidated balance sheets to total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows as of March 31, 2023 and December 31, 2022 (in thousands).


	As of
	March 31, 2023		December 31, 2022
Cash and cash equivalents	$	145,118	$	83,045
Restricted cash (presented within Other current assets)	668		665
Cash, cash equivalents and restricted cash	$	145,786	$	83,710

Trade and Other Receivables

Receivables are reported net of allowances for doubtful accounts. The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of customers to make required payments. The Company estimates the allowance for doubtful accounts based on a variety of factors including the length of time receivables are past due, the financial health of customers, unusual macroeconomic conditions, and historical experience. As of March 31, 2023 and December 31, 2022, the Company recognized an allowance for doubtful accounts of $1,851 and $1,051, respectively.

Debt Investments

Investments in debt securities are classified as trading, held-to-maturity or available-for-sale. Trading securities represent investments that are bought and sold principally for the purpose of selling in the near term. Held-to-maturity securities represent investments that the Company has both the ability and intent to hold to maturity. Available-for-sale securities represent investments in debt securities that are not classified as either trading or held-to-maturity.

Held-to-maturity securities are comprised of U.S. Treasury securities that the Company has both the ability and intent to hold to maturity. Held-to-maturity securities are carried at amortized cost, which is original cost net of periodic principal repayments and amortization of premiums and accretion of discounts. Accrued interest receivable is recorded separately in other current assets on the condensed consolidated balance sheets. Amortization of premiums and accretion of discounts are computed using the contractual level-yield method (contractual interest method), adjusted for actual prepayments. The contractual interest method recognizes the income effects of premiums and discounts over the contractual life of the securities based on the actual behavior of the underlying assets, including adjustments for actual prepayment activities, and reflects the contractual terms of the securities without regard to changes in estimated prepayments based on assumptions about future borrower behavior.

Held-to-maturity securities are evaluated individually on a quarterly basis for expected credit losses. If applicable, an allowance for credit losses is recorded with a corresponding credit loss expense (or reversal of credit loss expense). The allowance for credit losses excludes uncollectible accrued interest receivable, which is measured separately.

Warrants

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity (“ASC 815-40”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815-40, including whether the warrants are indexed to the Company’s own common stock, among other conditions for equity classification.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance and adjusted to the current fair value at each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the condensed consolidated statement of operations and comprehensive loss (see Note 8 - Warrants).

Forward Purchase Agreement

On February 3, 2023, the Company entered into a Forward Purchase Agreement (“FPA”) with ACM. On the same date, ACM partially assigned its rights under the FPA to Vellar. ACM and Vellar are together referred to as the “Purchasers”. Pursuant to the Forward Purchase Agreement, the Purchasers obtained 5,916,514 common shares (“Recycled Shares”) on the open market for $10.16 per share (“Redemption Price”), and such purchase price of $60,096 was funded by the use of AMCI trust account proceeds as a partial prepayment for the Forward Purchase Agreement redemption 3 years from the date of the Business Combination (“Maturity Date”). The Maturity Date may be accelerated, at the Purchasers discretion, if the Company share price trades below $3.00 per share for any 50 trading days during a 60 day consecutive trading-day period or the Company is delisted. On any date following the Business Combination, the Purchasers also have the option to early terminate the arrangement in whole or in part by providing optional early termination notice to the Company (the “Optional Early Termination”). For those shares early terminated (the “Terminated Shares”), the Purchasers will owe the Company an amount equal to the Terminated Shares times the Redemption Price, which may be reduced in the case of certain dilutive events (“Reset Price”).

At the Maturity Date, the Company is obligated to pay the Purchasers an amount equal to the product of (1) 7,500,000 less (b) the number of Terminated Shares multiplied by (2) $2.00 (the “Maturity Consideration”). In addition to the Maturity Consideration, on the Maturity Date, the Company shall pay to the Purchasers an amount equal to the product of (x) 500,000 and (y) the Redemption Price, totaling $5,079 (the “Share Consideration”). If the Purchasers were to utilize their Optional Early Termination to terminate the FPA early, neither the Maturity Consideration nor the Share Consideration would be due to the Purchasers.

The Purchasers’ Optional Early Termination economically results in the prepaid forward contract being akin to a written put option with the Purchaser’s right to sell all or a portion of the 5,916,514 common shares to the Company. The Company is entitled over the 36-month maturity period to either a return of the prepayment or the underlying shares, which the Purchasers will determine at their sole discretion.

The FPA consists of three freestanding financial instruments that are accounted for as follows:

1)The total prepayment of $60,547 (“Prepayment Amount”), which is accounted for as a reduction to equity to reflect the substance of the overall arrangement as a net repurchase of the Recycled Shares and sale of shares to the Purchasers pursuant to a subscription agreement.

2)The “FPA Put Option” which includes both the in-substance written put option and the portion of the Maturity Consideration in excess of the Minimum Maturity Consideration (the “Variable Maturity Consideration”). The FPA Put Option is a derivative instrument the Company has recorded as a liability and measured at fair value. The initial fair value of the FPA Put Option and subsequent changes in fair

value of the FPA Put Option are recorded within other expense, net on the condensed consolidated statement of operations and comprehensive loss.

3)The “Fixed Maturity Consideration,” which includes the minimum portion of the Maturity Consideration (the “Minimum Maturity Consideration”), calculated as 7,500,000 shares less 5,916,513 shares multiplied by $2.00 or $3,167, and the Share Consideration. Both the Minimum Maturity Consideration and the Share Consideration are considered to be free-standing debt instruments and as both will be paid on the same terms and at the same time, these are accounted for together. The Company has elected to measure these using the Fair Value Option (“FVO”) under ASC 825, Financial Instruments (“ASC 825”). The Fixed Maturity Consideration is recorded as a long-term liability on the condensed consolidated balance sheets. The initial fair value of the Fixed Maturity Consideration and subsequent changes in fair value of the Fixed Maturity Consideration are recorded within other expense, net on the condensed consolidated statement of operations and comprehensive loss.

For additional information, see “Restatement” above in Note 2, Summary of Significant Accounting Policies.

Revenue Recognition

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). The Company primarily earns revenue from services related to Biorefining (formerly known as carbon capture and transformation) which includes feasibility studies and basic engineering design of commercial plants, licensing of technologies and sales of biocatalysts. The other two revenue streams are: (1) joint development and contract research activities to develop novel biocatalysts and related technologies, and (2) supply of chemical building blocks for sustainable products produced using the Company’s proprietary technologies (referred to as CarbonSmart).

Revenue is measured based on the consideration specified in a contract with a customer. The Company records taxes collected from customers and remitted to governmental authorities on a net basis. The Company’s payment terms are between 30-60 days and can vary by customer type and products offered. Management has evaluated the terms of the Company’s arrangements and determined that they do not contain significant financing components.

Biorefining

The Company provides feasibility studies and basic design and engineering services used for detailed design, procurement, and construction of commercial plants that utilize the Company’s technologies, along with the sale of microbes and media. The services provided are recognized as a performance obligation satisfied over time. Revenue is recognized using the output method based on milestone completion, the cost-to-cost input method for certain engineering services, or the percentage of completion method as performance obligations are satisfied. Revenue for the sale of microbes and media is at a point in time, depending on when control transfers to the customer.

The Company licenses intellectual property to generate recurring revenue when its customers deploy our technology in their carbon capture and transformation plants. When licenses are considered to be distinct performance obligations, the recognition of revenue is dependent on the terms of the contract, which may include fixed consideration or royalties based on sales or usage, in which case the revenue is recognized when the subsequent sale or usage occurs or when the performance obligation to which some or all of the sales or usage-based royalty is allocated has been satisfied, whichever is later.

Joint Development and Contract Research

The Company performs R&D services related to novel technologies and development of biocatalysts for commercial applications, mainly to produce fuels and chemicals. The Company engages in two main types of R&D services – joint development agreements, and contract research, including projects with the U.S. Department of Energy and other US and foreign government agencies. Such services are recognized as a performance obligation satisfied over time. Revenue is recognized based on milestone completion, when payments are contingent upon the achievement of such milestones, or based on percentage-completion method when enforceable rights to payment exist. When no milestones or phases are clearly defined, management has determined that the cost incurred, input

method, is an appropriate measure of progress towards complete satisfaction of the performance obligations under ASC 606, and estimates its variable consideration under the expected value method.

Revenue is not recognized in advance of customer acceptance of a milestone when such acceptance is contractually required. Payments for R&D services with no contractual payments are not due from customers until a technical report is submitted; therefore, a contract asset is recognized at milestone completion but prior to the submission of a technical report. The contract asset represents the Company’s right to consideration for the services performed at milestone completion. Occasionally, customers provide payments in advance of the Company providing services which creates a contract liability for the Company. The contract liability represents the Company's obligation to provide services to a customer.

CarbonSmart

The Company supplies chemical building blocks from customers who have deployed our proprietary technologies in their carbon capture and transformation plants and sells them as CarbonSmart products. Revenue is recognized at a point in time when control transfers to our end customer, which varies depending on the shipping terms. The Company acts as the principal in such transactions and accordingly, recognizes revenue and cost of revenues on a gross basis. Amounts received for sales of CarbonSmart products are classified as Revenue from contract with customers - tangible products in the condensed consolidated statements of operations and comprehensive loss.

Collaboration Arrangements

The Company has certain partnership agreements that are within the scope of ASC 808, Collaborative Arrangements, which provides guidance on the presentation and disclosure of collaborative arrangements. Generally, the classification of the transaction under the collaborative arrangements is determined based on the nature of the contractual terms of the arrangement, along with the nature of the operations of the participants. The Company’s collaborative agreements generally include a provision of R&D services related to novel technologies and biocatalysts. Amounts received for these services are classified as Revenue from collaborative arrangements in the condensed consolidated statements of operations and comprehensive loss. The Company's R&D services are a major part of the Company's ongoing operations and therefore ASC 606 is applied to recognize revenue.

Fair Value of Financial Instruments

Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:

Level 1 — Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access;

Level 2 — Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities; and

Level 3 — Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, Fair Value Measurement, approximates the carrying amounts represented in the accompanying condensed consolidated balance sheets, primarily due to their short-term nature, except for the warrant liability.

Concentration of Credit Risk and Other Risks and Uncertainties

Revenue generated from the Company’s customers outside of the United States for the three months ended March 31, 2023 and 2022 was approximately 62% in each of the periods presented.

As of March 31, 2023 and December 31, 2022, approximately 41% and 35%, respectively, of trade accounts receivable and unbilled accounts receivable were due from customers located outside the United States. As of March 31, 2023 and December 31, 2022, the value of property, plant, and equipment outside the United States was immaterial.

The Company’s revenue by geographic region based on the customer’s location is presented in Note 5, Revenues.

Customers

Customers representing 10% or greater of revenue were as follows for the three months ended March 31, 2023 and 2022:


	Three Months Ended March 31,
	2023		2022
Customer A	30	%	19	%
Customer B	13	%	22	%
Customer C	10	%	8	%

Recently Adopted and Issued Accounting Pronouncements

There are no recently adopted or issued accounting pronouncements that are expected to have a material impact on the Company.

Summary of Significant Accounting Policies (Restated)

Basis of Presentation and Principles of Consolidation

•Legacy LanzaTech stockholders have the largest portion of voting rights (85.3% at the closing of the Business Combination) in the Company;

•Legacy LanzaTech’s existing senior management team comprise senior management of the Company;

•The operations of the Company primarily represent operations of Legacy LanzaTech; and

•In comparison with AMCI, Legacy LanzaTech has significantly more revenue and total assets.

Restatement

Description of Error Corrected:

The previously reported FPA Prepayment Amount, as described in Note 2, Summary of Significant Accounting Policies and Note 9, Forward Purchase Agreement, was incorrectly classified as an asset instead of as an equity transaction. Additionally, the FPA Put Option liability was incorrectly netted with the Prepayment Amount and presented as a net asset, instead of being separately presented as a liability. These errors impacted the prepaid forward contract derivative, the FPA Put Option liability, and additional paid-in capital in the Condensed Consolidated Balances Sheet as of June 30, 2023, as well as the related disclosure within Note 9, Fair Value.

The effect of the correction of the error noted above on the relevant financial statement line items is as follows:


	As of June 30, 2023
	As Previously Reported		Adjustments		As Restated
Condensed Consolidated Balance Sheet
Prepaid forward contract derivative	33,804		(33,804)		—
Total assets	$	302,337	$	(33,804)	$	268,533
FPA Put Option liability	—		26,743		26,743
Total liabilities	$	90,699	$	26,743	$	117,442
Additional paid-in capital	996,704		(60,547)		936,157
Total shareholders’ equity (deficit)	$	211,638	$	(60,547)	$	151,091
Total liabilities, contingently redeemable preferred stock, and shareholders' equity	$	302,337	$	(33,804)	$	268,533

	Period Ended June 30, 2023
	As Previously Reported		Adjustments		As Restated
Condensed Consolidated Statement of Changes in Redeemable Convertible Preferred Stock and Shareholders’ Equity/ Deficit
Forward Purchase Agreement prepayment	—		(60,547)		(60,547)
Additional Paid-in Capital - balance at March 31, 2023	988,188		(60,547)		927,641
Total shareholders’ deficit - balance at March 31, 2023	$	229,812	$	(60,547)	$	169,265
Additional Paid-in Capital - balance at June 30, 2023	996,704		(60,547)		936,157
Total shareholders’ deficit - balance at June 30, 2023	$	211,638	$	(60,547)	$	151,091

The change in accounting and related restatement for the FPA did not have any impact on the condensed consolidated statements of operations and comprehensive loss, the condensed consolidated statements of cash flows for the quarter ended June 30, 2023, or earnings per share calculation for the quarter ended June 30, 2023.

Variable Interest Entity (“VIE”)

the VIE, less amounts payable. Refer to Note 12, Related Party Transactions, for further details on the transactions with VIEs.

Going Concern

The accompanying condensed consolidated financial statements of the Company have been prepared in accordance with US GAAP and assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. The Company had cash and cash equivalents of $110,719, short-term held-to-maturity debt investments of $49,704 and an accumulated deficit of $(787,872) as of June 30, 2023 and cash outflows from operations of $(59,116) and a net loss of $(90,098) for the six months ended June 30, 2023. As a result of the Business Combination described in Note 1 closing on February 8, 2023, the Company received $153,285, which represents the proceeds from the Business Combination received net of (1) transaction expenses, (2) the PIPE investment and (3) the amount paid to ACM ARRT H LLC (“ACM”) and Vellar Opportunity Fund SPV LLC - Series 10 (“Vellar”) in relation to the Forward Purchase Agreement (see below).

The Company has historically funded its operations through debt financing and issuances of equity securities. Based on the Company’s financial position as of the date the condensed consolidated financial statements were issued, the Company projects that it will be able to cover its liquidity needs for the next twelve months.

Use of Estimates

Changes in facts and circumstances or additional information may result in revised estimates, and actual results may differ from these estimates.

Segment Information

operations, operating results, and planning for components below the consolidated level. Accordingly, the Company has determined that it has a single reportable and operating segment. See Note 5 - Revenues, for disaggregation of the Company’s revenues by customer location and contract type.

Foreign Currencies

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. As of June 30, 2023 and December 31, 2022, the Company had $110,719 and $83,045 of cash and cash equivalents, respectively.

Restricted Cash


	As of
	June 30, 2023		December 31, 2022
Cash and cash equivalents	$	110,719	$	83,045
Restricted cash (presented within Other current assets)	670		665
Cash, cash equivalents and restricted cash	$	111,389	$	83,710

Trade and Other Receivables

Receivables are reported net of allowances for doubtful accounts. The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of customers to make required payments. The Company estimates the allowance for doubtful accounts based on a variety of factors including the length of time receivables are past due, the financial health of customers, unusual macroeconomic conditions, and historical experience. As of June 30, 2023 and December 31, 2022, the Company recognized an allowance for doubtful accounts of $1,851 and $1,051, respectively.

Debt Investments

Held-to-maturity securities are comprised of U.S. Treasury securities that the Company has both the ability and intent to hold to maturity. Held-to-maturity securities are carried at amortized cost, which is original cost net of periodic principal repayments and amortization of premiums and accretion of discounts. Accrued interest receivable is also recorded within debt security investments on the condensed consolidated balance sheets. Amortization of premiums and accretion of discounts are computed using the contractual level-yield method (contractual interest method), adjusted for actual prepayments. The contractual interest method recognizes the income effects of premiums and discounts over the contractual life of the securities based on the actual behavior of the underlying assets, including adjustments for actual prepayment activities, and reflects the contractual terms of the securities without regard to changes in estimated prepayments based on assumptions about future borrower behavior.

Warrants

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded at fair value as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance and adjusted to the current fair value at each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss in other expense, net on the condensed consolidated statement of operations and comprehensive loss (see Note 7 - Warrants).

Forward Purchase Agreement

The FPA consists of three freestanding financial instruments that are accounted for as follows:

(1)The total prepayment of $60,547 (“Prepayment Amount”), which is accounted for as a reduction to equity to reflect the substance of the overall arrangement as a net repurchase of the Recycled Shares and sale of shares to the Purchasers pursuant to a subscription agreement.

(2)The “FPA Put Option” which includes both the in-substance written put option and the portion of the Maturity Consideration in excess of the Minimum Maturity Consideration (the “Variable Maturity Consideration”). The FPA Put Option is a derivative instrument the Company has recorded as a liability and measured at fair value. The initial fair value of the FPA Put Option and subsequent changes in fair value of the FPA Put Option are recorded within other expense, net on the condensed consolidated statement of operations and comprehensive loss.

(3)The “Fixed Maturity Consideration,” which includes the minimum portion of the Maturity Consideration (the “Minimum Maturity Consideration”), calculated as 7,500,000 shares less 5,916,513 shares multiplied by $2.00 or $3,167, and the Share Consideration. Both the Minimum Maturity Consideration and the Share Consideration are considered to be free-standing debt instruments and as both will be paid on the same terms and at the same time, these are accounted for together. The Company has elected to measure these using the Fair Value Option (“FVO”) under ASC 825, Financial Instruments (“ASC 825”). The Fixed Maturity Consideration is recorded as a long-term liability on the condensed consolidated balance sheets. The initial fair value of the Fixed Maturity Consideration and subsequent changes in fair value of the Fixed Maturity Consideration are recorded within other expense, net on the condensed consolidated statement of operations and comprehensive loss.

For additional information, see “Restatement” above in Note 2, Summary of Significant Accounting Policies.

Revenue Recognition

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). The Company primarily earns revenue from services related to biorefining (formerly known as carbon capture and transformation) which includes feasibility studies and basic engineering design of commercial plants, licensing of technologies and sales of biocatalysts. The other two revenue streams are: (1) joint development and contract research activities to develop and optimize novel biocatalysts, related processes and technologies, and (2) supply of chemical building blocks for sustainable products produced using the Company’s proprietary technologies (referred to as CarbonSmart).

Biorefining

The Company licenses intellectual property to generate recurring revenue when its customers deploy its technology in their biorefining plants. When licenses are considered to be distinct performance obligations, the recognition of revenue is dependent on the terms of the contract, which may include fixed consideration or royalties based on sales or usage, in which case the revenue is recognized when the subsequent sale or usage occurs or when the performance obligation to which some or all of the sales or usage-based royalty is allocated has been satisfied, whichever is later.

Joint Development and Contract Research

CarbonSmart

The Company supplies chemical building blocks from the customers who have deployed our proprietary technologies in their biorefining plants and sells them as CarbonSmart products. Revenue is recognized at a point in time when control transfers to our end customer, which varies depending on the shipping terms. The Company acts as the principal in such transactions and accordingly, recognizes revenue and cost of revenues on a gross basis. Amounts received for sales of CarbonSmart products are classified as Revenue from contract with customers - tangible products in the condensed consolidated statements of operations and comprehensive loss.

Collaboration Arrangements

Fair Value of Financial Instruments

use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:

Level 1 — Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access;

Level 3 — Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

Concentration of Credit Risk and Other Risks and Uncertainties

Revenue generated from the Company’s customers outside of the United States for the three months ended June 30, 2023 and 2022 was approximately 84% and 65%, respectively. Revenue generated from the Company’s customers outside of the United States for the six months ended June 30, 2023 and 2022 was approximately 75% and 64%, respectively.

As of June 30, 2023 and December 31, 2022, approximately 50% and 35%, respectively, of trade accounts receivable and unbilled accounts receivable were due from customers located outside the United States. As of June 30, 2023 and December 31, 2022, the value of property, plant, and equipment outside the United States was immaterial.

The Company’s revenue by geographic region based on the customer’s location is presented in Note 5, Revenues.

Customers

Customers representing 10% or greater of revenue were as follows for the three and six months ended June 30, 2023 and 2022:


	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Customer A	51	%	10	%	42	%	14	%
Customer B	5	%	22	%	9	%	22	%

Stock-Based Compensation

In exchange for certain employee and director services, compensation is given in the form of equity-based awards. The Company accounts for equity-based compensation in accordance with ASC 718, Compensation – Stock Compensation. Accordingly, equity-classified awards are recorded based on the grant date fair value and expensed over the requisite service period for the respective award. Liability-classified awards are remeasured at the end of each reporting period and expensed based on the percentage of requisite service that has been rendered.

research and development expenses. For awards with only service conditions that have a graded vesting schedule, the Company recognizes compensation cost on a straight-line basis over the requisite service period for the entire award. For awards with market or performance conditions that have a graded vesting schedule, the Company recognizes compensation cost on a straight-line basis over the requisite service period for each tranche of the award. Compensation expense resulting from performance awards is recognized over the requisite service period when it is probable that the performance condition will be met. The recognized compensation expense for performance awards is adjusted based on an estimate of awards ultimately expected to vest.

The Company estimates the fair value of service and performance-based options and SARs using a Black-Scholes option pricing model that uses assumptions including expected volatility, expected term, and the expected risk-free rate of return. The Company estimates the fair value of market-based RSUs using the Monte Carlo simulation model that uses assumptions including expected volatility, and the derived service period. The Company uses peer data to determine expected volatility and expected term. The Company estimates the fair value of RSUs based on the closing market price of its common stock on the date of measurement.

Recently Adopted and Issued Accounting Pronouncements

There are no recently adopted or issued accounting pronouncements that are expected to have a material impact on the Company.

Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

•Legacy LanzaTech stockholders have the largest portion of voting rights (85.3% at the closing of the Business Combination) in the Company;

•Legacy LanzaTech’s existing senior management team comprise senior management of the Company;

•The operations of the Company primarily represent operations of Legacy LanzaTech; and

•In comparison with AMCI, Legacy LanzaTech has significantly more revenue and total assets.

Variable Interest Entity (“VIE”)

The Company holds interests in certain VIEs for which it has been determined the Company is not the primary beneficiary. The Company's variable interests primarily relate to entities in which the Company has a non-controlling equity interest. Although these financial arrangements resulted in holding variable interests in these entities, they do not empower the Company to direct the activities of the VIEs that most significantly impact the VIEs' economic performance. The Company's interests in the VIEs are, therefore, accounted for under the equity method of accounting or at fair value (including, when applicable, the practicability exception to fair value under ASC 321-10-35). Refer to Note 6 - Investments, for further information. The Company is exposed to the VIEs’ losses and other impairment indicators up to the carrying value of each investment and any amounts receivable from the VIE, less amounts payable. Refer to Note 12, Related Party Transactions, for further details on the transactions with VIEs.

Going Concern

from operations of $(81,565) and a net loss of $(115,424) for the nine months ended September 30, 2023. As a result of the Business Combination described in Note 1 closing on February 8, 2023, the Company received $153,285, which represents the proceeds from the Business Combination received net of (1) transaction expenses, (2) the PIPE investment and (3) the amount paid to ACM ARRT H LLC (“ACM”) and Vellar Opportunity Fund SPV LLC - Series 10 (“Vellar”) in relation to the Forward Purchase Agreement (see below).

Use of Estimates

Changes in facts and circumstances or additional information may result in revised estimates, and actual results may differ from these estimates.

Segment Information

Foreign Currencies

financial statements of foreign operations into the Company’s reporting currency are recognized in accumulated other comprehensive income.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. As of September 30, 2023 and December 31, 2022, the Company had $91,397 and $83,045 of cash and cash equivalents, respectively.

Restricted Cash


	As of
	September 30, 2023		December 31, 2022
Cash and cash equivalents	$	91,397	$	83,045
Restricted cash (presented within Other current assets)	673		665
Cash, cash equivalents and restricted cash	$	92,070	$	83,710

Trade and Other Receivables

Receivables are reported net of allowances for doubtful accounts. The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of customers to make required payments. The Company estimates the allowance for doubtful accounts based on a variety of factors including the length of time receivables are past due, the financial health of customers, unusual macroeconomic conditions, and historical experience. As of September 30, 2023 and December 31, 2022, the Company recognized an allowance for doubtful accounts of $1,751 and $1,051, respectively.

Investment securities

The Company classifies investment securities according to their purpose and holding period. All investment securities are debt securities that have been classified as held-to-maturity (“HTM”) because the Company has both the ability and intent to hold the securities to maturity.

HTM debt securities are comprised of U.S. Treasury bills, U.S. Treasury notes, Yankee bonds, and corporate debt. HTM debt securities are carried at amortized cost, which is original cost net of periodic principal repayments and amortization of premiums and accretion of discounts. Accrued interest receivable is recorded within trade and other receivables, net of allowance on the condensed consolidated balance sheets. Amortization of premiums and accretion of discounts are computed using the contractual level-yield method (contractual interest method), adjusted for actual prepayments. The contractual interest method recognizes the income effects of premiums and discounts over the contractual life of the securities based on the actual behavior of the underlying assets, including adjustments for actual prepayment activities, and reflects the contractual terms of the securities without regard to changes in estimated prepayments based on assumptions about future borrower behavior.

Warrants

Forward Purchase Agreement

On February 3, 2023, the Company entered into a Forward Purchase Agreement (“FPA”) with ACM. On the same date, ACM partially assigned its rights under the FPA to Vellar. ACM and Vellar are together referred to as the “Purchasers”. Pursuant to the Forward Purchase Agreement, the Purchasers obtained 5,916,514 common shares (“Recycled Shares”) on the open market for $10.16 per share (“Redemption Price”), and such purchase price of $60,096 was funded by the use of AMCI trust account proceeds as a prepayment (“Prepayment Amount”) for the Forward Purchase Agreement redemption 3 years from the date of the Business Combination (“Maturity Date”). The Maturity Date may be accelerated, at the Purchasers discretion, if the Company share price trades below $3.00 per share for any 50 trading days during a 60 day consecutive trading-day period or the Company is delisted. On any date following the Business Combination, the Purchasers also have the option to early terminate the arrangement in whole or in part by providing optional early termination notice to the Company (the “Optional Early Termination”). For those shares early terminated (the “Terminated Shares”), the Purchasers will owe the Company an amount equal to the Terminated Shares times the Redemption Price, which may be reduced in the case of certain dilutive events (“Reset Price”).

The Purchasers’ Optional Early Termination economically results in the prepaid forward contract being akin to an in-substance written put option with the Purchaser’s right to sell all or a portion of the 5,916,514 common shares to the Company. The Company is entitled over the 36-month maturity period to either a return of the prepayment or the underlying shares, which the Purchasers will determine at their sole discretion.

The FPA consists of three freestanding financial instruments compromising the in-substance written put option (“FPA Put Option”), the minimum portion of the Maturity Consideration (the “Minimum Maturity Consideration”), and the Share Consideration. The FPA Put Option is a derivative instrument the Company has recorded as a liability and measured at fair value. The difference between the initial value of the derivative, including Maturity Consideration in excess of the Minimum Maturity Consideration (the “Variable Maturity Consideration”), and the Prepayment Amount was recorded in the condensed consolidated statement of operations and comprehensive loss.

Subsequent changes in fair value of the derivative liability are also recorded in other expense, net on the condensed consolidated statement of operations and comprehensive loss. The Prepayment Amount was accounted for as a reduction to equity to reflect the substance of the overall arrangement as a net repurchase of the Recycled Shares.

The Minimum Maturity Consideration, representing 7,500,000 less 5,916,513 multiplied by $2.00 or $3,167, and the Share Consideration are considered to be free-standing debt instruments. The Company has elected to measure these using the Fair Value Option (“FVO”) under ASC 825, Financial Instruments (“ASC 825”). As both the Minimum Maturity Consideration and the Share Consideration will be paid on the same terms and at the same time, these are accounted for together and referred to as the “Fixed Maturity Consideration”. The Variable Maturity Consideration is captured as part of the in-substance written put derivative liability (the FPA Put Option), as noted above. The Fixed Maturity Consideration is recorded as long-term liability on the condensed consolidated balance sheets. The initial value of the Fixed Maturity Consideration is recorded through the condensed consolidated statement of operations and comprehensive loss. Subsequent changes in fair value of the Fixed Maturity Consideration are also recorded in other expense, net on the condensed consolidated statement of operations and comprehensive loss.

Prior to filing these financial statements on Form 10-Q, we determined that our prior interpretation of the accounting guidance applicable to certain elements of the Forward Purchase Agreement (“FPA”) was incorrect. As a result, we have revised the accounting treatment of the FPA in our financial statements as of September 30, 2023 to reclassify the Prepayment Amount of $60.5 million, previously recorded as part of a net non-current derivative asset in the condensed consolidated balance sheet, to the equity section of the condensed consolidated balance sheet. The remaining liability balance of $38.1 million associated with the FPA, including the Minimum Maturity Consideration and the Share Consideration, are now reflected as non-current liabilities in our condensed consolidated balance sheet.

The change in accounting for the FPA did not have any impact on our liquidity, cash flows or results of operations for the third quarter. We intend to restate our financial statements for the quarters ended March 31, 2023 and June 30, 2023 to be consistent with this accounting treatment.

Revenue Recognition

Biorefining

The Company licenses intellectual property to generate recurring revenue, in the case of running royalties, or one-time revenue, in the case of fixed consideration royalties, when its customers deploy the Company’s technology in their biorefining plants. When licenses are considered to be distinct performance obligations, the recognition of

revenue is dependent on the terms of the contract, which may include fixed consideration or royalties based on sales or usage, in which case the revenue is recognized when the subsequent sale or usage occurs or when the performance obligation to which some or all of the sales or usage-based royalty is allocated has been satisfied, whichever is later.

Joint Development and Contract Research

CarbonSmart

The Company purchases chemical building blocks from the customers who have deployed our proprietary technologies in their biorefining plants and sells them as CarbonSmart products. Revenue is recognized at a point in time when control transfers to our end customer, which varies depending on the shipping terms. The Company acts as the principal in such transactions and accordingly, recognizes revenue and cost of revenues on a gross basis. Amounts received for sales of CarbonSmart products are classified as Revenue from contract with customers - tangible products in the condensed consolidated statements of operations and comprehensive loss.

Collaboration Arrangements

Fair Value of Financial Instruments

Level 1 — Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access;

Level 3 — Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

Concentration of Credit Risk and Other Risks and Uncertainties

Revenue generated from the Company’s customers outside of the United States for the three months ended September 30, 2023 and 2022 was approximately 75% and 54%, respectively. Revenue generated from the Company’s customers outside of the United States for the nine months ended September 30, 2023 and 2022 was approximately 75% and 61%, respectively.

As of September 30, 2023 and December 31, 2022, approximately 49% and 35%, respectively, of trade accounts receivable and unbilled accounts receivable were due from customers located outside the United States. As of September 30, 2023 and December 31, 2022, the value of property, plant, and equipment outside the United States was immaterial.

The Company’s revenue by geographic region based on the customer’s location is presented in Note 5, Revenues.

Customers

Customers representing 10% or greater of revenue were as follows for the three and nine months ended September 30, 2023 and 2022:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Customer A	36	%	—	%	39	%	10	%
Customer B	7	%	27	%	8	%	24	%
Customer C	—	%	21	%	—	%	10	%

Stock-Based Compensation

The Company’s equity-based awards include stock option awards, restricted stock units, stock-appreciation rights (“SARs”) and restricted stock issued by the Company, which vest based on either time and/or the achievement of certain market or performance conditions. The Company records forfeitures as they occur. Compensation expense is recognized in the Company’s consolidated statements of operations and comprehensive loss, primarily within research and development expenses. For awards with only service conditions that have a graded vesting schedule, the Company recognizes compensation cost on a straight-line basis over the requisite service period for the entire award. For awards with market or performance conditions that have a graded vesting schedule, the Company recognizes compensation cost on a straight-line basis over the requisite service period for each tranche of the award.

Compensation expense resulting from performance awards is recognized over the requisite service period when it is probable that the performance condition will be met. The recognized compensation expense for performance awards is adjusted based on an estimate of awards ultimately expected to vest.

Recently Adopted and Issued Accounting Pronouncements

There are no recently adopted or issued accounting pronouncements that are expected to have a material impact on the Company.

Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP"). The consolidated financial statements include the accounts of LanzaTech NZ, Inc. and its wholly-owned consolidated subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation.

As part of its evaluation, the Company makes judgments in determining whether an entity is a variable interest entity (“VIE”) and, if so, whether it is the primary beneficiary of the VIE and is thus required to consolidate the entity. A VIE is a legal entity that has a total equity investment that is insufficient to finance its activities without additional subordinated financial support or whose equity investors lack the characteristics of a controlling financial interest. Our variable interest arises from contractual, ownership or other monetary interests in the entity, which change with fluctuations in the fair value of the entity’s net assets. A VIE is consolidated by its primary beneficiary, the party that has both the power to direct the activities that most significantly impact the VIE’s economic performance, and the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. We consolidate a VIE when we are deemed to be the primary beneficiary. We assess whether or not we are the primary beneficiary of a VIE on an ongoing basis. If we are not deemed to be the primary beneficiary in a VIE, we account for the investment or other variable interests in a VIE in accordance with applicable US GAAP.

The Company holds interests in certain VIEs for which it has been determined the Company is not the primary beneficiary. The Company's variable interests primarily relate to entities in which the Company has a non-controlling equity interest. Although these financial arrangements resulted in holding variable interests in these entities, they do not empower the Company to direct the activities of the VIEs that most significantly impact the VIEs' economic performance. The Company's interests in the VIEs are, therefore, accounted for under the equity method of accounting or at fair value (including, when applicable, the practicability exception to fair value under ASC 321-10-35). Refer to Note 5 - Investments, for further information. The Company is exposed to the VIEs’ losses and other impairment indicators up to the carrying value of each investment and any amounts receivable from the VIE, less amounts payable. Refer to Note 12, Related Party Transactions, for further details on the transactions with VIEs.

Going Concern

The accompanying consolidated financial statements of the Company have been prepared in accordance with US GAAP and assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. The Company had cash and cash equivalents of $83,045 and an accumulated deficit of $(456,245) as of December 31, 2022 and cash outflows from operations of $(84,703) and a net loss of $(76,356) for the year ended December 31, 2022.

The Company has historically funded its operations through debt financing and issuance of equity securities. Based on the Company’s financial position as of the date these consolidated financial statements were available to be issued, the Company projects that it will be able to cover its liquidity needs for the next twelve months with cash on hand. Further, as a result of the Business Combination described in Note 1 closing on February 8, 2023, the Company received $153,042, which represents the proceeds from the Business Combination received net of transaction expenses paid at Closing and the amount paid to ACM ARRT H LLC in relation to the Forward Purchase Agreement. Accordingly, the Company’s consolidated financial statements have been prepared on the basis that it will continue as a going concern.

Use of Estimates

liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include fair value of equity awards granted to both employees and non-employees, revenue recognized over time, AM SAFE, Brookfield SAFE and the AM SAFE warrants.

The Company uses the percentage of completion for both input and output methods to recognize revenue over time for certain contract with a customer. Under the output method, the Company exercises judgment and estimation when determining the percentage of completion against the total transaction price initially estimated. Under the input method, the Company exercises judgment and estimation when selecting the most indicative measure of such performance.

Additionally, most of our arrangements provide fixed consideration, however, when there are variable consideration elements, the Company estimates the transaction price and whether revenue should be constrained. Significant estimates and judgments are also used when a material right is provided to the customer. In these instances, the Company estimates the stand-alone selling price and apportions the total transaction price to this material right. Refer to Revenue Recognition section in Note 2 hereunder.

Changes in facts and circumstances or additional information may result in revised estimates, and actual results may differ from these estimates.

Segment Information

While the Company offers a variety of services and operates in multiple countries, the Company’s business operates in one operating segment because most of the Company’s service offerings are delivered and supported on a global basis, most of the Company’s service offerings are deployed in a similar way, and the Company’s CODM evaluates the Company’s financial information and resources and assesses the performance of these resources on a consolidated basis. There are no segment managers who are held accountable by the CODM, or anyone else, for operations, operating results, and planning for components below the consolidated level. Accordingly, the Company has determined that it has a single reportable and operating segment. See Note 4, Revenues, for disaggregation of the Company’s revenues by customer location and contract type.

Foreign Currencies

The Company’s reporting currency is the U.S. Dollar. The Company has certain foreign subsidiaries where the functional currency is the local currency. All of the assets and liabilities of these subsidiaries are converted to U.S. dollars at the exchange rate in effect at the balance sheet date, income and expense accounts are translated at average rates for the period, and shareholder’s equity accounts are translated at historical rates. The effects of translating financial statements of foreign operations into our reporting currency are recognized as an adjustment in accumulated other comprehensive income (loss).

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. As of December 31, 2022 and December 31, 2021, the Company had $83,045 and $128,318 of cash and cash equivalents, respectively.

Restricted Cash and Other Cash Flows from Operating Activities

The Company is required to maintain a cash deposit with a bank which consists of collateral on certain travel and expense programs maintained by the bank. The following represents a reconciliation of cash and cash equivalents in the consolidated balance sheets to total cash, cash equivalents and restricted cash in the consolidated statements of cash flows as of December 31, 2022 and December 31, 2021 (in thousands).


	As of
	December 31, 2022		December 31, 2021
Cash and cash equivalents	$	83,045	$	128,318
Restricted cash (presented within Other current assets)	665		414
Cash, cash equivalents and restricted cash	$	83,710	$	128,732

Trade and Other Receivables

Receivables are reported net of allowances for doubtful accounts. The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of customers to make required payments. The Company estimates the allowance for doubtful accounts based on a variety of factors including the length of time receivables are past due, the financial health of customers, unusual macroeconomic conditions, and historical experience. As of December 31, 2022 and December 31, 2021, the Company recognized an allowance for doubtful accounts of $1,051 and $1,235, respectively.

Other Current Assets

Other current assets consist of prepaid expenses, materials and supplies, and other assets. Material and supplies consist of spare parts and consumables used for research and research equipment and is stated at the weighted average cost.

Property, Plant and Equipment, net

Property and equipment are stated at cost and include improvements that significantly increase capacities or extend the useful lives of existing plant and equipment. Depreciation is calculated using the straight-line method over the estimated useful life of the assets. Useful lives range from three to five years for instruments and equipment, three to five years for office equipment and furniture and software, five years for vehicles and, for leasehold improvements, the shorter of the life of the improvement or the remaining term of the lease.

The Company reviews the remaining useful life of its assets on a regular basis to determine whether changes have taken place that would suggest that a change to depreciation policies is warranted.

Upon retirement or disposal of property, plant and equipment, the cost and related accumulated depreciation are removed from the account, and the resulting gains or losses, if any, are recorded in the consolidated statements of operations and comprehensive loss. Net gains or losses related to asset dispositions are recognized in earnings in the period in which dispositions occur. Routine maintenance, repairs and replacements are expensed as incurred.

Leases

The Company determines if an arrangement is a lease at inception. Lease agreements under which the Company is a lessee are evaluated to classify the lease as a finance or operating lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. Lease assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. As most leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.

Leases with an initial term of 12 months or less are not recorded on the Company’s consolidated balance sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company accounts for lease components and non-lease components as a single lease component.

Impairment of Long-Lived Assets

The Company performs a recoverability assessment of each of its long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Indicators may include, but are not limited to, adverse changes in the regulatory environment in a jurisdiction where the Company operates, a decision to discontinue the development of a long-lived asset, early termination of a significant customer contract, or the introduction of newer technology.

When performing a recoverability assessment, the Company measures whether the estimated future undiscounted net cash flows expected to be generated by the asset exceeds its carrying value. In the event that an asset does not meet the recoverability test, the carrying value of the asset will be adjusted to fair value resulting in an impairment charge.

Management develops the assumptions used in the recoverability assessment based on active contracts as well as information received from third-party industry sources. The Company did not record an impairment during the years ended December 31, 2022 and 2021.

Equity Method Investments

Investments in entities over which the Company has significant influence, but not control, are accounted for using the equity method of accounting. Gain or loss from equity method investees, net, represents the Company’s proportionate share of net income or loss of its equity method investees and any gains or losses resulting from transactions in the investee’s equity.

Equity method investments are assessed for impairment whenever changes in the facts and circumstances indicate a loss in value may have occurred. When a loss is deemed to have occurred and is other than temporary, the carrying value of the equity method investment is written down to fair value. In evaluating whether a loss is other than temporary, the Company considers the length of time for which the conditions have existed and its intent and ability to hold the investment.

Equity Security Investments

Investments in entities over which the Company has neither significant influence, nor control, are accounted for as an equity security. For investments where the fair value is not readily determinable, the Company will account for its investment using the alternative measurement principals as permitted under Accounting Standards Codification ("ASC") 321, Investments — Equity Securities.

Subsequently, under the alternative measurement method, the Company will adjust the carrying value for observable changes in price and will reassess whether its investment continues to qualify for such method. Additionally, the Company will perform a qualitative assessment and recognize an impairment if there are sufficient indicators that the fair value of the investment is less than its carrying value. The changes in value and impairment charges (if any), are recorded in other expense, net in the consolidated statement of operations

ArcelorMittal Simple Agreement for Future Equity (“AM SAFE”)

In December 2021, the Company issued a SAFE that allowed an investor to participate in future equity financings through a share-settled redemption of the amount invested (such notional being the “invested amount”). The Company determined that the AM SAFE was not legal form debt (i.e., no creditors’ rights). The AM SAFE includes a provision allowing for cash redemption upon the occurrence of a change of control, the occurrence of which is outside the control of the Company. Therefore, the AM SAFE is classified as mark-to-market liability pursuant to ASC 480, Distinguishing Liability from Equity (“ASC 480”).

Brookfield SAFE

On October 2, 2022, the Company entered into a SAFE with Brookfield (the "Brookfield SAFE"). Under the Brookfield SAFE, the Company agreed to issue to Brookfield the right to certain shares of its capital stock, in exchange for the payment of $50,000 (the “Initial Purchase Amount”). The Brookfield SAFE is legal form debt. Management has elected to apply the Fair Value Option ("FVO") under ASC 825, Financial Instruments. As the Brookfield SAFE is accounted for under the FVO, the Brookfield SAFE is classified as mark-to-market liability.

Warrants

The Company has issued warrants to purchase its preferred shares that remain outstanding as of December 31, 2022 and 2021 representing 985,278 preferred shares, for each period respectively, which warrants expire at various dates through December 31, 2027. The exercise prices of the warrants range from $3.36 to $4.56 as of each of December 31, 2022 and 2021. The Company accounts for these warrants as liabilities based upon the characteristics and provisions of each instrument. The liabilities are included in other accrued liabilities on the Company's consolidated balance sheets at their fair value on the date of issuance and are revalued in each subsequent reporting period until such instruments are exercised or expire. The change in fair value between reporting periods is included in other expense, net in the consolidated statements of operations and comprehensive loss.

Further, the warrant related to the AM SAFE (“AM SAFE warrant”) of $1,989 is accounted for as a liability. The AM SAFE warrant is exercisable upon the earliest to occur of a business combination with a special purpose acquisition corporation, an initial public offering, a change in control and a future round of financing involving preferred shares (collectively, the “Corporate Transactions”). The number of shares available under the AM SAFE warrant equals $3,000 divided by the exercise price. The exercise price is the price per share of the PIPE shares in the case of a business combination with a special purpose acquisition corporation or 90% of the price per share in connection with the other Corporate Transactions. The AM SAFE warrant expires at the earliest of (a) the fifth anniversary of the first Corporate Transaction, (b) the consummation of a dissolution event, (c) a change of control, and (d) the date that is the ten-year anniversary of issuance of the AM SAFE warrant. This liability is recorded in current liabilities on the Company's consolidated balance sheets at fair value on the date of issuance and will be revalued each subsequent reporting period until such instrument is exercised or expires. The change in fair value between reporting periods is included in other expense, net in the consolidated statements of operations and comprehensive loss.

Long-Term Debt and Debt Issuance Costs

The Company’s debt consists of credit facilities with financial institutions. Costs directly related to the issuance of debt are reported on the consolidated balance sheets as a reduction from the carrying amount of the recognized debt liability and amortized over the term of the debt using the effective interest method. The only legal form debt outstanding as of December 31, 2022 is the Brookfield SAFE, which is accounted for under the FVO as described above. There is no debt outstanding as of December 31, 2021.

On September 28, 2021, the Company received notice of forgiveness for the Paycheck Protection Program (the “PPP Loan”) granted in 2020 under the Coronavirus Aid, Relief and Economic Security Act, for the total obligation of $3,065. The Company recorded the gain on extinguishment in the 2021 consolidated statement of operations and comprehensive loss.

Revenue Recognition

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). The Company primarily earns revenue from services related to carbon capture and transformation technology, which includes: feasibility studies and basic engineering design of commercial plants, licensing of technologies and sales of biocatalysts. The other two revenue streams are joint development and contract research activities to develop novel biocatalysts and related technologies and sale of ethanol produced using the Company’s proprietary technologies (referred to as CarbonSmart Ethanol).

Carbon Capture and Transformation

The Company licenses intellectual property to generate recurring revenue when its customers deploy our technology in their carbon capture and transformation plants. When licenses are considered to be distinct performance obligations, the recognition of revenue is dependent on the terms of the contract, which may include fixed consideration or royalties based on sales or usage, in which case, the revenue is recognized when the subsequent sale or usage occurs or when the performance obligation to which some or all of the sales or usage-based royalty is allocated has been satisfied, whichever is later.

Research and Development Services

The Company performs R&D services related to novel technologies and development of biocatalysts for commercial applications, mainly to produce fuels and chemicals. The Company engages in two main types of R&D services – joint development agreements, and other contract research, including projects with the U.S. Department of Energy and other US and foreign government agencies. Such services are recognized as a performance obligation satisfied over time. Revenue is recognized based on milestone completion, when payments are contingent upon the achievement of such milestones, or based on percentage-completion method when enforceable rights to payment exist. When no milestones or phases are clearly defined, management has determined that the cost incurred, input method, is an appropriate measure of progress towards complete satisfaction of the performance obligations under ASC 606, and estimates its variable consideration under the expected value method.

Collaboration Arrangements

The Company has certain partnership agreements that are within the scope of ASC 808, Collaborative Arrangements, which provides guidance on the presentation and disclosure of collaborative arrangements. Generally, the classification of the transaction under the collaborative arrangements is determined based on the nature of the contractual terms of the arrangement, along with the nature of the operations of the participants. The Company’s collaborative agreements generally include a provision of R&D services related to novel technologies and biocatalysts. Amounts received for these services are classified as Revenue from collaborative arrangements in the consolidated statements of operations and comprehensive loss. The Company's R&D services are a major part of the Company's ongoing operations and therefore ASC 606 is applied to recognize revenue.

CarbonSmart

The Company acquires ethanol from customers who have deployed our proprietary technologies in their carbon capture and transformation facilities and sells it as CarbonSmart ethanol to end customers. Revenue is recognized at

a point in time when control transfers to our end customer, which varies depending on the shipping terms. The Company acts as the principal in such transactions and accordingly, recognizes revenue and cost of revenues on a gross basis. Amounts received for sales of CarbonSmart ethanol are classified as Revenue from contract with customers - tangible products in the consolidated statements of operations and comprehensive loss.

Cost of Revenues

The Company’s R&D, engineering, and other direct costs of services and goods related to revenue agreements with customers, related parties, and collaborative partners represent cost of revenue. Costs include both internal and third-party fixed and variable costs and include materials, supplies, labor, and fringe benefits.

Research and Development

We incur costs associated with various R&D activities and expense these costs as incurred.

Stock-Based Compensation

In exchange for certain employee and director services, compensation is given in the form of equity awards. The Company accounts for equity-based compensation in accordance with ASC 718, Compensation – Stock Compensation. Accordingly, equity-classified awards are recorded based on the grant date fair value and expensed over the requisite service period for the respective award.

The Company’s equity-based awards include stock option awards and restricted stock issued by the Company, which vest based on either time or the achievement of certain performance conditions. The Company records forfeitures as they occur. Compensation expense resulting from time-vesting-based awards is recognized in the Company’s consolidated statements of operations and comprehensive loss, primarily within research and development expenses, at the grant date fair value over the requisite service period. Compensation expense resulting from performance awards recognized over the requisite service period when it is probable that the performance condition will be met. The calculated compensation expense for performance awards is adjusted based on an estimate of awards ultimately expected to vest. The Company estimates grant date fair value using a Black-Scholes option pricing model that uses assumptions including expected volatility, expected term, and the expected risk-free rate of return. The Company has determined that the Black-Scholes option pricing model, as well as the underlying assumptions used in its application, is appropriate in estimating the fair value of its award grants.

Benefit Plans

The Company sponsors a 401(k) defined contribution retirement plan for the benefit of its employees, substantially all of whom are eligible to participate after meeting minimum qualifying requirements. Contributions to the plan are at the discretion of the Company. For the years ended December 31, 2022 and 2021, the Company contributed $987 and $720, respectively, to the plan, which contributions are included within research and development expense in the consolidated statements of operations and comprehensive loss.

Income Taxes

The Company follows the asset and liability method of accounting for income taxes under ASC 740, Income Taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

Deferred income tax assets are evaluated to determine if valuation allowances are required or should be adjusted. Valuation allowances are established based on a more likely than not standard. The ability to realize deferred tax assets depends on the Company’s ability to generate sufficient taxable income within the carry back or carryforward periods provided for in the tax law for each tax jurisdiction. The Company considers the various

possible sources of taxable income when assessing the realization of its deferred tax assets. The valuation allowances recorded against deferred tax assets generated by taxable losses in certain jurisdictions will affect the provision for income taxes until the valuation allowances are released. The Company’s provision for income taxes will include no tax benefit for losses incurred and no tax expense with respect to income generated in these jurisdictions until the respective valuation allowance is eliminated.

The Company records uncertain tax positions on the basis of a two-step process whereby it is determined whether it is more likely than not that the tax positions will be sustained based on the technical merits of the position, and for those tax positions that meet the more likely than not criteria, the largest amount of tax benefit that is greater than 50% likely to be realized upon ultimate settlement with the related tax authority is recognized. The Company recognizes accrued interest and penalties related to unrecognized tax benefits in income tax expense.

Related Party Transactions

The Company follows ASC 850-10, Related Party Transactions, for the identification of related parties and disclosure of related party transactions.

Pursuant to ASC 850-10-20, related parties include: a) affiliates of the Company; b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825-10-15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. Refer to Note 5 - Investments, and Note 12, Related Party Transactions, for further information.

Net Loss Per Share

Basic net loss per share is computed by dividing net loss attributable to participating stock by the weighted average number of shares of participating stock outstanding during the period.

Diluted net loss per share reflects potential dilution and is computed by dividing net loss attributable to participating stock by the weighted average number of shares of participating stock outstanding during the period. The dilutive effect of outstanding awards, if any, is reflected in diluted earnings per share by application of the treasury stock method or if-converted method, as applicable. Refer to Note 3, Net Loss Per Share, for additional information.

Shareholders’ Equity

The securities of the Company are represented by common shares, par value $0.0001 per share. Each common share is entitled to one vote. With respect to payment of dividends and distribution of assets upon liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, all common shares shall participate pro rata in such payment whenever funds are legally available and when declared by the Board of Directors of the Company, subject to the prior rights of holders of all classes of stock outstanding.

Fair Value of Financial Instruments

use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:

Level 1 — Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access;

Level 3 — Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, Fair Value Measurement, approximates the carrying amounts represented in the accompanying consolidated balance sheets, primarily due to their short-term nature, except for the warrant liability.

Concentration of Credit Risk and Other Risks and Uncertainties

Revenue generated from the Company’s customers outside of the United States for the years ended December 31, 2022 and 2021 was approximately 61% and 38%, respectively.

As of December 31, 2022 and December 31, 2021, approximately 35% and 35%, respectively, of trade accounts receivable and unbilled accounts receivable were due from customers located outside the United States. As of December 31, 2022 and December 31, 2021, the value of property, plant, and equipment outside the United States was immaterial.

The Company’s revenue by geographic region based on the customer’s location is presented in Note 4, Revenues.

Customers

Customers representing 10% or greater of revenue were as follows for the years ended December 31, 2022 and 2021:


	Year Ended December 31,
	2022		2021
Customer A	22	%	27	%
Customer B	10	%	15	%
Customer C	7	%	12	%

Recently Adopted Accounting Pronouncements

In December 2019, the FASB issued Accounting Standard Update (“ASU”) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), as part of its simplification initiative to reduce the cost and complexity in accounting for income taxes. ASU 2019-12 removes certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also amends other aspects of the guidance to help simplify and promote consistent application of US GAAP. The Company adopted ASU 2019-12 as of January 1, 2021 with no material impact on its consolidated financial statements.

Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Cash and cash equivalents	$ 91,397	$ 110,719	$ 145,118	$ 83,045	$ 128,318

Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended		6 Months Ended	9 Months Ended	12 Months Ended
	May 13, 2023	Feb. 08, 2023	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2023	Sep. 30, 2023	Dec. 31, 2021	Mar. 27, 2023	Feb. 03, 2023	Dec. 31, 2022	Nov. 09, 2022
Warrants
Number of shares issuable by warrant (in shares)		985,278					985,278		10,000,000	985,278	316,250
Exercise of warrants (in shares)		594,309		594,309			691,453
Class of warrant or right, exercise price of warrants or rights (in dollars per share)		$ 9.91					$ 4.56			$ 3.36	$ 0.01
Fair value of shares		$ 5,890
Warrants outstanding (in shares)		12,574,200
Minimum
Warrants
Class of warrant or right, exercise price of warrants or rights (in dollars per share)		$ 3.36								$ 3.36
Maximum
Warrants
Class of warrant or right, exercise price of warrants or rights (in dollars per share)		4.56					$ 4.56
AM SAFE Warrant
Warrants
Number of shares issuable by warrant (in shares)			300,000	300,000	300,000	300,000
Class of warrant or right, exercise price of warrants or rights (in dollars per share)		$ 10.00	$ 10.00	$ 10.00	$ 10.00	$ 10.00
Fair value of shares			$ 1,800	$ 1,800	$ 1,800	$ 1,800
Shortfall Warrants
Warrants
Number of shares issuable by warrant (in shares)									4,083,486
Fair value of shares	$ 3,063		3,063		$ 3,063			$ 5,104
Price of warrant (in usd per warrant)								$ 10.00
Financial Instruments Subject to Mandatory Redemption, Reclassification Gain	$ 2,042		$ 2,042
Shortfall Warrants \| ACM
Warrants
Warrants issued (in shares)								2,073,486
Shortfall Warrants \| Vellar Opportunity Fund SPV LLC - Series 10
Warrants
Warrants issued (in shares)								2,010,000
Public Warrants and Private Placement Warrants
Warrants
Class of warrant or right, exercise price of warrants or rights (in dollars per share)			$ 11.50	$ 11.50	$ 11.50	$ 11.50
Price of warrant (in usd per warrant)			$ 11.50	$ 11.50	$ 11.50	$ 11.50
Threshold period days after the completion of the initial Business Combination for exercise of warrants				30 days	30 days	30 days
Threshold period for filling registration statement after business combination				5 years	5 years	5 years
Public Warrants and Private Placement Warrants \| Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00
Warrants
Redemption price per public warrant (in dollars per share)				$ 0.01	$ 0.01	$ 0.01
Redemption period				30 days	30 days	30 days
Trigger price (usd per share)				$ 18.00	$ 18.00	$ 18.00
Threshold trading days for redemption of public warrants				20 days	20 days	20 days
Minimum threshold written notice period for redemption of public warrants				30 days	30 days	30 days
Public warrants
Warrants
Warrants outstanding (in shares)		7,499,924	7,499,924	7,499,924	7,499,924	7,499,924
Private placement warrants
Warrants
Warrants outstanding (in shares)		4,774,276	4,774,276	4,774,276	4,774,276	4,774,276

Investments - Equity Method Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Equity Method Investments [Line Items]
Equity Method Investment in LanzaJet	$ 9,594	$ 10,164	$ 9,835	$ 10,561	$ 24,752
Equity Security Investment in SGLT	14,990	14,990	14,990	14,990
Total Investment	$ 24,584	$ 25,154	$ 24,825	25,551	24,752
LanzaJet
Schedule of Equity Method Investments [Line Items]
Equity Method Investment in LanzaJet				$ 10,561	12,433
SGLT
Schedule of Equity Method Investments [Line Items]
Equity Method Investment in LanzaJet					$ 12,319

Summary of Significant Accounting Policies - Long-Term Debt and Debt Issuance Costs (Details) $ in Thousands	Sep. 28, 2021 USD ($)
PPP Loan
Debt Instrument [Line Items]
Debt forgiveness	$ 3,065

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482900/835-30-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(f))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69F
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

SAFE (Details) - USD ($)		12 Months Ended
SAFE (Details) - USD ($)	Feb. 08, 2023	Dec. 31, 2022	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Oct. 02, 2022	Dec. 31, 2021
Derivative [Line Items]
AM SAFE liability		$ 28,986,000	$ 0	$ 0	$ 0		$ 28,271,000
Proceeds from Brookfield SAFE agreement		50,000,000
Required equity funding for qualifying projects						$ 50,000,000
Required equity funding for qualifying projects, remaining amount reduction						5,000,000
Brookfield SAFE liability		50,000,000	$ 23,350,000	$ 34,150,000	$ 19,400,000		$ 0
Required equity funding						$ 500,000,000
Shares issued in transaction (in shares)	196,222,737
AM SAFE Liability
Derivative [Line Items]
AM SAFE liability	$ 29,730,000	$ 28,986,000
Shares issued in transaction (in shares)	3,000,000
Stock repurchased (usd per share)	$ 9.91

Fair Value - Change in Fair Value of Derivative Warrant Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Derivative warrant liabilities at the beginning	$ 2,119	$ 1,145	$ 2,119	$ 1,145	$ 2,119	$ 1,145	$ 1,145	$ 582
Conversion of warrants to preferred shares	5,889		5,889		5,889		0	0
Change in fair value of derivative liabilities	3,770	(41)	3,770	78	3,770	427	974	563
Derivative warrant liabilities at the end	0	1,104	0	1,223	0	1,572	2,119	1,145
AM SAFE liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Derivative warrant liabilities at the beginning	28,986	28,271	28,986	28,271	28,986	28,271	28,271	0
Conversion of warrants to preferred shares							0	28,271
Change in fair value of derivative liabilities	744	(148)	744	(1,062)	744	(1,050)	715	0
Conversion of SAFE liability	29,730		29,730		29,730
Derivative warrant liabilities at the end	0	28,123	0	27,209	0	27,221	28,986	28,271
AM SAFE warrant
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Derivative warrant liabilities at the beginning	1,989	1,729	1,989	1,729	1,989	1,729	1,729	0
Conversion of warrants to preferred shares							0	1,729
Change in fair value of derivative liabilities	(189)	129	(189)	218	(189)	293	260	0
Conversion of AM SAFE warrant to equity classification	1,800		1,800		1,800
Derivative warrant liabilities at the end	0	1,858	0	1,947	0	2,022	1,989	1,729
Brookfield SAFE
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Derivative warrant liabilities at the beginning	50,000	$ 0	50,000	$ 0	50,000	$ 0	0
Conversion of warrants to preferred shares							50,000
Change in fair value of derivative liabilities	(30,600)		(15,850)		(26,650)		0
Derivative warrant liabilities at the end	19,400		34,150		23,350		50,000	$ 0
Forward Contracts
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Derivative warrant liabilities at the beginning	0		0		0
Change in fair value of derivative liabilities	44,593
Derivative warrant liabilities at the end	44,593						0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value			(26,743)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings			(26,743)
Fixed Maturity Consideration
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Derivative warrant liabilities at the beginning	0		0		0
Change in fair value of derivative liabilities	6,967		6,737		7,020
Derivative warrant liabilities at the end	6,967		6,737		7,020		0
Shortfall Warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Derivative warrant liabilities at the beginning	0		0		0
Change in fair value of derivative liabilities	5,104		3,063		3,063
Conversion of AM SAFE warrant to equity classification			3,063		3,063
Derivative warrant liabilities at the end	5,104		0		0		0
Private placement warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Derivative warrant liabilities at the beginning	0		0		0
Change in fair value of derivative liabilities	477		3,199		2,912
Recognized as a result of the Business Combination	(2,148)		(2,148)		(2,148)
Derivative warrant liabilities at the end	$ 2,626		$ 5,347		$ 5,060		$ 0

Leases (Tables)

12 Months Ended

Dec. 31, 2022

Leases [Abstract]

Lessee, Operating Lease, Liability, Maturity

As the lease has not commenced, it is not part of the disclosures in Note 15, Leases. The following table represents the future lease payments for this lease (in thousands):


Year ending December 31,
2023						—
2024						642
2025						1,303
2026						1,342
2027						—
Thereafter						—
Total cash payments						3,287

As of December 31, 2022, lease payments for operating leases for the Company’s office facility and laboratories are shown below (in thousands):


Year ending December 31,
2023	$	1,302
2024	2,602
2025	2,347
2026	2,418
2027	—
Thereafter	—
Total lease payments	$	8,669
Less: imputed interest	1,256
Total lease liabilities	$	7,413

Assets And Liabilities, Lessee

The following is a summary of weighted average remaining lease term and discount rate for all of the Company’s operating leases:


	Year Ended December 31,
	2022		2021
Weighted average remaining lease term (years)	3.5		2.4
Weighted average discount rate	7.50	%	7.50	%

Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity

The following future minimum lease payments due to us from the lease agreement at December 31, 2022, is as follows (in thousands)


Year ending December 31,
2023	$	34
2024	155
2025	155
2026	155
2027	155
Thereafter	1,240
	$	1,894

Property, Plant, and Equipment

12 Months Ended

Dec. 31, 2022

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Property, Plant and Equipment, net

The Company’s property, plant and equipment, net consisted of the following (in thousands):


	As of
	December 31, 2022		December 31, 2021
Land	$	64	$	64
Leasehold improvements	4,126		4,113
Instruments and equipment	33,093		26,627
Vehicles	85		71
Office Equipment and furniture	1,719		1,590
Other	871		728
Construction in progress	6,780		3,328
	$	46,738	$	36,521

Less accumulated depreciation and amortization	$	27,049	$	22,373

Total property, plant and equipment, net	$	19,689	$	14,148

Depreciation for the years ended December 31, 2022 and December 31, 2021 totaled $4,660 and $3,806, respectively.

Other Current Assets

12 Months Ended

Dec. 31, 2022

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Other Current Assets

As of December 31, 2022 and 2021 other current assets consisted of the following (in thousands):


	As of
	December 31, 2022		December 31, 2021
Materials and supplies	$	4,164	$	2,900
Prepaid assets	2,833		1,503
Other	4,160		1,376
	$	11,157	$	5,779

Leases - Lease Maturities (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Leases [Abstract]
Year one	$ 1,302
Year two	2,602
Year three	2,347
Year four	2,418
Year five	0
Thereafter	0
Total lease payments	8,669
Less: imputed interest	1,256
Total lease liabilities	$ 7,413

Summary of Significant Accounting Policies (Tables)

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Mar. 31, 2023

Jun. 30, 2023

Sep. 30, 2023

Dec. 31, 2022

Accounting Policies [Abstract]

Schedule of error corrections

The effect of the correction of the error noted above on the relevant financial statement line items is as follows:


	As of March 31, 2023
	As Previously Reported		Adjustments		As Restated
Condensed Consolidated Balance Sheet
Prepaid forward contract derivative	15,954		(15,954)		—
Total assets	$	307,957	$	(15,954)	$	292,003
FPA Put Option liability	—		44,593		44,593
Total liabilities	$	78,145	$	44,593	$	122,738
Additional paid-in capital	988,188		(60,547)		927,641
Total shareholders’ equity (deficit)	$	229,812	$	(60,547)	$	169,265
Total liabilities, contingently redeemable preferred stock, and shareholders' equity	$	307,957	$	(15,954)	$	292,003


	Period Ended March 31, 2023
	As Previously Reported		Adjustments		As Restated
Condensed Consolidated Statement of Changes in Redeemable Convertible Preferred Stock and Shareholders’ Equity/ Deficit
Forward Purchase Agreement prepayment	—		(60,547)		(60,547)
Additional Paid-in Capital - balance at March 31, 2023	988,188		(60,547)		927,641
Total shareholders’ deficit - balance at March 31, 2023	$	229,812	$	(60,547)	$	169,265

The effect of the correction of the error noted above on the relevant financial statement line items is as follows:


	As of June 30, 2023
	As Previously Reported		Adjustments		As Restated
Condensed Consolidated Balance Sheet
Prepaid forward contract derivative	33,804		(33,804)		—
Total assets	$	302,337	$	(33,804)	$	268,533
FPA Put Option liability	—		26,743		26,743
Total liabilities	$	90,699	$	26,743	$	117,442
Additional paid-in capital	996,704		(60,547)		936,157
Total shareholders’ equity (deficit)	$	211,638	$	(60,547)	$	151,091
Total liabilities, contingently redeemable preferred stock, and shareholders' equity	$	302,337	$	(33,804)	$	268,533

	Period Ended June 30, 2023
	As Previously Reported		Adjustments		As Restated
Condensed Consolidated Statement of Changes in Redeemable Convertible Preferred Stock and Shareholders’ Equity/ Deficit
Forward Purchase Agreement prepayment	—		(60,547)		(60,547)
Additional Paid-in Capital - balance at March 31, 2023	988,188		(60,547)		927,641
Total shareholders’ deficit - balance at March 31, 2023	$	229,812	$	(60,547)	$	169,265
Additional Paid-in Capital - balance at June 30, 2023	996,704		(60,547)		936,157
Total shareholders’ deficit - balance at June 30, 2023	$	211,638	$	(60,547)	$	151,091

Schedule of cash and cash equivalents

The following represents a reconciliation of cash and cash equivalents in the condensed consolidated balance sheets to total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows as of March 31, 2023 and December 31, 2022 (in thousands).


	As of
	March 31, 2023		December 31, 2022
Cash and cash equivalents	$	145,118	$	83,045
Restricted cash (presented within Other current assets)	668		665
Cash, cash equivalents and restricted cash	$	145,786	$	83,710


	As of
	September 30, 2023		December 31, 2022
Cash and cash equivalents	$	91,397	$	83,045
Restricted cash (presented within Other current assets)	673		665
Cash, cash equivalents and restricted cash	$	92,070	$	83,710

The following represents a reconciliation of cash and cash equivalents in the consolidated balance sheets to total cash, cash equivalents and restricted cash in the consolidated statements of cash flows as of December 31, 2022 and December 31, 2021 (in thousands).


	As of
	December 31, 2022		December 31, 2021
Cash and cash equivalents	$	83,045	$	128,318
Restricted cash (presented within Other current assets)	665		414
Cash, cash equivalents and restricted cash	$	83,710	$	128,732

Customer concentration risk

Customers representing 10% or greater of revenue were as follows for the three months ended March 31, 2023 and 2022:


	Three Months Ended March 31,
	2023		2022
Customer A	30	%	19	%
Customer B	13	%	22	%
Customer C	10	%	8	%

Customers representing 10% or greater of revenue were as follows for the three and six months ended June 30, 2023 and 2022:


	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Customer A	51	%	10	%	42	%	14	%
Customer B	5	%	22	%	9	%	22	%

Customers representing 10% or greater of revenue were as follows for the three and nine months ended September 30, 2023 and 2022:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Customer A	36	%	—	%	39	%	10	%
Customer B	7	%	27	%	8	%	24	%
Customer C	—	%	21	%	—	%	10	%

Customers representing 10% or greater of revenue were as follows for the years ended December 31, 2022 and 2021:


	Year Ended December 31,
	2022		2021
Customer A	22	%	27	%
Customer B	10	%	15	%
Customer C	7	%	12	%

Fair Value (Tables)

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Mar. 31, 2023

Jun. 30, 2023

Sep. 30, 2023

Dec. 31, 2022

Fair Value Disclosures [Abstract]

Summary of assets and liabilities that are measured at fair value on a recurring basis

The following table presents the Company’s fair value hierarchy for its assets and liabilities measured at fair value as of March 31, 2023 and December 31, 2022 (in thousands):


	Fair Value Measurement as of
	March 31, 2023
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	31,397	$	—	$	—	$	31,397
Total assets	$	31,397	$	—	$	—	$	31,397

Liabilities:
FPA Put Option liability	$	—	$	—	$	44,593	$	44,593
Fixed Maturity Consideration	—		—		6,967		6,967
Shortfall Warrants	—		—		5,104		5,104
Brookfield SAFE liability	—		—		19,400		19,400
Private placement warrants	—		—		2,626		2,626
Public warrants	2,189		—		—		2,189
Total liabilities	$	2,189	$	—	$	78,690	$	80,879


	Fair Value Measurement as of
	December 31, 2022
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	523	$	—	$	—	$	523

Liabilities:
Warrants on preferred shares	—		—		2,119		2,119
Brookfield SAFE liability	—		—		50,000		50,000
AM SAFE warrant	—		—		1,989		1,989
AM SAFE liability	—		—		28,986		28,986
Total Liabilities	$	—	$	—	$	83,094	$	83,094

The following table presents the Company’s fair value hierarchy for its assets and liabilities measured at fair value as of June 30, 2023 and December 31, 2022 (in thousands):


	Fair Value Measurement as of
	June 30, 2023
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	31,665	$	—	$	—	$	31,665
Total assets	$	31,665	$	—	$	—	$	31,665

Liabilities:
FPA Put Option liability	$	—	$	—	$	26,743	$	26,743
Fixed Maturity Consideration	—		—		6,737		6,737
Brookfield SAFE liability	—		—		34,150		34,150
Private placement warrants	—		—		5,347		5,347
Public warrants	3,075		—		—		3,075
Total liabilities	$	3,075	$	—	$	72,977	$	76,052


	Fair Value Measurement as of
	December 31, 2022
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	523	$	—	$	—	$	523

Liabilities:
Warrants on preferred shares	—		—		2,119		2,119
Brookfield SAFE liability	—		—		50,000		50,000
AM SAFE warrant	—		—		1,989		1,989
AM SAFE liability	—		—		28,986		28,986
Total Liabilities	$	—	$	—	$	83,094	$	83,094

The following table presents the Company’s fair value hierarchy for its assets and liabilities measured at fair value as of September 30, 2023 and December 31, 2022 (in thousands):


	Fair Value Measurement as of
	September 30, 2023
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	37,370	$	—	$	—	$	37,370
Total assets	$	37,370	$	—	$	—	$	37,370

Liabilities:
FPA Put Option liability	$	—	$	—	$	38,092	$	38,092
Fixed Maturity Consideration	—		—		7,020		7,020
Brookfield SAFE liability	—		—		23,350		23,350
Private placement warrants	—		—		5,060		5,060
Public warrants	4,575		—		—		4,575
Total liabilities	$	4,575	$	—	$	73,522	$	78,097


	Fair Value Measurement as of
	December 31, 2022
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	523	$	—	$	—	$	523

Liabilities:
Warrants on preferred shares	—		—		2,119		2,119
Brookfield SAFE liability	—		—		50,000		50,000
AM SAFE warrant	—		—		1,989		1,989
AM SAFE liability	—		—		28,986		28,986
Total Liabilities	$	—	$	—	$	83,094	$	83,094

The following table presents the Company’s fair value hierarchy for its assets and liabilities measured at fair value as of December 31, 2022 and December 31, 2021 (in thousands):


	Fair Value Measurement as of
	December 31, 2022
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	523	$	—	$	—	$	523

Liabilities:
Warrants on preferred shares	$	—	$	—	$	2,119	$	2,119
Brookfield SAFE liability	—		—		50,000		50,000
AM SAFE warrant	—		—		1,989		1,989
AM SAFE liability	—		—		28,986		28,986
Total liabilities	$	—	$	—	$	83,094	$	83,094


	Fair Value Measurement as of
	December 31, 2021
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	516	$	—	$	—	$	516

Liabilities:
Warrants	—		—		1,145		$	1,145
AM SAFE warrant	—		—		1,729		1,729
AM SAFE liability	—		—		28,271		28,271
Total Liabilities	$	—	$	—	$	31,145	$	31,145

Summary of quantitative information regarding Level 3 fair value measurement inputs

The following table represents the weighted average inputs used in calculating the fair value of the prepaid forward contract and the Fixed Maturity Consideration as of March 31, 2023:


	March 31, 2023
Stock price	$	3.88
Term (in years)	2.86
Expected volatility	55.0		%
Risk-free interest rate	3.81		%
Expected dividend yield	—		%

Warrants on preferred shares


	December 31, 2022
Stock price	$	5.21
Weighted average exercise price	$	3.96
Term (in years)	1.1
Expected volatility	73.4		%
Risk-free interest rate	4.47		%
Expected dividend yield	—		%

Shortfall Warrants


	March 31, 2023
Stock price	$	3.88
Weighted average exercise price	$	10.00
Term (in years)	5.0
Expected volatility	68.0		%
Risk-free interest rate	3.59		%
Expected dividend yield	—		%

Significant inputs for Level 3 AM SAFE liability fair value measurement at December 31, 2022 are as follows:


	Near Term		Long-Term
Key assumptions:
Probability weighting	61	%	39	%
Time to conversion (in years)	0.1		0.8
Liquidity price	100	%	90	%
Discount rate	24.7	%	24.7	%

The following table represents the weighted average inputs used in calculating the fair value of the preferred share warrants outstanding at conversion to equity on February 8, 2023:


	February 8, 2023
Stock price	$	9.91
Term (in years)	5.00
Expected volatility	70.0		%
Risk-free interest rate	3.82		%
Expected dividend yield	—		%

Significant inputs for Level 3 AM SAFE warrant fair value measurement at December 31, 2022 are as follows:


	Near Term		Long-Term
Key assumptions:
Probability weighting	61	%	39	%
Remaining life (in years)	5.0		5.0
Volatility	75	%	75	%
Interest rate	3.99	%	3.99	%
Time to conversion (in years)	0.1		0.8
Risk-free interest rate	4.12	%	4.75	%
Dividend yield	—	%	—	%

Significant inputs for Level 3 Brookfield SAFE measurement at March 31, 2023 are as follows:


	March 31, 2023
Initial purchase amount	$	50,000
Liquidity price	10.00
Stock price	3.88


	March 31, 2023			February 8, 2023
Stock price	$	3.88		$	9.91
Exercise price	$	11.50		$	11.50
Term (in years)	4.86			5.00
Expected volatility	45.0		%	2.0		%
Risk-free interest rate	3.60		%	3.82		%
Expected dividend yield	—		%	—		%

The following table represents the weighted average inputs used in calculating the fair value of the prepaid forward contract and the Fixed Maturity Consideration as of June 30, 2023:


	June 30, 2023
Stock price	$	6.83
Term (in years)	2.61
Expected volatility	50.0		%
Risk-free interest rate	4.59		%
Expected dividend yield	—		%

the following table represents the weighted average inputs used in calculating the fair value of the preferred share warrants outstanding as of December 31, 2022:


	December 31, 2022
Stock price	$	5.21
Weighted average exercise price	$	3.96
Term (in years)	1.1
Expected volatility	73.4		%
Risk-free interest rate	4.47		%
Expected dividend yield	—		%

The following table represents the weighted average inputs used in calculating the fair value of the Shortfall Warrants as of May 13, 2023 when the Shortfall Warrant Agreement was amended and the Shortfall Warrants were marked-to-market and reclassified to additional paid-in capital on the condensed consolidated balance sheet:


	May 13, 2023
Stock price	$	3.42
Weighted average exercise price	$	10.00
Term (in years)	4.87
Expected volatility	54.0		%
Risk-free interest rate	3.46		%
Expected dividend yield	—		%

Significant inputs for Level 3 AM SAFE liability fair value measurement at December 31, 2022 are as follows:


	Near Term		Long-Term
Key assumptions:
Probability weighting	61	%	39	%
Time to conversion (in years)	0.1		0.8
Liquidity price	100	%	90	%
Discount rate	24.7	%	24.7	%

The following table represents the weighted average inputs used in calculating the fair value of the preferred share warrants outstanding at conversion to equity on February 8, 2023:


	February 8, 2023
Stock price	$	9.91
Term (in years)	5.00
Expected volatility	70.0		%
Risk-free interest rate	3.82		%
Expected dividend yield	—		%

Significant inputs for Level 3 AM SAFE warrant fair value measurement at December 31, 2022 are as follows:


	Near Term		Long-Term
Key assumptions:
Probability weighting	61	%	39	%
Remaining life (in years)	5.0		5.0
Volatility	75	%	75	%
Interest rate	3.99	%	3.99	%
Time to conversion (in years)	0.1		0.8
Risk-free interest rate	4.12	%	4.75	%
Dividend yield	—	%	—	%

Significant inputs for Level 3 Brookfield SAFE measurement at June 30, 2023 are as follows:


	June 30, 2023
Initial purchase amount	$	50,000
Liquidity price	$	10.00
Stock price	$	6.83

he following table represents the weighted average inputs used in calculating the fair value of the Private Placement Warrants outstanding as of June 30, 2023 and at the time of the Business Combination:


	June 30, 2023
Stock price	$	6.83
Exercise price	$	11.50
Term (in years)	4.61
Expected volatility	32.5		%
Risk-free interest rate	4.13		%
Expected dividend yield	—		%

The following table represents the weighted average inputs used in calculating the fair value of the prepaid forward contract and the Fixed Maturity Consideration as of September 30, 2023:


	September 30, 2023
Stock price	$	4.67
Term (in years)	2.36
Expected volatility	50.0		%
Risk-free interest rate	4.89		%
Expected dividend yield	—		%

the following table represents the weighted average inputs used in calculating the fair value of the preferred share warrants outstanding as of December 31, 2022:


	December 31, 2022
Stock price	$	5.21
Weighted average exercise price	$	3.96
Term (in years)	1.1
Expected volatility	73.4		%
Risk-free interest rate	4.47		%
Expected dividend yield	—		%


	May 13, 2023
Stock price	$	3.42
Weighted average exercise price	$	10.00
Term (in years)	4.87
Expected volatility	54.0		%
Risk-free interest rate	3.46		%
Expected dividend yield	—		%

Significant inputs for Level 3 AM SAFE liability fair value measurement at December 31, 2022 are as follows:


	Near Term		Long-Term
Key assumptions:
Probability weighting	61	%	39	%
Time to conversion (in years)	0.1		0.8
Liquidity price	100	%	90	%
Discount rate	24.7	%	24.7	%

The following table represents the weighted average inputs used in calculating the fair value of the preferred share warrants outstanding at conversion to equity on February 8, 2023:


	February 8, 2023
Stock price	$	9.91
Term (in years)	5.00
Expected volatility	70.0		%
Risk-free interest rate	3.82		%
Expected dividend yield	—		%

Significant inputs for Level 3 AM SAFE warrant fair value measurement at December 31, 2022 are as follows (in thousands):


	Near Term		Long-Term
Key assumptions:
Probability weighting	61	%	39	%
Remaining life (in years)	5.0		5.0
Volatility	75	%	75	%
Interest rate	3.99	%	3.99	%
Time to conversion (in years)	0.1		0.8
Risk-free interest rate	4.12	%	4.75	%
Dividend yield	—	%	—	%

Significant inputs for Level 3 Brookfield SAFE measurement at September 30, 2023 are as follows:


	September 30, 2023
Initial purchase amount	$	50,000
Liquidity price	$	10.00
Stock price	$	4.67


	September 30, 2023
Stock price	$	4.67
Exercise price	$	11.50
Term (in years)	4.36
Expected volatility	52.5		%
Risk-free interest rate	4.66		%
Expected dividend yield	—		%

The following table represents the weighted average inputs used in calculating the fair value of the preferred share warrants outstanding as of December 31, 2022 and December 31, 2021:


	December 31, 2022			December 31, 2021
Stock price	$	5.21		$	3.15
Weighted average exercise price	3.96			3.96
Term (in years)	1.1			2.8
Expected volatility	73.4		%	70.6		%
Risk-free interest rate	4.5		%	0.8		%
Expected dividend yield	—		%	—		%

Significant inputs for Level 3 AM SAFE liability fair value measurement at December 31, 2022 are as follows:


	Near Term		Long-Term
Key assumptions:
Probability weighting	61	%	39	%
Time to conversion (in years)	0.1		0.8
Liquidity price	100	%	90	%
Discount rate	24.7	%	24.7	%

Significant inputs for Level 3 SAFE warrant fair value measurement at December 31, 2022 are as follows:


	Near Term		Long-Term
Key assumptions:
Probability weighting	61	%	39	%
Remaining life (in years)	5.0		5.0
Volatility	75	%	75	%
Interest rate	3.99	%	3.99	%
Time to conversion (in years)	0.1		0.8
Risk-free interest rate	4.12	%	4.75	%
Dividend yield	—	%	—	%

Summary of change in the fair value of the derivative warrant liabilities, measured using Level 3 inputs

The following tables represent reconciliations of the fair value measurements of the assets and liabilities using significant unobservable inputs (Level 3) (in thousands):


	FPA Put Option liability		Fixed Maturity Consideration		Shortfall Warrants		Warrants on Preferred Shares		AM SAFE liability		AM SAFE warrant		Brookfield SAFE		Private placement warrants
Balance as of January 1, 2023	$	—	$	—	$	—	$	(2,119)	$	(28,986)	$	(1,989)	$	(50,000)	$	—
Recognized as a result of the Business Combination	—		—		—		—		—		—		—		(2,148)
(Loss) gain recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss	(44,593)		(6,967)		(5,104)		(3,770)		(744)		189		30,600		(477)
Conversion of warrants to preferred shares	—		—		—		5,889		—		—		—		—
Conversion of SAFE liability	—		—		—		—		29,730		—		—		—
Conversion of AM SAFE warrant to equity classification	—		—		—		—		—		1,800		—		—

Balance as of March 31, 2023	$	(44,593)	$	(6,967)	$	(5,104)	$	—	$	—	$	—	$	(19,400)	$	(2,626)


	Warrants on Preferred Shares		AM SAFE liability		AM SAFE warrant


Balance as of January 1, 2022	$	(1,145)	$	(28,271)	$	(1,729)
Gain (loss) recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss	41		148		(129)
Balance as of March 31, 2022	$	(1,104)	$	(28,123)	$	(1,858)

The following tables represent reconciliations of the fair value measurements of the assets and liabilities using significant unobservable inputs (Level 3) (in thousands):


	FPA Put Option liability		Fixed Maturity Consideration		Shortfall Warrants		Warrants on Preferred Shares		AM SAFE liability		AM SAFE warrant		Brookfield SAFE		Private placement warrants
Balance as of January 1, 2023	$	—	$	—	$	—	$	(2,119)	$	(28,986)	$	(1,989)	$	(50,000)	$	—
Recognized as a result of the Business Combination	—		—		—		—		—		—		—		(2,148)
(Loss) gain recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss	(26,743)		(6,737)		(3,063)		(3,770)		(744)		189		15,850		(3,199)
Conversion of warrants to preferred shares	—		—		—		5,889		—		—		—		—
Conversion of SAFE liability	—		—		—		—		29,730		—		—		—
Conversion of warrant to equity classification	—		—		3,063		—		—		1,800		—		—

Balance as of June 30, 2023	$	(26,743)	$	(6,737)	$	—	$	—	$	—	$	—	$	(34,150)	$	(5,347)


	Warrants on Preferred Shares		AM SAFE liability		AM SAFE warrant


Balance as of January 1, 2022	$	(1,145)	$	(28,271)	$	(1,729)
Gain (loss) recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss	(78)		1,062		(218)
Balance as of June 30, 2022	$	(1,223)	$	(27,209)	$	(1,947)

The following tables represent reconciliations of the fair value measurements of the assets and liabilities using significant unobservable inputs (Level 3) (in thousands):


	Fixed Maturity Consideration		Shortfall Warrants		Warrants on Preferred Shares		AM SAFE liability		AM SAFE warrant		Brookfield SAFE		Private placement warrants
Balance as of January 1, 2023	$	—	$	—	$	(2,119)	$	(28,986)	$	(1,989)	$	(50,000)	$	—
Recognized as a result of the Business Combination	—		—		—		—		—		—		(2,148)

(Loss) gain recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss	(7,020)		(3,063)		(3,770)		(744)		189		26,650		(2,912)
Conversion of warrants to preferred shares	—		—		5,889		—		—		—		—
Conversion of SAFE liability to equity classification	—		—		—		29,730		—		—		—
Conversion of warrant to equity classification	—		3,063		—		—		1,800		—		—

Balance as of September 30, 2023	$	(7,020)	$	—	$	—	$	—	$	—	$	(23,350)	$	(5,060)


	Warrants on Preferred Shares		AM SAFE liability		AM SAFE warrant


Balance as of January 1, 2022	$	(1,145)	$	(28,271)	$	(1,729)
Gain (loss) recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss	(427)		1,050		(293)
Balance as of September 30, 2022	$	(1,572)	$	(27,221)	$	(2,022)


	Warrants		AM SAFE liability		AM SAFE warrant		Brookfield SAFE
Balance as of January 1, 2022	$	1,145	$	28,271	$	1,729	$	—
Issuance of Brookfield SAFE liability	—		—		—		50,000
Loss recognized in consolidated statement of operations and comprehensive loss	974		715		260		$	—
Balance as of December 31, 2022	$	2,119	$	28,986	$	1,989	$	50,000


	Warrants		AM SAFE liability		AM SAFE warrant		Brookfield SAFE


Balance as of January 1, 2021	$	582	$	—	$	—	$	—
Issuance of SAFE liability and warrant	—		28,271		1,729		—
Loss recognized in consolidated statement of operations and comprehensive loss	563		—		—		—
Balance as of December 31, 2021	$	1,145	$	28,271	$	1,729	$	—

Revenues - Disaggregation by Customer Location (Details) - USD ($) $ in Thousands	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Revenues	$ 19,605	$ 12,917	$ 9,646	$ 8,072	$ 9,852	$ 7,857	$ 22,563	$ 17,709	$ 42,168	$ 25,781	$ 37,343	$ 25,461
North America
Disaggregation of Revenue [Line Items]
Revenues	4,847	2,314	4,232	4,412	3,910	4,039	6,547	7,949	11,309	12,361	17,149	15,825
Europe, Middle East, Africa (EMEA)
Disaggregation of Revenue [Line Items]
Revenues	10,732	9,646	4,711	1,287	3,784	2,823	14,356	6,607	25,088	7,894	11,500	7,522
Asia
Disaggregation of Revenue [Line Items]
Revenues	2,137	418	50	1,888	1,853	410	468	2,263	2,690	4,151	5,752	1,477
Australia
Disaggregation of Revenue [Line Items]
Revenues	$ 1,889	$ 539	$ 653	$ 485	$ 305	$ 585	$ 1,192	$ 890	$ 3,081	$ 1,375	$ 2,942	$ 637

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

- Definition

+ References

+ Details

Property, Plant, and Equipment (Tables)

12 Months Ended

Dec. 31, 2022

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

The Company’s property, plant and equipment, net consisted of the following (in thousands):


	As of
	December 31, 2022		December 31, 2021
Land	$	64	$	64
Leasehold improvements	4,126		4,113
Instruments and equipment	33,093		26,627
Vehicles	85		71
Office Equipment and furniture	1,719		1,590
Other	871		728
Construction in progress	6,780		3,328
	$	46,738	$	36,521

Less accumulated depreciation and amortization	$	27,049	$	22,373

Total property, plant and equipment, net	$	19,689	$	14,148

Revenues - Disaggregated Revenue (Details) - USD ($) $ in Thousands	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Revenues	$ 19,605	$ 12,917	$ 9,646	$ 8,072	$ 9,852	$ 7,857	$ 22,563	$ 17,709	$ 42,168	$ 25,781	$ 37,343	$ 25,461
Carbon capture and transformation
Disaggregation of Revenue [Line Items]
Revenues			6,354			4,848					21,221	11,564
Licensing
Disaggregation of Revenue [Line Items]
Revenues	1,515	815	553	540	540	540	1,369	1,080	2,902	1,620	2,160	2,025
Engineering and other services
Disaggregation of Revenue [Line Items]
Revenues	10,912	8,878	5,801	2,955	5,367	4,308	14,678	9,675	25,572	12,630	19,061	9,539
Biorefining
Disaggregation of Revenue [Line Items]
Revenues	12,427	9,693		3,495	5,907		16,047	10,755	28,474	14,250
Research and development
Disaggregation of Revenue [Line Items]
Revenues	4,920	2,217	3,292	2,886	2,963	2,269	5,509	5,232	10,429	8,118	12,122	13,897
Joint development agreements
Disaggregation of Revenue [Line Items]
Revenues	1,933	1,080	2,036	1,571	1,420	1,027	3,116	2,447	5,049	4,018	6,021	11,700
Contract research
Disaggregation of Revenue [Line Items]
Revenues	2,987	1,137	1,256	1,315	1,543	1,242	2,393	2,785	5,380	4,100	6,101	2,197
CarbonSmart (tangible product)
Disaggregation of Revenue [Line Items]
Revenues	$ 2,258	$ 1,007	$ 0	$ 1,691	$ 982	$ 740	$ 1,007	$ 1,722	$ 3,265	$ 3,413	$ 4,000	$ 0

Stock-Based Compensation (Tables)

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Mar. 31, 2023

Jun. 30, 2023

Sep. 30, 2023

Dec. 31, 2022

Share-Based Payment Arrangement [Abstract]

Schedule of restricted stock activity

A summary of the unvested time-based and market-based equity-classified RSUs are presented in the following table:


	Number of RSUs (thousands)		Weighted Average Grant Date Fair Value
	Time-based	Market-based
January 1, 2023	—	—	$	—
Granted	3,082	3,830	2.43
Vested	—	—	—
Cancelled/forfeited	(11)	—	3.45
June 30, 2023	3,071	3,830	$	2.43

A summary of the unvested time-based and market-based equity-classified RSUs are presented in the following table:


	Number of RSUs (thousands)		Weighted Average Grant Date Fair Value
	Time-based	Market-based
January 1, 2023	—	—	$	—
Granted	3,143	3,930	2.49
Vested	(2)	—	3.45
Cancelled/forfeited	(28)	—	3.43
September 30, 2023	3,113	3,930	$	2.49

Stock options activity

Stock option awards outstanding as of March 31, 2023 and changes during the period ended March 31, 2023 were as follows:


	Shares under option (thousands)	Weighted average exercise price		Weighted average remaining contractual term (years)	Aggregate intrinsic value (thousands)
Outstanding at January 1, 2023	14,661	$	1.48	5.80	$	58,565
Vested and expecting to vest at January 1, 2023	14,661	1.48		5.80	58,565
Exercisable at January 1, 2023	11,203	$	1.44	5.15	$	45,204
Granted	259	9.97		—	34
Exercised	(472)	1.59		—	1,827
Cancelled/forfeited	(93)	1.18		—	673
Outstanding at March 31, 2023	14,355	$	1.63	5.81	$	33,903
Vested and expecting to vest at March 31, 2023	14,355	1.63		5.81	33,903
Exercisable at March 31, 2023	11,303	$	1.44	5.25	$	27,650

Stock option awards outstanding as of June 30, 2023 and changes during the period ended June 30, 2023 were as follows:


	Shares under option (thousands)	Weighted average exercise price		Weighted average remaining contractual term (years)	Aggregate intrinsic value (thousands)
Outstanding at January 1, 2023	14,661	$	1.48	5.80	$	58,565
Vested and expecting to vest at January 1, 2023	14,661	1.48		5.80	58,565
Exercisable at January 1, 2023	11,203	$	1.44	5.15	$	45,204
Granted	3,556	3.77		—	594
Exercised	(699)	1.55		—	2,337
Cancelled/forfeited	(100)	1.30		—	693
Outstanding at June 30, 2023	17,418	$	1.94	6.41	$	85,948
Vested and expecting to vest at June 30, 2023	17,418	1.94		6.41	85,948
Exercisable at June 30, 2023	11,240	$	1.48	5.11	$	60,321

Stock option awards outstanding as of September 30, 2023 and changes during the period ended September 30, 2023 were as follows:


	Shares subject to option (thousands)	Weighted average exercise price		Weighted average remaining contractual term (years)	Aggregate intrinsic value (thousands)
Outstanding at January 1, 2023	14,661	$	1.48	5.80
Vested and expecting to vest at January 1, 2023	14,661	1.48		5.80
Exercisable at January 1, 2023	11,203	$	1.44	5.15
Granted	3,556	3.77		—
Exercised	(1,075)	1.53		—
Cancelled/forfeited	(120)	1.76		—
Outstanding at September 30, 2023	17,022	$	1.95	6.21	$	47,653
Vested and expecting to vest at September 30, 2023	17,022	1.95		6.21	47,653
Exercisable at September 30, 2023	11,208	$	1.48	4.98	$	36,026

Stock option awards outstanding as of December 31, 2022 and changes during the period ended December 31, 2022 were as follows:


	Shares under option (thousands)	Weighted average exercise price		Weighted average remaining contractual term (years)	Aggregate intrinsic value (thousands)
Outstanding at January 1, 2022	16,822	$	1.50	6.16	$	27,796
Vested and expecting to vest at January 1, 2022	16,822	1.50		6.16	27,796
Exercisable at January 1, 2022	10,845	$	1.44	4.85	$	18,499

Exercised	(1,968)	1.60		—	3,520
Cancelled/forfeited	(191)	2.20		—	218
Expired	(2)	1.52		—	4
Outstanding at December 31, 2022	14,661	$	1.48	5.80	$	58,565
Vested and expecting to vest at December 31, 2022	14,661	1.48		5.80	58,565
Exercisable at December 31, 2022	11,203	$	1.44	5.15	$	45,204

Summary of Significant Accounting Policies - Shareholders' Equity (Details) - $ / shares	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Feb. 08, 2023	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Common shares, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001

Related Party Transactions

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Mar. 31, 2023

Jun. 30, 2023

Sep. 30, 2023

Dec. 31, 2022

Related Party Transactions

As of March 31, 2023 and December 31, 2022, the Company has an equity ownership in LanzaJet and SGLT (see Note 6 - Investments for further details). The table below summarizes amounts related to transactions with these related parties (in thousands):


	Three months ended
	March 31, 2023		March 31, 2022
Revenues	$	973	$	654

	As of
	March 31, 2023		December 31, 2022
Accounts receivable	$	626	$	1,821
Purchases and open accounts payable	3,048		3,195

LanzaJet

The accounts payable balance is for work that LanzaJet performed as a subcontractor to the Company. Refer to Note 6 - Investments, for more information.

In connection with the formation of LanzaJet, the Company entered into a transition services agreement with LanzaJet. The transition services agreement generally sets out the respective rights, responsibilities and obligations of the Company and LanzaJet with respect to R&D services, access to office and laboratory space, business development and other administrative support services. The transition services agreement may be terminated by mutual consent of the Company and LanzaJet, by LanzaJet at any time, and by the Company upon breach or non-payment by LanzaJet. There are no substantive termination penalties in the event the Company terminates. For the three months ended March 31, 2023 and March 31, 2022, the Company recognized revenue from related parties of approximately $45 and $67, respectively, under the transition services agreement.

The Company also provides certain engineering and other services related to a gas-to-jet demonstration plant currently in development by LanzaJet pursuant to the Investment Agreement described in Note 6 - Investments. In connection with this agreement, the Company recognized $338 in revenue for the three months ended March 31, 2023, and $23 for the three months ended March 31, 2022.

LanzaJet Note Purchase Agreement

On November 9, 2022, the Company and the other LanzaJet shareholders entered into a Note Purchase Agreement (the “Note Purchase Agreement”), pursuant to which LanzaJet Freedom Pines Fuels LLC (“FPF”), a wholly owned subsidiary of LanzaJet, will issue, from time to time, notes in an aggregate principal amount of up to $147.0 million (the “Notes”), comprised of approximately $113.5 million aggregate principal amount of 6.00% Senior Secured Notes due December 31, 2043 and $33.5 million aggregate principal amount of 6.00% Subordinated Secured Notes due December 31, 2043. The Company has committed to purchase $5.5 million of Subordinated Secured Notes in a funding which occurred on May 1, 2023. The Senior Secured Notes are secured by a security interest over substantially all assets of FPF, and both the Senior Secured Notes and the Subordinated Secured Notes are secured by a security interest over the intellectual property owned or in-licensed by LanzaJet.

Each purchaser of Notes under the Note Purchase Agreement is also entitled to receive a warrant for the right to purchase 575 shares of common stock of LanzaJet for each $10 of Notes purchased by such purchaser for an exercise price of $0.0575 per share, and for up to three years after the loan under the Note Purchase Agreement is fully funded. In the case of the Company, this will be equal to a right to purchase 316,250 shares of common stock of LanzaJet.

The Note Purchase Agreement may be amended with the approval of holders of at least 66 2∕3% of the Notes, except with respect to certain rights that require approval of all holders to amend. Upon an event of default under the Note Purchase Agreement, each purchaser may accelerate the payment of its own Notes. Enforcement against the collateral securing the Notes requires the approval of certain holders as specified in the Notes.

SGLT

The Company supplies SGLT with certain water-soluble organic compounds required in the Company's proprietary gas fermentation process, and small-size equipment. As a result, for the three months ended March 31, 2023 and March 31, 2022, the Company recognized revenue from related parties of approximately $0 and $18, respectively. The Company also provided engineering services and incurred costs of $249 and $126 for the three months ended March 31, 2023 and March 31, 2022, respectively.

Additionally, LanzaTech and SGLT entered into a license agreement in 2019, subsequently amended in 2021, to provide SGLT with the right to sublicense the intellectual property that LanzaTech previously licensed to SGLT. In exchange, the Company is entitled to receive licensing consideration, calculated as a percentage of the royalties received by SGLT from the sublicenses. Currently, SGLT sublicenses to certain of its subsidiaries that use LanzaTech's proprietary technology. The royalties received by SGLT are based on sales-and-usage of the sublicensed technology. For the three months ended March 31, 2023, and March 31, 2022, the Company did not recognize any sublicensing revenue as no royalties were received by SGLT.

Related Party Transactions

As of June 30, 2023 and December 31, 2022, the Company has an equity ownership in LanzaJet and SGLT (see Note 6 - Investments for further details). The table below summarizes amounts related to transactions with these related parties (in thousands), other than revenues which are disclosed within the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2023 and 2022, as well as Note 5 - Revenues:


	As of
	June 30, 2023		December 31, 2022
Accounts receivable	$	913	$	1,821
Notes receivable	5,267		—
Accounts payable	1,879		3,195

LanzaJet

The accounts payable balance is for work that LanzaJet performed as a subcontractor to the Company. Refer to Note 6 - Investments, for more information.

In connection with the formation of LanzaJet, the Company entered into a transition services agreement with LanzaJet. The transition services agreement generally sets out the respective rights, responsibilities and obligations of the Company and LanzaJet with respect to R&D services, access to office and laboratory space, business development and other administrative support services. The transition services agreement may be terminated by mutual consent of the Company and LanzaJet, by LanzaJet at any time, and by the Company upon breach or non-payment by LanzaJet. There are no substantive termination penalties in the event the Company terminates. For the three months ended June 30, 2023 and 2022, the Company recognized revenue from related parties of approximately $67 and $58, respectively, under the transition services agreement. For the six months ended June 30, 2023 and 2022, the Company recognized revenue from related parties of approximately $112 and $125, respectively, under the transition services agreement.

The Company also provides certain engineering and other services related to a gas-to-jet demonstration plant currently in development by LanzaJet pursuant to the Investment Agreement described in Note 6 - Investments. In connection with this agreement, the Company recognized $102 and $108 in revenue, respectively, for the three months ended June 30, 2023 and 2022, and recognized revenue of $440 and $131, respectively, for the six months ended June 30, 2023 and 2022.

LanzaJet Note Purchase Agreement

On November 9, 2022, the Company and the other LanzaJet shareholders entered into a Note Purchase Agreement (the “Note Purchase Agreement”), pursuant to which LanzaJet Freedom Pines Fuels LLC (“FPF”), a wholly owned subsidiary of LanzaJet, will issue, from time to time, notes in an aggregate principal amount of up to $147.0 million (the “Notes”), comprised of approximately $113.5 million aggregate principal amount of 6.00% Senior Secured Notes due December 31, 2043 and $33.5 million aggregate principal amount of 6.00% Subordinated Secured Notes due December 31, 2043. The Company committed to purchase $5.5 million of Subordinated Secured Notes, which was funded on May 1, 2023. The Senior Secured Notes are secured by a security interest over substantially all assets of FPF, and both the Senior Secured Notes and the Subordinated Secured Notes are secured by a security interest over the intellectual property owned or in-licensed by LanzaJet.

Each purchaser of Notes under the Note Purchase Agreement also received a warrant for the right to purchase 575,000 shares of common stock of LanzaJet for each $10 million of Notes purchased by such purchaser for an exercise price of $0.01 per share. The warrants are exercisable when the related loan commitment is funded, and may be exercised until the earlier of the third anniversary following the date the holder’s loan commitment is fully funded, or the end of the availability period as defined in the Note Purchase Agreement if the commitment has not been fully funded. In the case of the Company, LanzaTech received warrants to purchase 316,250 shares of common stock of LanzaJet, which became exercisable by the Company when the note was funded on May 1, 2023. Upon funding of the Notes, the warrants meet the accounting criteria to be considered in-substance common stock, and are accounted for as part of the equity-method investment. Refer to Note 6 Investment.

SGLT

The Company supplies SGLT with certain water-soluble organic compounds required in the Company's proprietary gas fermentation process, small-size equipment and consulting services. As a result, for the three months ended June 30, 2023 and 2022, the company recognized revenue of approximately $75 and $46, respectively. For the six months ended June 30, 2023 and 2022, the Company recognized revenue of approximately $75 and $64, respectively. The Company also provided engineering services and incurred costs of $164 and $137 for the three months ended June 30, 2023 and 2022, respectively, and provided engineering services and incurred costs of $414 and $263 for the six months ended June 30, 2023 and 2022, respectively.

exchange, the Company is entitled to receive licensing consideration, calculated as a percentage of the royalties received by SGLT from the sublicenses. Currently, SGLT sublicenses to certain of its subsidiaries that use LanzaTech's proprietary technology. The royalties received by SGLT are based on sales-and-usage of the sublicensed technology. For the three and six months ended June 30, 2023, the Company recognized sublicensing revenue of $249 and $249, respectively. For the three and six months ended June 30, 2022, the Company did not recognize any sublicensing revenue as no royalties were received by SGLT.

Related Party Transactions

As of September 30, 2023 and December 31, 2022, the Company has an equity ownership in LanzaJet and SGLT (see Note 6 - Investments for further details). The table below summarizes amounts related to transactions with these related parties (in thousands) :


	As of
	September 30, 2023		December 31, 2022
Accounts receivable	$	763	$	1,821
Notes receivable	5,351		—
Accounts payable	635		3,195

The following table presents revenue from related parties per disaggregated revenue categories:


	Three Months Ended September 30,		Nine Months Ended September 30,
	2023	2022	2023	2022
Revenue from related parties, included within Licensing	1,515	540	2,902	1,620
Revenue from related parties, included within Engineering and other services	104	164	766	496

The main transactions with related parties are described below:

LanzaJet

The Company and LanzaJet have entered into a master service agreements defining the terms when LanzaJet is a subcontractor for some of the Company’s projects, and conversely, when the Company is a subcontractor for LanzaJet’s projects. The accounts payable balance is for work that LanzaJet performed as a subcontractor to the Company.

In connection with the formation of LanzaJet, the Company entered into a transition services agreement with LanzaJet, refer to Note 6 - Investments, for more information. The transition services agreement generally sets out the respective rights, responsibilities and obligations of the Company and LanzaJet with respect to R&D services, access to office and laboratory space, business development and other administrative support services. The transition services agreement may be terminated by mutual consent of the Company and LanzaJet, by LanzaJet at any time, and by the Company upon breach or non-payment by LanzaJet. There are no substantive termination penalties in the event the Company terminates. For the three months ended September 30, 2023 and 2022, the Company recognized revenue from related parties of approximately $97 and $23, respectively, under the transition services agreement. For the nine months ended September 30, 2023 and 2022, the Company recognized revenue from related parties of approximately $209 and $148, respectively, under the transition services agreement.

The Company also provides certain engineering and other services related to a gas-to-jet demonstration plant currently in development by LanzaJet pursuant to the Investment Agreement described in Note 6 - Investments. In connection with this agreement, the Company recognized $6 and $39 in revenue, respectively, for the three months ended September 30, 2023 and 2022, and recognized revenue of $446 and $170, respectively, for the nine months ended September 30, 2023 and 2022.

LanzaJet Note Purchase Agreement

On November 9, 2022, the Company and the other LanzaJet shareholders entered into a Note Purchase Agreement (the “Note Purchase Agreement”), pursuant to which LanzaJet Freedom Pines Fuels LLC (“FPF”), a wholly owned subsidiary of LanzaJet, will issue, from time to time, notes in an aggregate principal amount of up to $147.0 million (the “Notes”), comprised of approximately $113.5 million aggregate principal amount of 6.00% Senior Secured Notes maturing December 31, 2043 and $33.5 million aggregate principal amount of 6.00% Subordinated Secured Notes maturing December 31, 2043. The Company committed to purchase $5.5 million of Subordinated Secured Notes, which was funded on May 1, 2023. The Senior Secured Notes are secured by a security interest over substantially all assets of FPF, and both the Senior Secured Notes and the Subordinated Secured Notes are secured by a security interest over the intellectual property owned or in-licensed by LanzaJet.

SGLT

The Company supplies SGLT with certain water-soluble organic compounds required in the Company's proprietary gas fermentation process, small-size equipment and consulting services. As a result, for the three months ended September 30, 2023 and 2022, the Company recognized revenue of approximately $0 and $87, respectively. For the nine months ended September 30, 2023 and 2022, the Company recognized revenue of approximately $75 and $151, respectively. The Company also provided engineering services and incurred costs of $199 and $630 for the three months ended September 30, 2023 and 2022, respectively, and provided engineering services and incurred costs of $612 and $893 for the nine months ended September 30, 2023 and 2022, respectively.

Additionally, LanzaTech and SGLT entered into a license agreement in 2019, subsequently amended in August 2023, to provide SGLT with the right to sublicense the intellectual property that LanzaTech previously licensed to SGLT. In exchange, the Company is entitled to receive fixed licensing consideration, calculated as a percentage of the maximum amount of royalties owed to SGLT from its sublicenses. For the three and nine months ended September 30, 2023, the Company recognized sublicensing revenue of $951 and $1,200, respectively. Prior to June 2023, the Company was only entitled to royalties from SGLT if SGLT received sublicense royalty payments. For the three and nine months ended September 30, 2022, the Company did not recognize any sublicensing revenue as no royalties were received by SGLT.

Related Party Transactions

As of December 31, 2022 and December 31, 2021, the Company had an equity ownership in LanzaJet and SGLT with a combined carrying value of $25,551 and $24,752, respectively. The table below summarizes amounts related to transactions with these related parties (in thousands):


	Year Ended December 31,
	2022		2021
Revenues	$	2,970	$	3,253

	As of
	December 31, 2022		December 31, 2021
Accounts receivable	$	1,821	$	1,071
Contract assets	—		60
Purchases and open accounts payable	3,195		2,575

LanzaJet

The accounts payable balance is for work that LanzaJet performed as a subcontractor to the Company. Refer to Note 5, Investments, for more information.

In connection with the formation of LanzaJet, the Company entered into a transition services agreement with LanzaJet. The transition services agreement generally sets out the respective rights, responsibilities and obligations of the Company and LanzaJet with respect to R&D services, access to office and laboratory space, business development and other administrative support services. The transition services agreement may be terminated by mutual consent of the Company and LanzaJet, by LanzaJet at any time, and by the Company upon breach or non-payment by LanzaJet. There are no substantive termination penalties in the event the Company terminates. For the years ended December 31, 2022 and December 31, 2021, the Company recognized revenue from related parties of approximately $185 and $495, respectively, under the transition services agreement.

The Company also provides certain engineering and other services related to a gas-to-jet demonstration plant currently in development by LanzaJet pursuant to the Investment Agreement described in Note 5, Investments. In connection with this agreement, the Company recognized an immaterial amount of revenue for the year ended December 31, 2022, and $428 for the year ended December 31, 2021.

The Company also leases certain land to a subsidiary of LanzaJet. Refer to Note 15, Leases, for more information.

LanzaJet Note Purchase Agreement

On November 9, 2022, the Company and the other LanzaJet shareholders entered into a Note Purchase Agreement (the “Note Purchase Agreement”), pursuant to which LanzaJet Freedom Pines Fuels LLC (“FPF”), a wholly owned subsidiary of LanzaJet, will issue, from time to time, notes in an aggregate principal amount of up to $147.0 million (the “Notes”), comprised of approximately $113.5 million aggregate principal amount of 6.00% Senior Secured Notes due December 31, 2043 and $33.5 million aggregate principal amount of 6.00% Subordinated Secured Notes due December 31, 2043. The Company has committed to purchase $5.5 million of Subordinated Secured Notes in a funding scheduled to occur on May 1, 2023. The Senior Secured Notes are secured by a security interest over substantially all assets of FPF, and both the Senior Secured Notes and the Subordinated Secured Notes are secured by a security interest over the intellectual property owned or in-licensed by LanzaJet. LanzaJet also provides a guarantee of any costs and expenses required to complete the initial facility and achieve commercial operation.

Note Purchase Agreement, each purchaser may accelerate its own Notes. Enforcement against the collateral securing the Notes requires the approval of certain holders as specified in the Notes.

SGLT

The Company supplies SGLT with certain water-soluble organic compounds required in the Company's proprietary gas fermentation process, and small-size equipment. As a result, for the years ended December 31, 2022 and December 31, 2021, the Company recognized revenue from related parties of approximately $289 and $282, respectively. The Company also provided engineering services and incurred costs of $645 and $1,223 for the years ended December 31, 2022 and December 31, 2021, respectively.

Additionally, LanzaTech and SGLT entered into a license agreement in 2019, subsequently amended in 2021, to provide SGLT with the right to sublicense the intellectual property that LanzaTech previously licensed to SGLT. In exchange, the Company is entitled to receive licensing consideration, calculated as a percentage of the royalties received by SGLT from the sublicenses. Currently, SGLT sublicenses to certain of its subsidiaries that use LanzaTech's proprietary technology. The royalties received by SGLT are based on sales-and-usage of the sublicensed technology. For the years ended December 31, 2022, and December 31, 2021, the Company did not earn any sublicensing revenue as no royalties were received by SGLT.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

+ Details

CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND SHAREHOLDERS’ EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Previously Reported	Revision of Prior Period, Adjustment	Common Stock Outstanding	Common Stock Outstanding Previously Reported	Common Stock Outstanding Revision of Prior Period, Adjustment	Additional Paid-in Capital	Additional Paid-in Capital Previously Reported	Additional Paid-in Capital Revision of Prior Period, Adjustment	Accumulated Deficit	Accumulated Deficit Previously Reported	Accumulated Deficit Revision of Prior Period, Adjustment	Accumulated Other Comprehensive Income	Accumulated Other Comprehensive Income Previously Reported	Accumulated Other Comprehensive Income Revision of Prior Period, Adjustment
Beginning balance, Redeemable Convertible Preferred Stock (in shares) at Dec. 31, 2020	112,558,444	25,729,542	86,828,902
Beginning balance, temporary equity at Dec. 31, 2020	$ 394,408	$ 394,408	$ 0
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of Series F Preferred Stock, net of issuance cost (in shares)	15,898,496
Issuance of Series F Preferred Stock, net of issuance cost of $0	$ 83,073
Exercise of warrants (in shares)	691,453
Exercise of warrants	$ 3,150
Ending balance, Redeemable Convertible Preferred Stock (in shares) at Dec. 31, 2021	129,148,393	29,521,810	99,626,583
Ending balance, temporary equity at Dec. 31, 2021	$ 480,631	$ 480,631	$ 0
Beginning balance, Common stock, shares outstanding (in shares) at Dec. 31, 2020				7,246,285	1,656,415	5,589,870
Balance at the beginning at Dec. 31, 2020	(311,216)	(311,216)	0	$ 1	$ 0	$ 1	$ 18,817	$ 18,818	$ (1)	$ (333,200)	$ (333,200)	$ 0	$ 3,166	$ 3,166	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	2,531						2,531
Repurchase of equity instruments	(396)						(396)
Net loss	(46,689)									(46,689)
Issuance of common stock upon exercise of options (in shares)				1,970,875
Issuance of common stock upon exercise of options	758						758
Foreign currency translation	$ 95												95
Ending balance, Common stock, shares outstanding (in shares) at Dec. 31, 2021	9,217,160			9,217,160	2,106,934	7,110,226
Balance at the end at Dec. 31, 2021	$ (354,917)	$ (354,917)	$ 0	$ 1	$ 0	$ 1	21,710	21,711	(1)	(379,889)	(379,889)	0	3,261	3,261	0
Ending balance, Redeemable Convertible Preferred Stock (in shares) at Mar. 31, 2022	129,148,393
Ending balance, temporary equity at Mar. 31, 2022	$ 480,631
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	738						738
Net loss	(16,778)									(16,778)
Issuance of common stock upon exercise of options (in shares)				5,031
Issuance of common stock upon exercise of options	7						7
Foreign currency translation	(28)												(28)
Ending balance, Common stock, shares outstanding (in shares) at Mar. 31, 2022				9,222,191
Balance at the end at Mar. 31, 2022	$ (370,978)			$ 1			22,455			(396,667)			3,233
Beginning balance, Redeemable Convertible Preferred Stock (in shares) at Dec. 31, 2021	129,148,393	29,521,810	99,626,583
Beginning balance, temporary equity at Dec. 31, 2021	$ 480,631	$ 480,631	$ 0
Ending balance, Redeemable Convertible Preferred Stock (in shares) at Jun. 30, 2022	129,148,393
Ending balance, temporary equity at Jun. 30, 2022	$ 480,631
Beginning balance, Common stock, shares outstanding (in shares) at Dec. 31, 2021	9,217,160			9,217,160	2,106,934	7,110,226
Balance at the beginning at Dec. 31, 2021	$ (354,917)	$ (354,917)	$ 0	$ 1	$ 0	$ 1	21,710	21,711	(1)	(379,889)	(379,889)	0	3,261	3,261	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(32,707)
Ending balance, Common stock, shares outstanding (in shares) at Jun. 30, 2022				9,222,462
Balance at the end at Jun. 30, 2022	$ (386,586)			$ 1			23,131			(412,596)			2,878
Beginning balance, Redeemable Convertible Preferred Stock (in shares) at Dec. 31, 2021	129,148,393	29,521,810	99,626,583
Beginning balance, temporary equity at Dec. 31, 2021	$ 480,631	$ 480,631	$ 0
Ending balance, Redeemable Convertible Preferred Stock (in shares) at Sep. 30, 2022	129,148,393
Ending balance, temporary equity at Sep. 30, 2022	$ 480,631
Beginning balance, Common stock, shares outstanding (in shares) at Dec. 31, 2021	9,217,160			9,217,160	2,106,934	7,110,226
Balance at the beginning at Dec. 31, 2021	$ (354,917)	$ (354,917)	$ 0	$ 1	$ 0	$ 1	21,710	21,711	(1)	(379,889)	(379,889)	0	3,261	3,261	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(54,974)
Ending balance, Common stock, shares outstanding (in shares) at Sep. 30, 2022				9,232,086
Balance at the end at Sep. 30, 2022	$ (407,640)			$ 1			23,800			(434,863)			3,422
Beginning balance, Redeemable Convertible Preferred Stock (in shares) at Dec. 31, 2021	129,148,393	29,521,810	99,626,583
Beginning balance, temporary equity at Dec. 31, 2021	$ 480,631	$ 480,631	$ 0
Ending balance, Redeemable Convertible Preferred Stock (in shares) at Dec. 31, 2022	129,148,393	29,521,810	99,626,583
Ending balance, temporary equity at Dec. 31, 2022	$ 480,631	$ 480,631	$ 0
Beginning balance, Common stock, shares outstanding (in shares) at Dec. 31, 2021	9,217,160			9,217,160	2,106,934	7,110,226
Balance at the beginning at Dec. 31, 2021	$ (354,917)	(354,917)	0	$ 1	$ 0	$ 1	21,710	21,711	(1)	(379,889)	(379,889)	0	3,261	3,261	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	2,527						2,527
Repurchase of equity instruments	(649)						(649)
Net loss	$ (76,356)									(76,356)
Issuance of common stock upon exercise of options (in shares)	1,968,000			1,204,891
Issuance of common stock upon exercise of options	$ 1,194						1,194
Transfer from foreign currency translation to equity security investment	928												928
Foreign currency translation	$ (1,449)												(1,449)
Ending balance, Common stock, shares outstanding (in shares) at Dec. 31, 2022	10,422,051			10,422,051	2,382,358	8,039,693
Balance at the end at Dec. 31, 2022	$ (428,722)	$ (428,722)	$ 0	$ 1	$ 0	$ 1	24,782	24,783	(1)	(456,245)	(456,245)	0	2,740	2,740	0
Beginning balance, Redeemable Convertible Preferred Stock (in shares) at Mar. 31, 2022	129,148,393
Beginning balance, temporary equity at Mar. 31, 2022	$ 480,631
Ending balance, Redeemable Convertible Preferred Stock (in shares) at Jun. 30, 2022	129,148,393
Ending balance, temporary equity at Jun. 30, 2022	$ 480,631
Beginning balance, Common stock, shares outstanding (in shares) at Mar. 31, 2022				9,222,191
Balance at the beginning at Mar. 31, 2022	(370,978)			$ 1			22,455			(396,667)			3,233
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	676						676
Net loss	(15,929)									(15,929)
Issuance of common stock upon exercise of options (in shares)				271
Issuance of common stock upon exercise of options	0						0
Foreign currency translation	(355)												(355)
Ending balance, Common stock, shares outstanding (in shares) at Jun. 30, 2022				9,222,462
Balance at the end at Jun. 30, 2022	$ (386,586)			$ 1			23,131			(412,596)			2,878
Ending balance, Redeemable Convertible Preferred Stock (in shares) at Sep. 30, 2022	129,148,393
Ending balance, temporary equity at Sep. 30, 2022	$ 480,631
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	653						653
Net loss	(22,267)									(22,267)
Issuance of common stock upon exercise of options (in shares)				9,624
Issuance of common stock upon exercise of options	16						16
Transfer from foreign currency translation to investment	928
Foreign currency translation	(384)												(384)
Ending balance, Common stock, shares outstanding (in shares) at Sep. 30, 2022				9,232,086
Balance at the end at Sep. 30, 2022	$ (407,640)			$ 1			23,800			(434,863)			3,422
Beginning balance, Redeemable Convertible Preferred Stock (in shares) at Dec. 31, 2022	129,148,393	29,521,810	99,626,583
Beginning balance, temporary equity at Dec. 31, 2022	$ 480,631	$ 480,631	$ 0
Increase (Decrease) in Temporary Equity [Roll Forward]
Exercise of warrants (in shares)	594,309
Exercise of warrants	$ 5,890
In-kind payment of preferred dividend	$ 241,529
Conversion of preferred stock into common stock (in shares)	(129,742,702)
Conversion of preferred stock into common stock	$ (728,050)
Ending balance, Redeemable Convertible Preferred Stock (in shares) at Mar. 31, 2023	0
Ending balance, temporary equity at Mar. 31, 2023	$ 0
Beginning balance, Common stock, shares outstanding (in shares) at Dec. 31, 2022	10,422,051			10,422,051	2,382,358	8,039,693
Balance at the beginning at Dec. 31, 2022	$ (428,722)	(428,722)	$ 0	$ 1	$ 0	$ 1	24,782	24,783	(1)	(456,245)	(456,245)	0	2,740	2,740	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	3,505						3,505
RSA vesting (in shares)				2,535,825
Repurchase of equity instruments (in shares)				(771,141)
In-kind payment of preferred dividend	(241,529)									(241,529)
Conversion of preferred stock into common stock (in shares)				153,895,644
Conversion of preferred stock into common stock	728,050			$ 15			728,035
Recapitalization, net of transaction expenses (Note 3) (in shares)				28,898,374
Recapitalization, net of transaction expenses (Note 3)	236,973			$ 3			236,970
Forward Purchase Agreement prepayment	(60,547)	0					(60,547)
Reclassification of warrants to equity	1,800						1,800
Repurchase of equity instruments	(7,650)						(7,650)
Net loss	$ (63,312)									(63,312)
Issuance of common stock upon exercise of options (in shares)	472,000			470,843
Issuance of common stock upon exercise of options	$ 746						746
Foreign currency translation	$ (49)												(49)
Ending balance, Common stock, shares outstanding (in shares) at Mar. 31, 2023	195,451,596			195,451,596
Balance at the end at Mar. 31, 2023	$ 169,265	$ 229,812		$ 19			927,641			(761,086)			2,691
Beginning balance, Redeemable Convertible Preferred Stock (in shares) at Dec. 31, 2022	129,148,393	29,521,810	99,626,583
Beginning balance, temporary equity at Dec. 31, 2022	$ 480,631	$ 480,631	$ 0
Ending balance, Redeemable Convertible Preferred Stock (in shares) at Jun. 30, 2023	0
Ending balance, temporary equity at Jun. 30, 2023	$ 0
Beginning balance, Common stock, shares outstanding (in shares) at Dec. 31, 2022	10,422,051			10,422,051	2,382,358	8,039,693
Balance at the beginning at Dec. 31, 2022	$ (428,722)	(428,722)	$ 0	$ 1	$ 0	$ 1	24,782	24,783	(1)	(456,245)	(456,245)	0	2,740	2,740	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (90,098)
Issuance of common stock upon exercise of options (in shares)	699,000
Ending balance, Common stock, shares outstanding (in shares) at Jun. 30, 2023	195,674,502			195,674,502
Balance at the end at Jun. 30, 2023	$ 151,091	$ 211,638		$ 19			936,157			(787,872)			2,787
Beginning balance, Redeemable Convertible Preferred Stock (in shares) at Dec. 31, 2022	129,148,393	29,521,810	99,626,583
Beginning balance, temporary equity at Dec. 31, 2022	$ 480,631	$ 480,631	$ 0
Ending balance, Redeemable Convertible Preferred Stock (in shares) at Sep. 30, 2023	0
Ending balance, temporary equity at Sep. 30, 2023	$ 0
Beginning balance, Common stock, shares outstanding (in shares) at Dec. 31, 2022	10,422,051			10,422,051	2,382,358	8,039,693
Balance at the beginning at Dec. 31, 2022	$ (428,722)	(428,722)	$ 0	$ 1	$ 0	$ 1	24,782	$ 24,783	$ (1)	(456,245)	$ (456,245)	$ 0	2,740	$ 2,740	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (115,424)
Issuance of common stock upon exercise of options (in shares)	1,075,000
Ending balance, Common stock, shares outstanding (in shares) at Sep. 30, 2023	196,055,228			196,055,228
Balance at the end at Sep. 30, 2023	$ 128,475			$ 19			939,868			(813,198)			1,786
Beginning balance, Redeemable Convertible Preferred Stock (in shares) at Mar. 31, 2023	0
Beginning balance, temporary equity at Mar. 31, 2023	$ 0
Ending balance, Redeemable Convertible Preferred Stock (in shares) at Jun. 30, 2023	0
Ending balance, temporary equity at Jun. 30, 2023	$ 0
Beginning balance, Common stock, shares outstanding (in shares) at Mar. 31, 2023	195,451,596			195,451,596
Balance at the beginning at Mar. 31, 2023	$ 169,265	229,812		$ 19			927,641			(761,086)			2,691
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	5,122						5,122
Forward Purchase Agreement prepayment	(60,547)	0
Reclassification of warrants to equity	3,063						3,063
Net loss	(26,786)									(26,786)
Issuance of common stock upon exercise of options (in shares)				222,906
Issuance of common stock upon exercise of options	331						331
Foreign currency translation	$ 96												96
Ending balance, Common stock, shares outstanding (in shares) at Jun. 30, 2023	195,674,502			195,674,502
Balance at the end at Jun. 30, 2023	$ 151,091	$ 211,638		$ 19			936,157			(787,872)			2,787
Ending balance, Redeemable Convertible Preferred Stock (in shares) at Sep. 30, 2023	0
Ending balance, temporary equity at Sep. 30, 2023	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	3,151						3,151
Net loss	(25,326)									(25,326)
Issuance of common stock upon exercise of options (in shares)				380,726
Issuance of common stock upon exercise of options	560						560
Foreign currency translation	$ (1,001)												(1,001)
Ending balance, Common stock, shares outstanding (in shares) at Sep. 30, 2023	196,055,228			196,055,228
Balance at the end at Sep. 30, 2023	$ 128,475			$ 19			$ 939,868			$ (813,198)			$ 1,786

Related Party Transactions - Schedule of Related Party Transactions (Details) - USD ($) $ in Thousands	3 Months Ended								6 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Revenues		$ 19,605	$ 12,917	$ 9,646		$ 8,072	$ 9,852	$ 7,857	$ 22,563	$ 17,709	$ 42,168	$ 25,781	$ 37,343	$ 25,461
Contract assets		24,313	21,776	18,460	$ 18,000				21,776		24,313		18,000	11,700	$ 6,186
Related Party
Related Party Transaction [Line Items]
Revenues				973				$ 654
Related Party \| Transactions with Equity Method Investees
Related Party Transaction [Line Items]
Revenues	$ 2,970				3,253
Equity Method Investee \| Transactions with Equity Method Investees
Related Party Transaction [Line Items]
Accounts receivable		763	913	626	1,821				913		763		1,821	1,071
Notes receivable		5,351	5,267		0				5,267		5,351		0
Contract assets					0								0	60
Purchases and open accounts payable		$ 635	$ 1,879	$ 3,048	$ 3,195				$ 1,879		$ 635		$ 3,195	$ 2,575

- Definition

+ References

+ Details

Net Loss Per Share - Narrative (Details) $ in Thousands		1 Months Ended	3 Months Ended		6 Months Ended		9 Months Ended		12 Months Ended
Net Loss Per Share - Narrative (Details) $ in Thousands	Feb. 08, 2023 USD ($) denominator shares	Feb. 07, 2023 shares	Mar. 31, 2023 USD ($) shares	Mar. 31, 2022 shares	Jun. 30, 2023 shares	Jun. 30, 2022 shares	Sep. 30, 2023 shares	Sep. 30, 2022 shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 shares
Earnings Per Share [Abstract]
Recapitalization exchange ratio	4.3747
Conversion ratio	1									1
Cumulative accrued and undeclared and unpaid dividend amount \| $									$ 237,000
Liquidity price of SAFE and SAFE warrants									100.00%
Liquidity price of SAFE and SAFE warrants, condition one									90.00%
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Conversion ratio	1									1
Aggregate purchase of stock (in shares)			36,012,752	149,459,933	45,982,284	149,303,108	45,722,414	149,253,801	147,330,749	149,491,092
In-kind payment of preferred dividend \| $	$ 241,529		$ 241,529
Dividends, Denominator \| denominator	10
Common stock dividends (in shares)	24,152,942
Redeemable convertible preferred stock (if converted)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Aggregate purchase of stock (in shares)		129,148,393	0	129,148,393	0	129,148,393	0	129,148,393	129,148,393	129,148,393

Investments (Tables)

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Mar. 31, 2023

Jun. 30, 2023

Sep. 30, 2023

Dec. 31, 2022

Equity Method Investments and Joint Ventures [Abstract]

Investments

The Company’s equity investments consisted of the following (in thousands):


	As of
	March 31, 2023		December 31, 2022
Equity Method Investment in LanzaJet	$	9,835	$	10,561
Equity Security Investment in SGLT	$	14,990	14,990
Total Investment	$	24,825	$	25,551

The Company’s investments consisted of the following (in thousands):


	As of
	December 31, 2022		December 31, 2021
Equity Method Investment in LanzaJet	$	10,561	$	12,433
Equity Method Investment in SGLT	—		12,319
Equity Security Investment in SGLT	14,990		—
Total Investment	$	25,551	$	24,752

Equity method investments

The Company’s equity investments consisted of the following (in thousands):


	As of
	September 30, 2023		December 31, 2022
Equity Method Investment in LanzaJet	$	9,594	$	10,561
Equity Security Investment in SGLT	14,990		14,990
Total Investment	$	24,584	$	25,551

The following table presents summarized aggregated financial information of the equity method investments:


	Year Ended December 31,
	2022		2021
Selected Statement of Operations Information(1):
Revenues	$	40,985	$	40,244
Gross profit	7,319		(5,703)
Net loss	(6,221)		(9,695)
Net loss attributable to the Company	(1,422)		(1,606)

	Year Ended December 31,
	2022		2021
Selected Balance Sheet Information(2):
Current assets	$	72,711	$	56,204
Non-current assets	114,736		270,454
Current liabilities	15,534		64,499
Non-current liabilities	114,934		58,802

__________________

(2)The balance sheet information reflects only LanzaJet as of December 31, 2022.

Debt securities, Held-to-maturity

The Company has held-to-maturity securities consisting of U.S. Treasury securities. All held-to-maturity securities have contractual maturities due in one year or less.


	As of
	June 30, 2023		March 31, 2023
Amortized cost, net of accrued interest	$	49,611	$	49,103
Accrued interest	93		30
Total	$	49,704	$	49,133

Aggregate Fair Value	49,593		49,098
Gross unrealized gains	5		1
Gross unrealized losses	(23)		(6)

HTM debt securities are classified as short-term or long-term based upon the contractual maturity of the underlying investment.


	September 30, 2023
(in thousands)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value		Accrued Interest
Short-term
US Treasury bills and notes	$	20,178	$	—	$	(7)	$	20,171	$	45
Corporate debt securities	14,833		3		(26)		14,810		109
Total debt securities due within a year	$	35,011	$	3	$	(33)	$	34,981	$	154

After 1 year through 5 years
Corporate debt	6,780		3		(3)		6,780		24
Yankee debt securities	3,000		2		—		3,002		—
Total debt securities due after 1 year through 5 years	$	9,780	$	5	$	(3)	$	9,782	$	24

Total HTM Debt Securities	44,791		8		(36)		44,763		178

- Definition

Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-5

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-5

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-5B

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-5

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (aaa)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-5

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-5

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-5

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-5

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-5

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-5

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-5

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-5A

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-5A

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-5A

Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-5B

Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-5B

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-5B

Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-5B

+ Details

Cover Page	9 Months Ended
Cover Page	Sep. 30, 2023
Cover [Abstract]
Document Type	POS AM
Entity Registrant Name	LanzaTech Global, Inc.
Entity Central Index Key	0001843724
Amendment Flag	true
Amendment Description	LanzaTech Global, Inc. filed a Registration Statement on Form S-1 on February 13, 2023, as amended on March 29, 2023, May 5, 2023, and May 22, 2023, which was declared effective by the Securities and Exchange Commission (“SEC”) on May 24, 2023 (as amended, the “Registration Statement”). This Post-Effective Amendment No. 1 to Form S-1 (the “Post-Effective Amendment”) is being filed to update the Registration Statement to (i) include information contained in the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023 and June 30, 2023, which were initially filed with the SEC on May 15, 2023 and August 9, 2023, respectively, and were subsequently amended on December 4, 2023; (ii) include information contained in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, which was filed with the SEC on November 13, 2023; and (iii) to update certain other information in the Registration Statement.As described in the Company's Current Report on Form 8-K filed with the SEC on November 9, 2023, on November 8, 2023, the Audit Committee of the Company, after considering the recommendations of management, concluded that the Company’s previously issued consolidated financial statements as of and for the quarters ended March 31, 2023 and June 30, 2023 (collectively, the “Previous Financial Statements”) should no longer be relied upon. Similarly, any previously filed or furnished reports, related earnings releases, investor presentations or similar communications of the Company describing the Previous Financial Statements should no longer be relied upon. The determination relates to the Company’s interpretation of the accounting guidance applicable to the Company’s forward purchase agreement, dated February 3, 2023, with ACM ARRT H LLC (as assigned in part to Vellar Opportunity Fund SPV LLC, the “FPA”).The Company is filing this Post-Effective Amendment for the purpose of revising the accounting treatment of the FPA in the Previous Financial Statements, to reclassify the prepayment amount, previously recorded as part of the non-current net derivative asset in the condensed consolidated balance sheet, to the equity section of the condensed consolidated balance sheet with any remaining balance of the prepaid forward contract, including the minimum maturity consideration and the share consideration, as non-current liabilities in its condensed consolidated balance sheet in the Previous Financial Statements, included in this Post-Effective Amendment.No additional securities are being registered under this Post-Effective Amendment. All applicable registration fees were paid at the time of the original filing of the Registration Statement.

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Millions	Feb. 08, 2023	Feb. 03, 2023	Mar. 08, 2022	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Dec. 07, 2022	Nov. 09, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Common shares, par value (in dollars per share)	$ 0.0001			$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001			$ 0.0001
Shares issued in transaction (in shares)	196,222,737
Sale of stock price (usd per share)								$ 10.00
Purchase price			$ 1,800.0
Agreement term		3 years
Sale of private placement warrants (in shares)	985,278	10,000,000					985,278		316,250	985,278
Shortfall Warrants
Subsequent Event [Line Items]
Sale of private placement warrants (in shares)		4,083,486
Maturity Consideration
Subsequent Event [Line Items]
Derivative instrument, contingent consideration, liability (shares)		7,500,000
Stock price (in usd per share)		$ 2.00
Share Consideration
Subsequent Event [Line Items]
Derivative instrument, contingent consideration, liability (shares)		500,000
Derivative liabilities		$ 5.1
Subsequent Event \| Shortfall Warrants
Subsequent Event [Line Items]
Warrants, notification period		45 days
Subsequent Event \| Forward Purchase Agreement
Subsequent Event [Line Items]
Shares issued in transaction (in shares)		5,916,514
Sale of stock price (usd per share)		$ 10.16
Purchase price		$ 60.1
Subsequent Event \| Forward Purchase Agreement \| Class A Common stock
Subsequent Event [Line Items]
Derivative instrument, contingent consideration, liability (shares)		10,000,000
Common shares, par value (in dollars per share)		$ 0.0001

Investments - Held to Maturity Securities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023
Schedule of Held-to-Maturity Securities [Line Items]
Amortized Cost	$ 35,011
Gross Unrealized Gains	3
Gross Unrealized Losses	(33)
Estimated Fair Value	34,981
Accrued Interest	154
Amortized Cost	9,780
Gross Unrealized Gains	5
Gross Unrealized Losses	(3)
Estimated Fair Value	9,782
Accrued Interest	24
Amortized Cost	44,791
Gross Unrealized Gains	8	$ 5	$ 1
Gross Unrealized Losses	(36)	(23)	(6)
Estimated Fair Value	44,763	$ 49,593	$ 49,098
Accrued Interest	178
US Treasury Bills and Notes
Schedule of Held-to-Maturity Securities [Line Items]
Amortized Cost	20,178
Gross Unrealized Gains	0
Gross Unrealized Losses	(7)
Estimated Fair Value	20,171
Accrued Interest	45
Corporate Debt Securities
Schedule of Held-to-Maturity Securities [Line Items]
Amortized Cost	14,833
Gross Unrealized Gains	3
Gross Unrealized Losses	(26)
Estimated Fair Value	14,810
Accrued Interest	109
Amortized Cost	6,780
Gross Unrealized Gains	3
Gross Unrealized Losses	(3)
Estimated Fair Value	6,780
Accrued Interest	24
Yankee Debt Securities
Schedule of Held-to-Maturity Securities [Line Items]
Amortized Cost	3,000
Gross Unrealized Gains	2
Gross Unrealized Losses	0
Estimated Fair Value	3,002
Accrued Interest	$ 0

Redeemable, Convertible Preferred Stock - Narrative (Details) $ in Thousands		3 Months Ended	12 Months Ended
	Feb. 08, 2023 USD ($) shares	Mar. 31, 2023 USD ($) shares	Dec. 31, 2022	Dec. 31, 2021 USD ($) shares
Temporary Equity [Line Items]
Conversion ratio	1
In-kind payment of preferred dividend \| $	$ 241,529	$ 241,529
Common stock dividends (in shares)	24,152,942
Preferred Stock, Dividend Rate, Percentage			8.00%
Exercise of warrants (in shares)	594,309	594,309		691,453
Exercise of warrants \| $		$ 5,890		$ 3,150
Issuance of Series F Preferred Stock, net of issuance cost (in shares)				15,898,496
Issuance of Series F Preferred Stock, net of issuance cost of $0 \| $				$ 83,073
Common Stock
Temporary Equity [Line Items]
Conversion of preferred stock into common stock (in shares)	153,895,644	153,895,644

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

Components of (loss) income before income taxes and gain from equity method investees, net

The components of (loss) income before income taxes and gain from equity method investees, net are as follows (in thousands):


	Year Ended December 31,
	2022		2021
United States	$	(73,271)	$	(39,860)

Foreign	(3,085)		(6,829)
Total	$	(76,356)	$	(46,689)

Reconciliation of income taxes computed at statutory federal income tax rate

The following table is a reconciliation of income taxes computed at the statutory federal income tax rate (21.0% federal income tax rate in the United States for 2022 and 2021) to the income tax expense (benefit) reflected in the consolidated statement of operations and comprehensive loss (in thousands, except percentages):


	Year Ended December 31,
	2022				2021
Income tax (benefit) at the statutory federal income tax rate	$	(16,035)	21.0	%	$	(9,805)	21.0	%
Foreign tax rate differential	(72)		0.1	%	(605)		1.3	%
State and local taxes	(6,961)		9.1	%	(4,068)		8.7	%

Foreign exchange differences	—		—	%	(143)		0.3	%
Stock-based compensation	288		(0.4)	%	501		(1.1)	%
Interest income on receivable	—		—	%	882		(1.9)	%
Equity method investment	(701)		0.9	%	(443)		0.9	%
Non-deductible legal costs	—		—	%	1,291		(2.8)	%
Gain from redomiciliation of intellectual property	—		—	%	4,890		(10.5)%
Valuation allowance	26,286		(34.4)	%	7,958		(17.0)	%
PPP loan forgiveness	—		—	%	$	(644)	1.4	%
Deferred True-Up	(2,836)		3.7%		—		—%
Other	31		—	%	186		(0.3)	%
Total income tax benefit	$	—	—	%	$	—	—	%

Significant components of deferred tax assets and liabilities

Significant components of deferred tax assets and liabilities were as follows (in thousands):


	Year Ended December 31,
Deferred tax assets:	2022		2021
Net operating loss and credit carryforwards	$	133,537	$	107,979
Stock-based compensation	2,071		—
Operating lease liability	2,473		1,878
Accrued bonus	1,514		981
Accrued expenses	239		1,566
Deferred revenue	126		309
Equity method investment	2,040		1,243
Other	460		925
	$	142,460	$	114,881

Valuation allowance	(139,562)		(113,276)
Net deferred tax asset	$	2,898	$	1,605
Deferred tax liabilities:
Operating lease asset	(2,125)		(1,429)
Other	(773)		(176)
Total deferred tax liabilities	$	(2,898)	$	(1,605)

Net deferred income tax assets and liabilities:	$	—	$	—

Summary of Significant Accounting Policies - Warrants (Details) - USD ($)	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Feb. 08, 2023	Feb. 03, 2023	Dec. 31, 2022	Nov. 09, 2022	Dec. 31, 2021
Warrants
Sale of private placement warrants (in shares)				985,278	10,000,000	985,278	316,250	985,278
Class of warrant or right, exercise price of warrants or rights (in dollars per share)				$ 9.91		$ 3.36	$ 0.01	$ 4.56
Warrants	$ 9,636,000	$ 8,422,000	$ 9,919,000			$ 4,108,000
Warrant, denominator						$ 3,000,000
Liquidity price of SAFE and SAFE warrants, condition one						90.00%
Maximum
Warrants
Class of warrant or right, exercise price of warrants or rights (in dollars per share)				4.56				$ 4.56
Minimum
Warrants
Class of warrant or right, exercise price of warrants or rights (in dollars per share)				$ 3.36		$ 3.36

Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Net operating loss and credit carryforwards	$ 133,537	$ 107,979
Stock-based compensation	2,071	0
Operating lease liability	2,473	1,878
Accrued bonus	1,514	981
Accrued expenses	239	1,566
Deferred revenue	126	309
Equity method investment	2,040	1,243
Other	460	925
Gross deferred tax asset	142,460	114,881
Valuation allowance	(139,562)	(113,276)
Net deferred tax asset	2,898	1,605
Deferred tax liabilities:
Operating lease asset	(2,125)	(1,429)
Other	(773)	(176)
Total deferred tax liabilities	(2,898)	(1,605)
Net deferred income tax assets and liabilities:	$ 0	$ 0

LanzaTech 10K Commitment and Contingencies (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022
Lessee, Lease, Description [Line Items]
Year one				$ 1,302
Year two				2,602
Year three				2,347
Year four				2,418
Year five				0
Thereafter				0
Total lease payments				8,669
Headquarters In Skokie, Illinois
Lessee, Lease, Description [Line Items]
Year one	$ 3,287	$ 3,287	$ 3,287	0
Year two	3,287	3,287	3,287	642
Year three	$ 3,287	$ 3,287	$ 3,287	1,303
Year four				1,342
Year five				0
Thereafter				0
Total lease payments				$ 3,287

Fair Value - Level 3 Fair Value Measurements (Details) $ in Thousands	Sep. 30, 2023 USD ($) $ / shares	Jun. 30, 2023 USD ($) $ / shares	May 13, 2023 $ / shares	Mar. 31, 2023 USD ($) $ / shares	Feb. 08, 2023	Dec. 31, 2022 $ / shares	Dec. 31, 2021 $ / shares
Stock price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input					9.91	5.21	3.15
Long-Term Debt, Measurement Input	4.67	6.83		3.88
Derivative Asset, Measurement Input	4.67	6.83		3.88
Stock price \| Private placement warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	4.67	6.83		3.88	9.91
Stock price \| Shortfall Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input			3.42	3.88
Exercise price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input						3.96	3.96
Exercise price \| Private placement warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	11.50	11.50		11.50	11.50
Exercise price \| Shortfall Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input			10.00	10.00
Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input					5.00	1.1	2.8
Derivative Asset, Measurement Input	2.36	2.61		2.86
Term \| SAFE Warrant, Near Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input						5.0
Term \| SAFE Warrant, Long Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input						5.0
Term \| Private placement warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	4.36	4.61		4.86	5.00
Term \| Shortfall Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input			4.87	5.0
Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input					0.700	0.734	0.706
Derivative Asset, Measurement Input	0.500	0.500		0.550
Expected volatility \| SAFE Warrant, Near Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input						0.75
Expected volatility \| SAFE Warrant, Long Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input						0.75
Expected volatility \| Private placement warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.525	0.325		0.450	0.020
Expected volatility \| Shortfall Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input			0.540	0.680
Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input					0.0382	0.0447	0.008
Derivative Asset, Measurement Input	0.0489	0.0459		0.0381
Risk-free interest rate \| SAFE Warrant, Near Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input						0.0412
Risk-free interest rate \| SAFE Warrant, Long Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input						0.0475
Risk-free interest rate \| Private placement warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.0466	0.0413		0.0360	0.0382
Risk-free interest rate \| Shortfall Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input			0.0346	0.0359
Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input					0	0	0
Derivative Asset, Measurement Input	0	0		0
Expected dividend yield \| SAFE Warrant, Near Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input						0
Expected dividend yield \| SAFE Warrant, Long Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input						0
Expected dividend yield \| Private placement warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0	0		0	0
Expected dividend yield \| Shortfall Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input			0	0
Probability weighting \| SAFE Warrant, Near Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input						0.61
Probability weighting \| SAFE Warrant, Long Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input						0.39
Probability weighting \| Near Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivatives liability, measurement input						0.61
Probability weighting \| Long-Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivatives liability, measurement input						0.39
Interest rate \| SAFE Warrant, Near Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input						0.0399
Interest rate \| SAFE Warrant, Long Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input						0.0399
Time to conversion \| SAFE Warrant, Near Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input						0.1
Time to conversion \| SAFE Warrant, Long Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input						0.8
Time to conversion \| Near Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivatives liability, measurement input						0.1
Time to conversion \| Long-Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivatives liability, measurement input						0.8
Liquidity price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Long-Term Debt, Measurement Input	10.00	10.00		10.00
Liquidity price \| Near Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivatives liability, measurement input						1
Liquidity price \| Long-Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivatives liability, measurement input						0.90
Discount rate \| Near Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivatives liability, measurement input						0.247
Discount rate \| Long-Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivatives liability, measurement input						0.247
Measurement Input, Initial Purchase Amount
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Long-Term Debt, Measurement Input \| $	50,000	50,000		50,000

Stock-Based Compensation - Narrative (Details)	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
Stock-Based Compensation - Narrative (Details)	Sep. 30, 2023 USD ($) share_type installment day $ / shares shares	Jun. 30, 2023 USD ($) share_type installment $ / shares shares	Mar. 31, 2023 USD ($) scheme	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Jun. 30, 2023 USD ($) share_type installment $ / shares shares	Jun. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) share_type installment day $ / shares shares	Sep. 30, 2022 USD ($)	Dec. 31, 2023	Dec. 31, 2022 USD ($) scheme $ / shares shares	Dec. 31, 2021 USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of share based stock schemes \| scheme			5									5
Compensation expense			$ 764,000			$ 738,000						$ 2,527,000	$ 2,531,000
Unrecognized compensation costs			$ 4,321,000									$ 3,354,000
Stock price (usd per share) \| $ / shares	$ 11.50	$ 11.50					$ 11.50		$ 11.50
Trading days							20 days		20 days
Options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Compensation expense	$ 1,234,000	$ 2,445,000		$ 653,000	$ 676,000		$ 3,209,000	$ 1,414,000	$ 4,443,000	$ 2,067,000
Unrecognized compensation costs	9,550,000	10,801,000					$ 10,801,000		$ 9,550,000
Unrecognized cost, recognition period			2 years 4 months 13 days				2 years 6 months 3 days		2 years 3 months 14 days			2 years 25 days
RSAs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Award requisite service period			3 years				3 years		3 years			3 years
Compensation expense	0	0					$ 2,741,000	$ 0	$ 2,741,000	$ 0		$ 2,741,000
Unrecognized cost, recognition period			10 years				10 years		10 years			10 years
Unvested shares outstanding (in shares) \| shares												2,535,825
Unvested shares weighted average fair value (usd per share) \| $ / shares												$ 1.08
Shares withheld for tax withholding obligation (in shares) \| shares												771,141
Tax payment												$ 7,650,000
RSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Compensation expense	1,895,000						$ 2,677,000		$ 4,594,000
Unrecognized compensation costs	$ 12,936,000	$ 14,068,000					$ 14,068,000		$ 12,936,000
Unrecognized cost, recognition period							2 years 3 months 29 days		1 year 11 months 23 days
Unvested shares weighted average fair value (usd per share) \| $ / shares	$ 2.49	$ 2.43					$ 2.43		$ 2.49			$ 0
Number of Share Based Stock Type \| share_type	2	2					2		2
Award vesting installments \| installment	3	3					3		3
Stock Appreciation Rights (SARs)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Award vesting installments \| installment	3	3					3		3
Expiration period							10 years		10 years
Time Based RSU
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unvested shares outstanding (in shares) \| shares	3,113,000	3,071,000					3,071,000		3,113,000			0
Time Based RSU \| Employees and Other Service Providers
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period											3 years
Time Based RSU \| Director
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period											1 year
Market Based RSU
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unvested shares outstanding (in shares) \| shares	3,930,000	3,830,000					3,830,000		3,930,000			0
Vesting period											3 years
Vesting Component Triggering Event, Day \| day	151								151
Phantom RSU
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Award vesting installments \| installment	3	3					3		3
RSA Conditional
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Compensation expense												$ 0	$ 0
Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Award requisite service period			2 years									2 years
Minimum \| Options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Award requisite service period							2 years		2 years
Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Award requisite service period			5 years									5 years
Maximum \| Options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Award requisite service period							5 years		5 years

Leases - Narrative (Details) $ in Thousands	1 Months Ended		12 Months Ended
Leases - Narrative (Details) $ in Thousands	Feb. 28, 2022 renewal_option	May 31, 2020 renewal_option	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Leases [Abstract]
Weighted average discount rate			7.50%	7.50%
Operating lease, cost			$ 2,167	$ 2,126
Variable lease, cost			2,227	2,575
Lease cost			$ 2,370	$ 2,059
Term of contract	12 years	10 years
Number of renewal options \| renewal_option	13	5
Renewal term		1 year

Summary of Significant Accounting Policies - Schedule of Restatement (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Prepaid forward contract derivative	$ 0	$ 0
Total assets	268,533	292,003	$ 246,347	$ 176,856				$ 193,011
FPA Put Option liability	26,743	44,593	38,092	0
Total liabilities	117,442	122,738	117,872	124,947				67,297
Additional paid-in capital	936,157	927,641	939,868	24,782				21,710
Total shareholders’ deficit	151,091	169,265	128,475	(428,722)	$ (407,640)	$ (386,586)	$ (370,978)	(354,917)	$ (311,216)
Total liabilities, contingently redeemable preferred stock, and shareholders' deficit	268,533	292,003	$ 246,347	176,856				193,011
Forward Purchase Agreement prepayment	(60,547)	(60,547)
Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Prepaid forward contract derivative	33,804	15,954
Total assets	302,337	307,957
FPA Put Option liability	0	0
Total liabilities	90,699	78,145
Additional paid-in capital	996,704	988,188
Total shareholders’ deficit	211,638	229,812		$ (428,722)				$ (354,917)	$ (311,216)
Total liabilities, contingently redeemable preferred stock, and shareholders' deficit	302,337	307,957
Forward Purchase Agreement prepayment	0	0
Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Prepaid forward contract derivative	(33,804)	(15,954)
Total assets	(33,804)	(15,954)
FPA Put Option liability	26,743	44,593
Total liabilities	26,743	44,593
Additional paid-in capital	(60,547)	(60,547)
Total shareholders’ deficit	(60,547)	(60,547)
Total liabilities, contingently redeemable preferred stock, and shareholders' deficit	(33,804)	(15,954)
Forward Purchase Agreement prepayment	$ (60,547)	$ (60,547)

Fair Value - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		5 Months Ended	6 Months Ended		8 Months Ended	9 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Feb. 08, 2023	Feb. 03, 2023	Nov. 09, 2022
Warrants
Sale of private placement warrants (in shares)									985,278	985,278	985,278	10,000,000	316,250
Class of warrant or right, exercise price of warrants or rights (in dollars per share)									$ 3.36	$ 4.56	$ 9.91		$ 0.01
Gain on change in fair value of SAFE and warrant liabilities	$ (20,979)	$ (60)		$ (4,663)	$ (766)		$ (14,249)	$ (330)	$ 1,949	$ 563
Brookfield SAFE liability									50,000
Brookfield SAFE liability	19,400		$ 34,150	$ 34,150		$ 23,350	$ 23,350		50,000	0
Other Expense
Warrants
Gain on change in fair value of SAFE and warrant liabilities									$ 974	$ 563
Other Expense \| Public warrants
Warrants
Gain on change in fair value of SAFE and warrant liabilities	286		600			2,100
Other Expense \| Private placement warrants
Warrants
Gain on change in fair value of SAFE and warrant liabilities	$ 477		$ 3,199			$ 2,912

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended		6 Months Ended		9 Months Ended		12 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net loss	$ (63,312,000)	$ (16,778,000)	$ (90,098,000)	$ (32,707,000)	$ (115,424,000)	$ (54,974,000)	$ (76,356,000)	$ (46,689,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	3,505,000	738,000	8,715,000	1,414,000	11,933,000	2,067,000	2,527,000	2,531,000
Gain on change in fair value of SAFE and warrant liabilities	(20,979,000)	(60,000)	(4,663,000)	(766,000)	(14,249,000)	(330,000)	1,949,000	563,000
Loss on change in fair value of the prepaid forward contract and the Fixed Maturity Consideration	51,109,000	0	33,029,000	0	44,661,000	0
Provision for losses on trade and other receivables	800,000	0	800,000	0	700,000	0
Bad debt expense and recoveries							0	(27,000)
Depreciation of property, plant and equipment	1,257,000	1,059,000	2,605,000	2,222,000	3,981,000	3,433,000	4,660,000	3,806,000
Amortization of discount on debt security investment			(508,000)	0	(933,000)	0
Non-cash lease expense	532,000	438,000	387,000	886,000	946,000	1,343,000	1,825,000	1,679,000
Non-cash recognition of licensing revenue	(553,000)	(540,000)	(1,136,000)	(1,080,000)	(1,700,000)	(1,620,000)	(2,160,000)	(2,022,000)
Gain from equity method investees, net	608,000	282,000			941,000	(2,346,000)	(1,992,000)	(1,945,000)
PPP loan forgiveness							0	(3,065,000)
Gain from disposal of PPE							(49,000)	0
Loss (gain) from equity method investees, net			478,000	(2,813,000)	941,000	(2,346,000)	1,422,000	1,606,000
Net foreign exchange loss (gain)	(171,000)	65,000	194,000	(605,000)	423,000	1,311,000	668,000	55,000
Changes in operating assets and liabilities:
Accounts receivable, net	1,618,000	808,000	3,129,000	(3,296,000)	1,088,000	(8,710,000)	(8,817,000)	2,670,000
Contract assets	(408,000)	(4,792,000)	(3,668,000)	(3,807,000)	(6,488,000)	(3,270,000)	(6,246,000)	(5,514,000)
Accrued interest on debt investment			(93,000)	0	(178,000)	0
Other assets	(8,593,000)	(1,807,000)	(8,942,000)	(4,638,000)	(6,723,000)	(5,981,000)	(5,127,000)	(941,000)
Accounts payable and accrued salaries and wages	1,692,000	1,113,000	1,881,000	4,077,000	(1,484,000)	463,000	8,243,000	1,256,000
Contract liabilities	(60,000)	299,000	(150,000)	(237,000)	29,000	(471,000)	(488,000)	5,762,000
Operating lease liabilities	(667,000)	(491,000)	(19,000)	(996,000)	(212,000)	(1,518,000)	(2,028,000)	(1,618,000)
Other liabilities	(188,000)	1,548,000	(1,057,000)	(159,000)	1,124,000	(733,000)	(1,312,000)	908,000
Net cash used in operating activities	(33,810,000)	(18,118,000)	(59,116,000)	(42,505,000)	(81,565,000)	(71,336,000)	(84,703,000)	(42,591,000)
Cash Flows From Investing Activities:
Purchase of property, plant and equipment	(1,367,000)	(1,891,000)	(5,318,000)	(4,894,000)	(7,137,000)	(6,530,000)	(10,735,000)	(5,752,000)
Purchase of debt securities	(49,103,000)	0	(49,103,000)	0	(93,858,000)	0
Proceeds from maturity of debt securities					50,000,000	0
Forward Purchase Agreement prepayment	(60,096,000)	0	(60,096,000)	0	(60,096,000)	0
Purchase of additional interest in equity method investment			(288,000)	0	(288,000)	0
Origination of related party loan			(5,212,000)	0	(5,212,000)	0
Proceeds from disposal of property, plant and equipment							49,000	5,000
Net cash used in investing activities	(110,566,000)	(1,891,000)	(120,017,000)	(4,894,000)	(116,591,000)	(6,530,000)	(10,686,000)	(5,747,000)
Cash Flows From Financing Activities:
Proceeds from issue of equity instruments of the Company	746,000	7,000	0	7,000	0	23,000	1,194,000	83,831,000
Proceeds from the Business Combination and PIPE, net of transaction expenses (Note 3)	213,381,000	0	213,381,000	0	213,381,000	0
Proceeds from exercise of options			1,077,000	0	1,637,000	0
Proceeds from exercise of a warrant							0	3,150,000
Proceeds from issue of SAFE and warrant instruments							50,000,000	30,000,000
Repurchase of equity instruments of the Company	(7,650,000)	0	(7,650,000)	0	(7,650,000)	0	(649,000)	(396,000)
Repayment of borrowings							0	(570,000)
Net cash provided by financing activities	206,477,000	7,000	206,808,000	7,000	207,368,000	23,000	50,545,000	116,015,000
Net increase (decrease) in cash, cash equivalents and restricted cash	62,101,000	(20,002,000)	27,675,000	(47,392,000)	9,212,000	(77,843,000)	(44,844,000)	67,677,000
Cash, cash equivalents and restricted cash at beginning of period	83,710,000	128,732,000	83,710,000	128,732,000	83,710,000	128,732,000	128,732,000	60,909,000
Effects of currency translation on cash, cash equivalents and restricted cash	(25,000)	(103,000)	4,000	(71,000)	(852,000)	145,000	(178,000)	146,000
Cash, cash equivalents and restricted cash at end of period	145,786,000	108,627,000	111,389,000	81,269,000	92,070,000	51,034,000	83,710,000	128,732,000
Supplemental disclosure of non-cash investing and financing activities:
Acquisition of property, plant and equipment under accounts payable	234,000	60,000	125,000	713,000	219,000	107,000	246,000	708,000
Reclassification of capitalized costs related to the business combination to equity	1,514,000	0	1,514,000	0	1,514,000	0
Cashless conversion of warrants on preferred shares	5,890,000	0	5,890,000	0	5,890,000	0
Recognition of public and private warrant liabilities in the Business Combination	4,624,000	0	4,624,000	0	4,624,000	0
Reclassification of AM SAFE warrant to equity	1,800,000	0	1,800,000	0	1,800,000	0
Conversion of AM SAFE liability into common stock	29,730,000	0	29,730,000	0	29,730,000	0
Conversion of Legacy LanzaTech NZ, Inc. preferred stock and in-kind dividend into common stock	$ 722,160,000	$ 0	722,160,000	0	722,160,000	0
Reclassification of Shortfall warrant to equity			$ 3,063,000	$ 0	$ 3,063,000	$ 0
Receipt of common shares as payment for option exercises							1,944,000	938,000
Right-of-use asset additions							4,108,000	0
PPP loan forgiveness							$ 0	$ 3,065,000

Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash Reconciliation (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Cash and cash equivalents	$ 91,397	$ 110,719	$ 145,118	$ 83,045				$ 128,318
Restricted cash (presented within Other current assets)	673	670	668	665				414
Cash, cash equivalents and restricted cash	$ 92,070	$ 111,389	$ 145,786	$ 83,710	$ 51,034	$ 81,269	$ 108,627	$ 128,732	$ 60,909

Redeemable, Convertible Preferred Stock

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Mar. 31, 2023

Jun. 30, 2023

Sep. 30, 2023

Dec. 31, 2022

Temporary Equity Disclosure [Abstract]

Redeemable, Convertible Preferred Stock

The Company had six outstanding series of contingently redeemable convertible preferred stock. The dollar amounts and share counts in the table below are adjusted to reflect the impact of the exchange ratio on the shares authorized, shares issued and outstanding, and issue price. The authorized, issued and outstanding shares, issue price, and carrying value as of December 31, 2022 are as follows (in thousands, except share and per share amounts):


	Shares Authorized	Shares Issued and Outstanding	Issue Price	Carrying Amount
Series A	20,414,445	20,414,445	$0.40 - $0.90	$	12,230
Series B	7,582,934	7,582,934	2.37	18,000
Series C	18,613,084	18,121,698	3.36	60,850
Series D	44,946,572	44,452,681	4.56	188,402
Series E	22,678,139	22,678,139	5.23	118,076
Series F	15,898,496	15,898,496	5.23	83,073
	130,133,670	129,148,393		$	480,631

All redeemable, convertible preferred stock was converted into common shares on the Closing Date of the Business Combination on a 1:1 basis. Immediately before the conversion, all cumulative dividends were declared, totaling a dividend payable of $241,529. This dividend was paid in-kind and subsequently converted, as a result of the Business Combination, into an additional 24,152,942 common shares. After the in-kind dividend payment and the conversion, the former preferred shareholders held 153,895,644 common shares.

There were no changes in redeemable convertible preferred stock issued and outstanding during the three months ended March 31, 2022.

Prior to the Business Combination, redemption features of the preferred shares were not fixed and did not have a determinable price on fixed or determinable dates. As of December 31, 2022, the preferred shares were not currently redeemable, and it was not probable that the preferred shares would become redeemable, since it was uncertain whether or when circumstances exist that would constitute a deemed liquidation event. Accordingly, the Company did not adjust the carrying value of the preferred shares to their redemption values.

Redeemable, Convertible Preferred Stock

Prior to the Business Combination, the Company had six outstanding series of contingently redeemable convertible preferred stock. The dollar amounts and share counts in the table below are adjusted to reflect the impact of the exchange ratio on the shares authorized, shares issued and outstanding, and issue price. The authorized, issued and outstanding shares, issue price, and carrying value as of December 31, 2022 are as follows (in thousands, except share and per share amounts):


	Shares Authorized	Shares Issued and Outstanding	Issue Price	Carrying Amount
Series A	20,414,445	20,414,445	$0.40 - $0.90	$	12,230
Series B	7,582,934	7,582,934	2.37	18,000
Series C	18,613,084	18,121,698	3.36	60,850
Series D	44,946,572	44,452,681	4.56	188,402
Series E	22,678,139	22,678,139	5.23	118,076
Series F	15,898,496	15,898,496	5.23	83,073
	130,133,670	129,148,393		$	480,631

There were no changes in redeemable convertible preferred stock issued and outstanding during the three and six months ended June 30, 2022.

Redeemable, Convertible Preferred Stock


	Shares Authorized	Shares Issued and Outstanding	Issue Price	Carrying Amount
Series A	20,414,445	20,414,445	$0.40 - $0.90	$	12,230
Series B	7,582,934	7,582,934	2.37	18,000
Series C	18,613,084	18,121,698	3.36	60,850
Series D	44,946,572	44,452,681	4.56	188,402
Series E	22,678,139	22,678,139	5.23	118,076
Series F	15,898,496	15,898,496	5.23	83,073
	130,133,670	129,148,393		$	480,631

Redeemable, Convertible Preferred Stock

The Company has six outstanding series of contingently redeemable convertible preferred stock.The dollar amounts and share counts in the table below are adjusted to reflect the impact of the exchange ratio on the shares authorized, shares issued and outstanding, and issue price. The authorized, issued and outstanding shares, issue price, and carrying value as of December 31, 2022 and December 31, 2021, are as follows (in thousands, except share and per share amounts):


	Shares Authorized	Shares Issued and Outstanding	Issue Price	Carrying Amount
Series A	20,414,445	20,414,445	$0.40 - 0.90	$	12,230
Series B	7,582,934	7,582,934	2.37	18,000
Series C	18,613,084	18,121,698	3.36	60,850
Series D	44,946,572	44,452,681	4.56	188,402
Series E	22,678,139	22,678,139	5.23	118,076
Series F	15,898,496	15,898,496	5.23	83,073
	130,133,670	129,148,393		$	480,631

There were no changes in redeemable convertible preferred stock issued and outstanding during the year ended December 31, 2022. The holders of preferred shares are entitled to receive dividends on an as converted to common shares basis as if all preferred shares had been converted into common shares on the date of such event. Dividends are cumulative and are payable in arrears at the rate of 8% of the original issue price.

In March 2021, a warrant was exercised for a total issuance of 691,453 Series D preferred shares which led to an increase in redeemable convertible preferred stock of $3,150 during the year ended December 31, 2021. In April 2021, the Company closed a Series F round with the issuance of 15,898,496 Series F preferred shares for the net proceeds of $83,073.

Redemption features of preferred shares are not fixed and do not have a determinable price on fixed or determinable dates. As of December 31, 2022, the preferred shares are not currently redeemable, and it is not probable that the preferred shares will become redeemable, since it is uncertain whether or when circumstances exist that would constitute a deemed liquidation event. Accordingly, the Company has not adjusted the carrying value of the preferred shares to their redemption values.

Property, Plant, and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross				$ 46,738	$ 36,521
Less accumulated depreciation and amortization				27,049	22,373
Total property, plant and equipment, net	$ 22,818	$ 22,280	$ 19,794	19,689	14,148
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross				64	64
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross				4,126	4,113
Instruments and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross				33,093	26,627
Vehicles
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross				85	71
Office Equipment and furniture
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross				1,719	1,590
Other
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross				871	728
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross				$ 6,780	$ 3,328

CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND SHAREHOLDERS’ EQUITY (DEFICIT) (Parenthetical)	12 Months Ended
	Dec. 31, 2021 USD ($)
Statement of Stockholders' Equity [Abstract]
Stock issuance cost	$ 0

Property, Plant, and Equipment - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation	$ 1,376	$ 1,348	$ 1,257	$ 1,211	$ 1,163	$ 1,059	$ 2,605	$ 2,222	$ 3,981	$ 3,433	$ 4,660	$ 3,806

Redeemable, Convertible Preferred Stock (Tables)

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Mar. 31, 2023

Jun. 30, 2023

Sep. 30, 2023

Dec. 31, 2022

Temporary Equity Disclosure [Abstract]

Redeemable convertible preferred stock

The authorized, issued and outstanding shares, issue price, and carrying value as of December 31, 2022 are as follows (in thousands, except share and per share amounts):


	Shares Authorized	Shares Issued and Outstanding	Issue Price	Carrying Amount
Series A	20,414,445	20,414,445	$0.40 - $0.90	$	12,230
Series B	7,582,934	7,582,934	2.37	18,000
Series C	18,613,084	18,121,698	3.36	60,850
Series D	44,946,572	44,452,681	4.56	188,402
Series E	22,678,139	22,678,139	5.23	118,076
Series F	15,898,496	15,898,496	5.23	83,073
	130,133,670	129,148,393		$	480,631

The dollar amounts and share counts in the table below are adjusted to reflect the impact of the exchange ratio on the shares authorized, shares issued and outstanding, and issue price. The authorized, issued and outstanding shares, issue price, and carrying value as of December 31, 2022 are as follows (in thousands, except share and per share amounts):


	Shares Authorized	Shares Issued and Outstanding	Issue Price	Carrying Amount
Series A	20,414,445	20,414,445	$0.40 - $0.90	$	12,230
Series B	7,582,934	7,582,934	2.37	18,000
Series C	18,613,084	18,121,698	3.36	60,850
Series D	44,946,572	44,452,681	4.56	188,402
Series E	22,678,139	22,678,139	5.23	118,076
Series F	15,898,496	15,898,496	5.23	83,073
	130,133,670	129,148,393		$	480,631


	Shares Authorized	Shares Issued and Outstanding	Issue Price	Carrying Amount
Series A	20,414,445	20,414,445	$0.40 - $0.90	$	12,230
Series B	7,582,934	7,582,934	2.37	18,000
Series C	18,613,084	18,121,698	3.36	60,850
Series D	44,946,572	44,452,681	4.56	188,402
Series E	22,678,139	22,678,139	5.23	118,076
Series F	15,898,496	15,898,496	5.23	83,073
	130,133,670	129,148,393		$	480,631

The authorized, issued and outstanding shares, issue price, and carrying value as of December 31, 2022 and December 31, 2021, are as follows (in thousands, except share and per share amounts):


	Shares Authorized	Shares Issued and Outstanding	Issue Price	Carrying Amount
Series A	20,414,445	20,414,445	$0.40 - 0.90	$	12,230
Series B	7,582,934	7,582,934	2.37	18,000
Series C	18,613,084	18,121,698	3.36	60,850
Series D	44,946,572	44,452,681	4.56	188,402
Series E	22,678,139	22,678,139	5.23	118,076
Series F	15,898,496	15,898,496	5.23	83,073
	130,133,670	129,148,393		$	480,631

Summary of Significant Accounting Policies - Property, Plant and Equipment, net (Details)	Dec. 31, 2022
Instruments and equipment \| Minimum
Property, Plant and Equipment [Line Items]
Useful life	3 years
Instruments and equipment \| Maximum
Property, Plant and Equipment [Line Items]
Useful life	5 years
Office Equipment and furniture \| Minimum
Property, Plant and Equipment [Line Items]
Useful life	3 years
Office Equipment and furniture \| Maximum
Property, Plant and Equipment [Line Items]
Useful life	5 years
Vehicles
Property, Plant and Equipment [Line Items]
Useful life	5 years

Forward Purchase Agreement	3 Months Ended	6 Months Ended	9 Months Ended
Forward Purchase Agreement	Mar. 31, 2023	Jun. 30, 2023	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Forward Purchase Agreement	Forward Purchase Agreement (Restated) As discussed in Note 2 - Summary of Significant Accounting Policies, the FPA consists of the Prepayment Amount, the FPA Put Option and the Fixed Maturity Consideration. The Prepayment Amount of $60,547 is presented as a reduction to additional paid-in capital in our condensed consolidated balance sheet. The value of the FPA Put Option represents the economics of the written put option, inclusive of the Variable Maturity Consideration, and is valued at $44,593 as of March 31, 2023. The Fixed Maturity Consideration is valued at $6,967 as of March 31, 2023. This represents the fair value of the Share Consideration and Fixed Maturity Consideration and is measured in accordance with the FVO. Expensed transaction costs, representing the stock acquisition fees, in the amount of $451 are recorded in other expense, net.	Forward Purchase Agreement (Restated) As discussed in Note 2 - Summary of Significant Accounting Policies, the FPA consists of the Prepayment Amount, the FPA Put Option and the Fixed Maturity Consideration. The Prepayment Amount of $60,547 is presented as a reduction to additional paid-in capital in our condensed consolidated balance sheet. The value of the FPA Put Option represents the economics of the written put option, inclusive of the Variable Maturity Consideration, and is valued at 26,743 as of June 30, 2023. The Fixed Maturity Consideration is valued at $6,737 as of June 30, 2023. This represents the fair value of the Share Consideration and Fixed Maturity Consideration and is measured in accordance with the FVO. Expensed transaction costs, representing the stock acquisition fees, in the amount of $451 are recorded in other expense, net.	Forward Purchase Agreement As discussed in Note 2 - Summary of Significant Accounting Policies, the FPA consists of the prepaid forward contract and the Fixed Maturity Consideration. The prepaid forward contract is evaluated as an in-substance written put option that meets the definition of a derivative, referred to as the FPA Put Option in our condensed consolidated balance sheets. The value of the FPA Put Option represents the economics of the written put option, including the Variable Maturity Consideration and is valued at $38,092 as of September 30, 2023 . The Fixed Maturity Consideration is valued at $7,020 as of September 30, 2023. This represents the fair value of the Share Consideration and Fixed Maturity Consideration and is measured in accordance with the FVO. Expensed transaction costs, representing the stock acquisition fees, in the amount of $451 are recorded in other expense, net.

Summary of Significant Accounting Policies - Brookfield SAFE (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Accounting Policies [Abstract]
Proceeds from Brookfield SAFE agreement	$ 50,000

Redeemable, Convertible Preferred Stock - Authorized, Issued and Outstanding Shares, Issue Price, and Carrying Value (Details) - USD ($) $ / shares in Units, $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Temporary Equity [Line Items]
Shares authorized (in shares)	20,000,000	20,000,000	20,000,000	130,133,670				130,133,670
Shares issued (in shares)	0	0	0	129,148,393				129,148,393
Shares outstanding (in shares)	0	0	0	129,148,393	129,148,393	129,148,393	129,148,393	129,148,393	112,558,444
Carrying Amount	$ 0	$ 0	$ 0	$ 480,631	$ 480,631	$ 480,631	$ 480,631	$ 480,631	$ 394,408
Series A
Temporary Equity [Line Items]
Shares authorized (in shares)				20,414,445
Shares issued (in shares)				20,414,445
Shares outstanding (in shares)				20,414,445
Carrying Amount				$ 12,230
Series A \| Minimum
Temporary Equity [Line Items]
Issue price (in dollars per share)				$ 0.40
Series A \| Maximum
Temporary Equity [Line Items]
Issue price (in dollars per share)				$ 0.90
Series B
Temporary Equity [Line Items]
Shares authorized (in shares)				7,582,934
Shares issued (in shares)				7,582,934
Shares outstanding (in shares)				7,582,934
Issue price (in dollars per share)				$ 2.37
Carrying Amount				$ 18,000
Series C
Temporary Equity [Line Items]
Shares authorized (in shares)				18,613,084
Shares issued (in shares)				18,121,698
Shares outstanding (in shares)				18,121,698
Issue price (in dollars per share)				$ 3.36
Carrying Amount				$ 60,850
Series D
Temporary Equity [Line Items]
Shares authorized (in shares)				44,946,572
Shares issued (in shares)				44,452,681
Shares outstanding (in shares)				44,452,681
Issue price (in dollars per share)				$ 4.56
Carrying Amount				$ 188,402
Series E
Temporary Equity [Line Items]
Shares authorized (in shares)				22,678,139
Shares issued (in shares)				22,678,139
Shares outstanding (in shares)				22,678,139
Issue price (in dollars per share)				$ 5.23
Carrying Amount				$ 118,076
Series F
Temporary Equity [Line Items]
Shares authorized (in shares)				15,898,496
Shares issued (in shares)				15,898,496
Shares outstanding (in shares)				15,898,496
Issue price (in dollars per share)				$ 5.23
Carrying Amount				$ 83,073

Share-Based Compensation - Restricted Stock Units Activity (Details) - $ / shares shares in Thousands	6 Months Ended	9 Months Ended
	Jun. 30, 2023	Sep. 30, 2023
RSUs
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance, weighted average fair value (usd per share)	$ 0	$ 0
Granted, weighted average fair value (usd per share)	2.43	2.49
Exercised, weighted average fair value (usd per share)	0	3.45
Cancelled/forfeited, weighted average fair value (usd per share)	3.45	3.43
Ending balance, weighted average fair value (usd per share)	$ 2.43	$ 2.49
Time Based RSU
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance (in shares)	0	0
Granted (in shares)	3,082	3,143
Exercised (in shares)	0	(2)
Cancelled/forfeited (in shares)	(11)	(28)
Ending balance (in shares)	3,071	3,113
Market Based RSU
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance (in shares)	0	0
Granted (in shares)	3,830	3,930
Exercised (in shares)	0	0
Cancelled/forfeited (in shares)	0	0
Ending balance (in shares)	3,830	3,930

Related Party Transactions (Tables)

6 Months Ended

9 Months Ended

12 Months Ended

Jun. 30, 2023

Sep. 30, 2023

Dec. 31, 2022

The table below summarizes amounts related to transactions with these related parties (in thousands), other than revenues which are disclosed within the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2023 and 2022, as well as Note 5 - Revenues:


	As of
	June 30, 2023		December 31, 2022
Accounts receivable	$	913	$	1,821
Notes receivable	5,267		—
Accounts payable	1,879		3,195

The table below summarizes amounts related to transactions with these related parties (in thousands) :


	As of
	September 30, 2023		December 31, 2022
Accounts receivable	$	763	$	1,821
Notes receivable	5,351		—
Accounts payable	635		3,195

The following table presents revenue from related parties per disaggregated revenue categories:


	Three Months Ended September 30,		Nine Months Ended September 30,
	2023	2022	2023	2022
Revenue from related parties, included within Licensing	1,515	540	2,902	1,620
Revenue from related parties, included within Engineering and other services	104	164	766	496

The table below summarizes amounts related to transactions with these related parties (in thousands):


	Year Ended December 31,
	2022		2021
Revenues	$	2,970	$	3,253

	As of
	December 31, 2022		December 31, 2021
Accounts receivable	$	1,821	$	1,071
Contract assets	—		60
Purchases and open accounts payable	3,195		2,575

Leases

12 Months Ended

Dec. 31, 2022

Leases [Abstract]

Leases

The Company leases certain office space and laboratory facilities. The Company’s lease agreements typically do not contain any significant guarantees of asset values at the end of a lease, renewal options or restrictive covenants. Pursuant to ASC 842, Leases, all leases are classified as operating leases. During 2022 and 2021, the discount rate used in the calculation of lease liabilities was 7.50%, which is the estimate of the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term.

Total operating lease costs and variable lease costs for the years ended December 31, 2022 and 2021 were $2,167 and $2,126 and $2,227 and $2,575, respectively. Cash paid for amounts included in the measurement of operating lease liabilities for the years ended December 31, 2022 and 2021 was $2,370 and $2,059, respectively.

As of December 31, 2022, lease payments for operating leases for the Company’s office facility and laboratories are shown below (in thousands):


Year ending December 31,
2023	$	1,302
2024	2,602
2025	2,347
2026	2,418
2027	—
Thereafter	—
Total lease payments	$	8,669
Less: imputed interest	1,256
Total lease liabilities	$	7,413

The following is a summary of weighted average remaining lease term and discount rate for all of the Company’s operating leases:


	Year Ended December 31,
	2022		2021
Weighted average remaining lease term (years)	3.5		2.4
Weighted average discount rate	7.50	%	7.50	%

Lessor accounting

In May 2020, the Company executed an agreement to lease certain land to a subsidiary of LanzaJet for a period of 10 years with an option to renew this lease for five additional periods of one year with minimum annual rent due. This agreement is accounted for as an operating lease. In February 2022, the lease agreement with LanzaJet was amended to extend the pre-development term of the lease until the earlier of commencement of construction of the alcohol-to-jet fuel facility on the leased land or December 31, 2023, increased the annual base rent amount and increased the term from 10 years to 12 years. Additionally, the subsidiary of LanzaJet was granted an option to renew this lease for thirteen additional periods of one year. In August 2022, the lease agreement was amended further to increase the annual rent due upon commencement of construction of the alcohol-to-jet fuel facility. We recognize lease revenue on a straight-line basis over the life of the lease agreement. The following future minimum lease payments due to us from the lease agreement at December 31, 2022, is as follows (in thousands)


Year ending December 31,
2023	$	34
2024	155
2025	155
2026	155
2027	155
Thereafter	1,240
	$	1,894

Leases

As of December 31, 2022, lease payments for operating leases for the Company’s office facility and laboratories are shown below (in thousands):


Year ending December 31,
2023	$	1,302
2024	2,602
2025	2,347
2026	2,418
2027	—
Thereafter	—
Total lease payments	$	8,669
Less: imputed interest	1,256
Total lease liabilities	$	7,413

The following is a summary of weighted average remaining lease term and discount rate for all of the Company’s operating leases:


	Year Ended December 31,
	2022		2021
Weighted average remaining lease term (years)	3.5		2.4
Weighted average discount rate	7.50	%	7.50	%

Lessor accounting


Year ending December 31,
2023	$	34
2024	155
2025	155
2026	155
2027	155
Thereafter	1,240
	$	1,894

Leases - Supplemental Information (Details)	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Weighted average remaining lease term (years)	3 years 6 months	2 years 4 months 24 days
Weighted average discount rate	7.50%	7.50%

Reverse Recapitalization - Cash Flow Reconciliation (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended	9 Months Ended
	Mar. 31, 2023	Jun. 30, 2023	Sep. 30, 2023
Business Combination and Asset Acquisition [Abstract]
Cash - AMCI trust account	$ 64,090	$ 64,090	$ 64,090
Public Warrants and Private Placement Warrants recorded on the Closing Date	(4,624)	(4,624)	(4,624)
Cash - PIPE financing	155,000	155,000	155,000
Conversion of the AM SAFE	29,730	29,730	29,730
Transaction costs allocated to equity	(7,223)	(7,223)	(7,223)
Proceeds From Reverse Recapitalization Transaction	236,973	236,973	236,973
Less: Transaction costs allocated to equity and paid in the three months ended March 31, 2023	(5,709)	(5,709)	(5,709)
Less: par value of shares held by PIPE investors and public stockholders	(3)	(3)	(3)
Effect of the Business Combination and PIPE financing	213,381	213,381	213,381
Total additional paid-in capital from recapitalization	$ 236,970	$ 236,970	$ 236,970

Fair Value - Financial Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Liabilities:
Warrants	$ 9,636	$ 8,422	$ 9,919	$ 4,108
Brookfield SAFE liability				50,000
AM SAFE liability	0	0	0	28,986	$ 28,271
Fair Value, Recurring
Assets:
Cash equivalents	37,370	31,665	31,397	523	516
Total assets	37,370	31,665	31,397
Liabilities:
FPA Put Option liability	38,092	26,743	44,593
Fixed Maturity Consideration	7,020	6,737	6,967
Warrants				2,119	1,145
Brookfield SAFE liability	23,350	34,150	19,400	50,000
AM SAFE liability				28,986	28,271
Total liabilities	78,097	76,052	80,879	83,094	31,145
Fair Value, Recurring \| AM SAFE warrant
Liabilities:
Warrants				1,989	1,729
Fair Value, Recurring \| Shortfall Warrants
Liabilities:
Warrants			5,104
Fair Value, Recurring \| Private placement warrants
Liabilities:
Warrants	5,060	5,347	2,626
Fair Value, Recurring \| Public warrants
Liabilities:
Warrants	4,575	3,075	2,189
Fair Value, Recurring \| Level 1
Assets:
Cash equivalents	37,370	31,665	31,397	523	516
Total assets	37,370	31,665	31,397
Liabilities:
FPA Put Option liability	0	0	0
Fixed Maturity Consideration	0	0	0
Warrants				0	0
Brookfield SAFE liability	0	0	0	0
AM SAFE liability				0	0
Total liabilities	4,575	3,075	2,189	0	0
Fair Value, Recurring \| Level 1 \| AM SAFE warrant
Liabilities:
Warrants				0	0
Fair Value, Recurring \| Level 1 \| Shortfall Warrants
Liabilities:
Warrants			0
Fair Value, Recurring \| Level 1 \| Private placement warrants
Liabilities:
Warrants	0	0	0
Fair Value, Recurring \| Level 1 \| Public warrants
Liabilities:
Warrants	4,575	3,075	2,189
Fair Value, Recurring \| Level 2
Assets:
Cash equivalents	0	0	0	0	0
Total assets	0	0	0
Liabilities:
FPA Put Option liability	0	0	0
Fixed Maturity Consideration	0	0	0
Warrants				0	0
Brookfield SAFE liability	0	0	0	0
AM SAFE liability				0	0
Total liabilities	0	0	0	0	0
Fair Value, Recurring \| Level 2 \| AM SAFE warrant
Liabilities:
Warrants				0	0
Fair Value, Recurring \| Level 2 \| Shortfall Warrants
Liabilities:
Warrants			0
Fair Value, Recurring \| Level 2 \| Private placement warrants
Liabilities:
Warrants	0	0	0
Fair Value, Recurring \| Level 2 \| Public warrants
Liabilities:
Warrants	0	0	0
Fair Value, Recurring \| Level 3
Assets:
Cash equivalents	0	0	0	0	0
Total assets	0	0	0
Liabilities:
FPA Put Option liability	38,092	26,743	44,593
Fixed Maturity Consideration	7,020	6,737	6,967
Warrants				2,119	1,145
Brookfield SAFE liability	23,350	34,150	19,400	50,000
AM SAFE liability				28,986	28,271
Total liabilities	73,522	72,977	78,690	83,094	31,145
Fair Value, Recurring \| Level 3 \| AM SAFE warrant
Liabilities:
Warrants				$ 1,989	$ 1,729
Fair Value, Recurring \| Level 3 \| Shortfall Warrants
Liabilities:
Warrants			5,104
Fair Value, Recurring \| Level 3 \| Private placement warrants
Liabilities:
Warrants	5,060	5,347	2,626
Fair Value, Recurring \| Level 3 \| Public warrants
Liabilities:
Warrants	$ 0	$ 0	$ 0

Net Loss Per Share - Antidilutive Shares (Details) - shares	1 Months Ended	3 Months Ended		6 Months Ended		9 Months Ended		12 Months Ended
	Feb. 07, 2023	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares		36,012,752	149,459,933	45,982,284	149,303,108	45,722,414	149,253,801	147,330,749	149,491,092
Redeemable convertible preferred stock (if converted)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	129,148,393	0	129,148,393	0	129,148,393	0	129,148,393	129,148,393	129,148,393
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares		14,355,066	16,790,437	17,423,238	16,633,612	17,021,827	16,584,305	14,661,253	16,821,596
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares				6,901,360	0	7,042,901	0
RSAs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares		0	2,535,825	0	2,535,825	0	2,535,825	2,535,825	2,535,825
Brookfield SAFE
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares		5,000,000	0	5,000,000	0	5,000,000	0
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares		16,657,686	985,278	16,657,686	985,278	16,657,686	985,278	985,278	985,278

Income Taxes

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Mar. 31, 2023

Jun. 30, 2023

Sep. 30, 2023

Dec. 31, 2022

Income Tax Disclosure [Abstract]

Income Taxes

The Company is subject to federal and state income taxes in the United States, as well as income taxes in foreign jurisdictions in which it conducts business. The Company does not provide for federal income taxes on the undistributed earnings of its foreign subsidiaries as such earnings are reinvested indefinitely. The Company and its foreign subsidiaries have historically been loss generating entities that have resulted in no excess earnings to consider for repatriation and accordingly there are no deferred income taxes recognized for the three months ended March 31, 2023 and 2022.

The Company recorded an income tax expense of $0 for the three months ended March 31, 2023 and March 31, 2022, representing an effective tax rate of 0%. The difference between the U.S. federal statutory rate of 21% and the Company's effective tax rate in the first three months ended March 31, 2023 and March 31, 2022 is primarily due to a full valuation allowance related to the Company's U.S. and foreign deferred tax assets. The Company reassesses the need for a valuation allowance on a quarterly basis. If it is determined that a portion or all of the valuation allowance is not required, it will generally be a benefit to the income tax provision in the period such determination is made.

The Company conducts business in multiple jurisdictions within and outside the United States. Consequently, the Company is subject to periodic income tax examinations by domestic and foreign income tax authorities. The Company is subject to audits for tax years 2017 and onward for federal purposes. There are tax years which remain

subject to examination in various other state and foreign jurisdictions that are not material to the Company's financial statements.

Income Taxes

The Company recorded an income tax expense of $0 for the three and six months ended June 30, 2023 and June 30, 2022, representing an effective tax rate of 0%. The difference between the U.S. federal statutory rate of 21% and the Company's effective tax rate in the three and six months ended June 30, 2023 and June 30, 2022 is primarily due to a full valuation allowance related to the Company's U.S. and foreign deferred tax assets. The Company reassesses the need for a valuation allowance on a quarterly basis. If it is determined that a portion or all of the valuation allowance is not required, it will generally be a benefit to the income tax provision in the period such determination is made.

Income Taxes

The Company recorded an income tax expense of $0 for the three and nine months ended September 30, 2023 and 2022, representing an effective tax rate of 0%. The difference between the U.S. federal statutory rate of 21% and the Company's effective tax rate in the three and nine months ended September 30, 2023 and 2022 is primarily due to a full valuation allowance related to the Company's U.S. and foreign deferred tax assets. The Company reassesses the need for a valuation allowance on a quarterly basis. If it is determined that a portion or all of the valuation allowance is not required, it will generally be a benefit to the income tax provision in the period such determination is made.

Income Taxes

The components of (loss) income before income taxes and gain from equity method investees, net are as follows (in thousands):


	Year Ended December 31,
	2022		2021
United States	$	(73,271)	$	(39,860)

Foreign	(3,085)		(6,829)
Total	$	(76,356)	$	(46,689)

The Company does not have any current or deferred taxes in either the United States or our foreign operations.


	Year Ended December 31,
	2022				2021
Income tax (benefit) at the statutory federal income tax rate	$	(16,035)	21.0	%	$	(9,805)	21.0	%
Foreign tax rate differential	(72)		0.1	%	(605)		1.3	%
State and local taxes	(6,961)		9.1	%	(4,068)		8.7	%

Foreign exchange differences	—		—	%	(143)		0.3	%
Stock-based compensation	288		(0.4)	%	501		(1.1)	%
Interest income on receivable	—		—	%	882		(1.9)	%
Equity method investment	(701)		0.9	%	(443)		0.9	%
Non-deductible legal costs	—		—	%	1,291		(2.8)	%
Gain from redomiciliation of intellectual property	—		—	%	4,890		(10.5)%
Valuation allowance	26,286		(34.4)	%	7,958		(17.0)	%
PPP loan forgiveness	—		—	%	$	(644)	1.4	%
Deferred True-Up	(2,836)		3.7%		—		—%
Other	31		—	%	186		(0.3)	%
Total income tax benefit	$	—	—	%	$	—	—	%

Deferred Taxes

Significant components of deferred tax assets and liabilities were as follows (in thousands):


	Year Ended December 31,
Deferred tax assets:	2022		2021
Net operating loss and credit carryforwards	$	133,537	$	107,979
Stock-based compensation	2,071		—
Operating lease liability	2,473		1,878
Accrued bonus	1,514		981
Accrued expenses	239		1,566
Deferred revenue	126		309
Equity method investment	2,040		1,243
Other	460		925
	$	142,460	$	114,881

Valuation allowance	(139,562)		(113,276)
Net deferred tax asset	$	2,898	$	1,605
Deferred tax liabilities:
Operating lease asset	(2,125)		(1,429)
Other	(773)		(176)
Total deferred tax liabilities	$	(2,898)	$	(1,605)

Net deferred income tax assets and liabilities:	$	—	$	—

At December 31, 2022 and 2021, the Company had $391,759 and $299,194, respectively, of tax losses and credits carried forward subject to shareholder continuity and acceptance in the countries where the Company has tax losses carried forward. R&D tax credits included within these amounts are $35,147 for both periods, which may be available to offset future income tax liabilities. At December 31, 2022 and 2021, the net operating loss and credit carryforwards are comprised of $318,382 and $239,559 in the United States, $29,691 and $22,203 in state and local, $43,655 and $39,705 in foreign jurisdictions, respectively. At December 31, 2022 and 2021, the Company had net operating loss carryforwards of approximately $146,467 and $136,454, respectively, that expire in various years from 2023 through 2037, plus $210,145 and $127,593, respectively, for which there is no expiration date.

Section 382 of the Internal Revenue Code imposes an annual limitation on the utilization of net operating loss carryforwards based on a statutory rate of return and the value of the corporation at the time of a “change of ownership” as defined by Section 382. The Company had a change in ownership in November 2014. Therefore, the Company’s ability to utilize its net operating loss carryforwards incurred prior to the 2014 ownership change, will be subject in future periods to annual limitations.

In assessing the realizability of deferred tax assets, the Company assesses whether it is more-likely-than-not that a portion or all of the deferred tax assets will not be realized. The Company considers the scheduled reversal of deferred tax liabilities, tax planning strategies and projected future taxable income in making this assessment. At December 31, 2022 and 2021, a valuation allowance of $139,562 and $113,276, respectively, was recorded against certain deferred tax assets based on this assessment. The Company believes it is more-likely-than-not that the tax benefit of the remaining net deferred tax assets will be realized. The amount of net deferred tax assets considered realizable could be increased or reduced in the future if the Company’s assessment of future taxable income or tax planning strategies changes.

The Company and its foreign subsidiaries have historically been loss generating entities that have resulted in no excess earnings to consider for repatriation and accordingly there are no deferred income taxes recognized as of December 31, 2022 and 2021.

At December 31, 2022 and 2021, the Company had no tax liability or benefit related to uncertain tax positions. No interest or penalties related to uncertain taxes have been recognized on the accompanying consolidated statements of operations. Management does not expect a significant change in uncertain tax positions during the twelve months subsequent to December 31, 2022.

The Company conducts business in multiple jurisdictions within and outside the United States. Consequently, the Company is subject to periodic income tax examinations by domestic and foreign income tax authorities. During December 2021, the Internal Revenue Service completed an income tax examination of the Company’s U.S. federal income tax return for the year ended December 31, 2016, which resulted in no impact to the Company’s consolidated financial statements. The Company has no other ongoing tax examinations with domestic or foreign taxing authorities.

During 2021, the Company migrated its country of domicile from New Zealand to Delaware in the United States. On migration, the Company was deemed to have disposed of all its assets and liabilities to a third-party at market value which resulted in taxable income to the Company for New Zealand income tax purposes. The migration to Delaware is classified as a tax-free reorganization for U.S. federal income tax purposes.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

Subsequent Events	3 Months Ended	12 Months Ended
Subsequent Events	Mar. 31, 2023	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events The Company has evaluated events occurring subsequent to March 31, 2023 through May 15, 2023, the date the condensed consolidated financial statements were initially issued. For additional information, see “Restatement” in Note 2, Summary of Significant Accounting Policies. The Company has identified: On May 1, 2023 the Company committed to purchase Subordinated Secured Notes as part of the LanzaJet Note Purchase Agreement. Refer to Note 13 - Related Party Transactions, for more information. On May 13, 2023, the Company amended the Shortfall Warrant agreement, which resulted in the reclassification of the Shortfall Warrants to equity on that date as the amended agreement met the requirements for equity classification in ASC 815-40. This reclassification will be reflected in the period ended June 30, 2023.	Subsequent Events The Company has evaluated events occurring subsequent to December 31, 2022 through March 28, 2023, the date the consolidated financial statements were available to be issued. The Company has identified: Closing of the Business Combination On February 8, 2023 (the “Closing Date”), AMCI, consummated the previously announced Business Combination (refer to Note 1) pursuant to the terms of the Agreement and Plan of Merger (the “Closing”), dated as of March 8, 2022 (as amended on December 7, 2022, the Merger Agreement), by and among the Merger Sub (AMCI, AMCI Merger Sub, Inc., a Delaware corporation) and LanzaTech NZ, Inc. Pursuant to the Merger Agreement, on the Closing Date, (i) AMCI changed its name to “LanzaTech Global, Inc.” (New LanzaTech), and (ii) Merger Sub merged with and into LanzaTech NZ, Inc., with LanzaTech NZ, Inc. as the surviving company in the Business Combination. After giving effect to such Business Combination, LanzaTech NZ, Inc. became a wholly owned subsidiary of New LanzaTech. The Business Combination will be accounted for as a reverse recapitalization. LanzaTech is deemed the accounting predecessor and New LanzaTech is the successor SEC registrant. Under this method of accounting, AMCI is treated as the acquired company for financial statement reporting purposes. Accordingly, the consolidated balance sheets and results of operations of LanzaTech will become the historical financial statements of New LanzaTech, and AMCI’s assets, liabilities and results of operations will be consolidated with LanzaTech’s beginning on the acquisition date. The net assets of LanzaTech will be recognized at carrying value, with no goodwill or other intangible assets recorded. The Company is still evaluating all of the accounting impacts of the Closing of the Business Combination, and will account for them in its consolidated financials for the period ended March 31, 2023. Forward Purchase Agreement On February 3, 2023, AMCI, LanzaTech NZ, Inc. and ACM ARRT H LLC (the "Seller") entered into an agreement (the "Forward Purchase Agreement") for an over-the-counter equity prepaid forward transaction (the “Forward Purchase Transaction”). Pursuant to the terms of the Forward Purchase Agreement, the Seller can purchase up to 10,000,000 Class A common shares, par value $0.0001 per share, of AMCI before the Closing from holders of AMCI's common shares (other than AMCI), including from holders who have previously elected to redeem their AMCI's common shares (the “Recycled Shares”). As of the Closing Date, the Seller obtained 5,916,514 Recycled Shares on the open market for approximately $10.16 per share (“Redemption Price”), and such purchase price of $60.1 million was funded by the use of proceeds from the Business Combination deposited in a trust account, as a prepayment (“Prepayment Amount”) for the Forward Purchase Agreement redemption at the end of three years (“Maturity Date”). The Seller has the right at the end of three years to return the shares and keep the Prepayment Amount plus the fees described below, or may, at the Seller’s sole discretion, to partially or fully terminate this transaction over the course of the three year term by returning cash in an amount equal to the number of shares terminated from time to time (“Terminated Shares”) multiplied by the Redemption Price, which price may be reduced in the case of certain dilutive events (“Reset Price”). At the end of the three-year term, New LanzaTech is obligated to pay the Seller an amount equal to the product of (1) 7,500,000 less (b) the number of Terminated Shares multiplied by (2) $2.00 (the “Maturity Consideration”). In addition to the Prepayment Amount and the Maturity Consideration, on the Maturity Date, New LanzaTech shall pay to the Seller an amount equal to the product of (x) 500,000 and (y) the Redemption Price, totaling $5.1 million (the “Share Consideration”). In addition, the Seller may request, at its sole discretion, warrants of New LanzaTech exercisable for shares in an amount equal to 10,000,000 less the number of Recycled Shares (“Shortfall Warrants”). The Shortfall Warrants warrants have an exercise price equal to the Reset Price. The form of the Shortfall Warrants shall be agreed upon by LanzaTech, AMCI and the Seller within 45 days of the executed Forward Purchase Agreement. The Seller has requested 4,083,486 Shortfall Warrants based on the number of Recycled Shares purchased. In connection with the Forward Purchase Agreement, the Seller assigned its rights, duties and obligations with respect to a portion of the shares purchased under the Forward Purchase Agreement to Vellar Opportunity Fund SPV LLC - Series 10.

Income Taxes - Narrative (Details) - USD ($)	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
Income Taxes - Narrative (Details) - USD ($)	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Income Taxes [Line Items]
Deferred tax liabilities, net	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Effective income tax rate reconciliation	0.00%		0.00%	0.00%		0.00%	0.00%	0.00%			0.00%	0.00%
Statutory tax rate (as a percent)											21.00%	21.00%
Tax losses and credits carried forward											$ 391,759,000	$ 299,194,000
Net operating loss carryforwards, subject to expiration											146,467,000	136,454,000
Net operating loss carryforwards, not subject to expiration											210,145,000	127,593,000
Deferred tax assets valuation allowance											139,562,000	113,276,000
Foreign earnings repatriated	$ 0		$ 0	$ 0		$ 0	$ 0	$ 0			0	0
Deferred income tax											0	0
Income tax expense	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	0	0
Accrued interest and penalties											0	0
State and local
Income Taxes [Line Items]
Tax losses and credits carried forward											29,691,000	22,203,000
Foreign
Income Taxes [Line Items]
Tax losses and credits carried forward											43,655,000	39,705,000
United States \| Domestic
Income Taxes [Line Items]
Tax losses and credits carried forward											318,382,000	$ 239,559,000
R&D tax credits
Income Taxes [Line Items]
Tax credits											$ 35,147,000

Net Loss Per Share

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Mar. 31, 2023

Jun. 30, 2023

Sep. 30, 2023

Dec. 31, 2022

Earnings Per Share [Abstract]

Net Loss Per Share

Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock of the Company outstanding during the period. Diluted net loss per share is computed by giving effect to all potential shares of common stock of the Company, including outstanding stock options, warrants, and contingently redeemable preferred stock, to the extent dilutive. Earnings per share calculation for all periods prior to the Business Combination have been retrospectively restated to the equivalent number of shares reflecting the exchange ratio established in the Merger Agreement of 4.3747.

The following table presents the calculation of basic and diluted net loss per share for the Company’s common stock (in thousands, except shares and per share amounts):


	Three Months Ended March 31,
	2023		2022
Numerator:
Net loss for basic and diluted earnings per common share	$	(63,312)	$	(16,778)
Unpaid cumulative dividends on preferred stock	(4,117)		(9,523)
Net loss allocated to common shareholders	$	(67,429)	$	(26,301)
Denominator:
Weighted-average shares used in calculating net loss per share, basic and diluted	116,530,963		9,219,499
Net loss per common share, basic and diluted(1)	$	(0.58)	$	(2.85)

__________________

As of March 31, 2023 and 2022, potential shares of common stock not included in the computation of loss per share because their effect would be antidilutive include the following:


	Three Months Ended March 31,
	2023	2022
Redeemable convertible preferred stock (if converted)	—	129,148,393
Options	14,355,066	16,790,437
RSAs	—	2,535,825
Brookfield SAFE	5,000,000	—
Warrants	16,657,686	985,278
Total	36,012,752	149,459,933

The preferred shares automatically converted into common shares upon the Business Combination at a 1:1 ratio. On February 8, 2023, upon conversion of the preferred shares, the cumulative accrued, declared and unpaid dividends on the preferred shares became payable. The total amount of cumulative accrued, undeclared and unpaid dividends was approximately $241,529 on the Closing Date. As stipulated by the Merger Agreement, this amount was divided by 10 and resulted in the issuance of an additional 24,152,942 common shares. Prior to the Business Combination, the additional 129,148,393 of potential shares of common stock resulting from any such conversion are not included in the computation of diluted net loss per share because doing so would be anti-dilutive.

In connection with the AM SAFE and Brookfield SAFE, see Note 10 - Fair Value, the Company could issue additional potential shares of common stock. Shares related to the AM SAFE were issued on the Closing Date. Shares related to the Brookfield SAFE and AM SAFE warrant have not been issued as of March 31, 2023. The terms of the AM SAFE warrant became exercisable for a fixed number of shares as of the Closing Date, see Note 8 – Warrants. As a result, these potential shares are included in the warrants line item in the potential share table above as of March 31, 2023. The per share issuance price for the Brookfield SAFE upon closing of the Business Combination is the liquidity price as defined in the Brookfield SAFE agreement. As a result of the Business Combination, the Brookfield SAFE became convertible into a maximum number of shares, which is included in the table above for the three months ended March 31, 2023. None of these potential shares of common stock are included in the computation of diluted net loss per share until actually issued because doing so would be anti-dilutive.

Net Loss Per Share

Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock of the Company outstanding during the period. Diluted net loss per share is computed by giving effect to all potential shares of common stock of the Company, including equity-classified share-based compensation, the Brookfield SAFE, warrants, and contingently redeemable preferred stock, to the extent dilutive. Earnings per share calculation for all periods prior to the Business Combination have been retrospectively restated to the equivalent number of shares reflecting the exchange ratio established in the Merger Agreement of 4.3747.

The following table presents the calculation of basic and diluted net loss per share for the Company’s common stock (in thousands, except shares and per share amounts):


	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Numerator:
Net loss for basic and diluted earnings per common share	$	(26,786)	$	(15,929)	$	(90,098)	$	(32,707)
Unpaid cumulative dividends on preferred stock	—		(9,654)		(4,117)		(19,177)
Net loss allocated to common shareholders	$	(26,786)	$	(25,583)	$	(94,215)	$	(51,884)
Denominator:
Weighted-average shares used in calculating net loss per share, basic and diluted	195,537,601		9,222,214		156,472,730		9,222,870
Net loss per common share, basic and diluted(1)	$	(0.14)	$	(2.77)	$	(0.60)	$	(5.63)

__________________

As of June 30, 2023 and 2022, potential shares of common stock not included in the computation of loss per share because their effect would be antidilutive include the following:


	June 30,
	2023	2022
Redeemable convertible preferred stock (if converted)	—	129,148,393
Options	17,423,238	16,633,612
RSUs	6,901,360	—
RSAs	—	2,535,825
Brookfield SAFE	5,000,000	—
Warrants	16,657,686	985,278
Total	45,982,284	149,303,108

In connection with the AM SAFE and Brookfield SAFE, see Note 9 - Fair Value, the Company could issue additional potential shares of common stock. Shares related to the AM SAFE were issued on the Closing Date. Shares related to the Brookfield SAFE and AM SAFE warrant have not been issued as of June 30, 2023. The terms of the AM SAFE warrant became exercisable for a fixed number of shares as of the Closing Date, see Note 7 – Warrants. As a result, these potential shares are included in the warrants line item in the potential share table above as of June 30, 2023. The per share issuance price for the Brookfield SAFE upon closing of the Business Combination is the liquidity price as defined in the Brookfield SAFE agreement. As a result of the Business Combination, the Brookfield SAFE became convertible into a maximum number of shares, which is included in the table above as of June 30, 2023. None of these potential shares of common stock are included in the computation of diluted net loss per share until actually issued because doing so would be anti-dilutive.

Net Loss Per Share

Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock of the Company outstanding during the period. Diluted net loss per share is computed by giving effect to all common stock equivalents of the Company, including equity-classified share-based compensation, the Brookfield SAFE, warrants, and contingently redeemable preferred stock, to the extent dilutive. Earnings per share calculation for all periods prior to the Business Combination have been retrospectively restated to the equivalent number of shares reflecting the exchange ratio established in the Merger Agreement of 4.3747.

The following table presents the calculation of basic and diluted net loss per share for the Company’s common stock (in thousands, except shares and per share amounts):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Numerator:
Net loss for basic and diluted earnings per common share	$	(25,326)	$	(22,267)	$	(115,424)	$	(54,974)
Unpaid cumulative dividends on preferred stock	—		(9,748)		(4,117)		(28,925)
Net loss allocated to common shareholders	$	(25,326)	$	(32,015)	$	(119,541)	(83,899)
Denominator:
Weighted-average shares used in calculating net loss per share, basic and diluted	195,869,537		9,229,781		169,797,443		9,223,884
Net loss per common share, basic and diluted(1)	$	(0.13)	$	(3.47)	$	(0.70)	$	(9.10)

__________________

As of September 30, 2023 and 2022, common stock equivalents not included in the computation of loss per share because their effect would be antidilutive include the following:


	September 30,
	2023	2022
Redeemable convertible preferred stock (if converted)	—	129,148,393
Options	17,021,827	16,584,305
RSUs	7,042,901	—
RSAs	—	2,535,825
Brookfield SAFE	5,000,000	—
Warrants	16,657,686	985,278
Total	45,722,414	149,253,801

The preferred shares automatically converted into common shares upon the Business Combination at a 1:1 ratio. On February 8, 2023, upon conversion of the preferred shares, the cumulative accrued, declared and unpaid dividends on the preferred shares became payable. The total amount of cumulative accrued, undeclared and unpaid dividends was approximately $241,529 on the Closing Date. As stipulated by the Merger Agreement, this amount was divided by 10 and resulted in the issuance of an additional 24,152,942 common shares. Prior to the Business Combination, the additional 129,148,393 of common stock equivalents resulting from any such conversion are not included in the computation of diluted net loss per share because doing so would be anti-dilutive.

In connection with the AM SAFE and Brookfield SAFE, see Note 9 - Fair Value, the Company could issue additional potential shares of common stock. Shares related to the AM SAFE were issued on the Closing Date. Shares related to the Brookfield SAFE and AM SAFE warrant have not been issued as of September 30, 2023. The terms of the AM SAFE warrant became exercisable for a fixed number of shares as of the Closing Date, see Note 7 – Warrants. As a result, these common stock equivalents are included in the warrants line item in the potential share table above as of September 30, 2023. The per share issuance price for the Brookfield SAFE upon closing of the Business Combination is the liquidity price as defined in the Brookfield SAFE agreement. As a result of the Business Combination, the Brookfield SAFE became convertible into a maximum number of shares, which is included in the table above as of September 30, 2023. None of these common stock equivalents are included in the computation of diluted net loss per share until actually issued because doing so would be anti-dilutive.

Net Loss Per Share

Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock of the Company outstanding during the period. Diluted net loss per share is computed by giving effect to all potential shares of common stock of the Company, including outstanding stock options, warrants, and contingently redeemable preferred stock, to the extent dilutive. Earnings per share calculations for all periods prior to the Business Combination have been retrospectively restated to the equivalent number of shares reflecting the exchange ratio established in the Merger Agreement of 4.3747.

The following table presents the calculation of basic and diluted net loss per share for the Company’s common stock (in thousands, except shares and per share amounts):


	Year Ended December 31,
	2022		2021
Numerator:
Net loss for basic and diluted earnings per common share	$	(76,356)	$	(46,689)
Unpaid cumulative dividends on preferred stock	(38,672)		(36,758)
Net loss allocated to common shareholders	$	(115,028)	$	(83,447)
Denominator:
Weighted-average shares used in calculating net loss per share, basic and diluted	9,302,080		8,585,999
Net loss per common share, basic and diluted(1)	$	(12.37)	$	(9.72)

__________________

As of December 31, 2022 and 2021, potential shares of common stock not included in the computation of loss per share because their effect would be antidilutive include the following:


	Year Ended December 31,
	2022	2021
Redeemable convertible preferred stock (if converted)	129,148,393	129,148,393
Options	14,661,253	16,821,596
RSAs	2,535,825	2,535,825
Warrants	985,278	985,278
Total	147,330,749	149,491,092

Under the organizational documents of the Company, the preferred shares and undeclared dividends are convertible by the holder at any time at their option. In addition, the preferred shares will automatically convert into common shares upon either (i) the determination of the holders of certain requisite preferred shares of the Company (which determination will be submitted for approval by such stockholders in connection with the Business Combination described in Note 1, Description of the Business), or (ii) a firmly underwritten initial public offering of the Company’s shares that satisfies certain requirements (but not, for the avoidance of doubt, upon a business combination with a special purpose acquisition company, such as the Business Combination, unless such conversion is otherwise effected pursuant to clause (i) above). Such conversion would be at a 1:1 ratio, adjusted for certain corporate events. Upon conversion of the preferred shares, the cumulative accrued, declared and unpaid dividends will become payable. The total amount of cumulative accrued, undeclared and unpaid dividend is approximately $237 million. The additional 129,148,393 of potential shares of common stock resulting from any such conversion are not included in the computation of diluted net loss per share in the years ended December 31, 2022 and 2021, respectively, because doing so would be anti-dilutive.

In connection with the AM SAFE and Brookfield SAFE, see Note 7 - Fair Value, the Company could issue additional potential shares of common stock upon closing of the Business Combination. Further, under the AM

SAFE warrant, additional potential shares of common stock could be issued upon closing of the Business Combination and exercise of the warrant. These potential shares of common stock have not been issued as of December 31, 2022. The per share issuance price for the AM SAFE and AM SAFE warrant upon closing of the Business Combination is 100% of the liquidity price. If another qualified liquidity event occurs instead, the issuance price is 90% of the liquidity price. The per share issuance price for the Brookfield SAFE upon closing of the Business Combination or any other qualified liquidity event is the liquidity price as defined in the Brookfield SAFE agreement.

Net Loss Per Share - Schedule of Calculation of Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Net Income (Loss) Available to Common Stockholders, Basic [Abstract]
Net loss for basic and diluted earnings per common share	$ (25,326)	$ (26,786)	$ (63,312)	$ (22,267)	$ (15,929)	$ (16,778)	$ (90,098)	$ (32,707)	$ (115,424)	$ (54,974)	$ (76,356)	$ (46,689)
Unpaid cumulative dividends on preferred stock	0	0	(4,117)	(9,748)	(9,654)	(9,523)	(4,117)	(19,177)	(4,117)	(28,925)	(38,672)	(36,758)
Net loss allocated to common shareholders	$ (25,326)	$ (26,786)	$ (67,429)	$ (32,015)	$ (25,583)	$ (26,301)	$ (94,215)	$ (51,884)	$ (119,541)	$ (83,899)	$ (115,028)	$ (83,447)
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted-average shares used in calculating net loss per share, basic and diluted (in shares)	195,869,537	195,537,601	116,530,963	9,229,781	9,222,214	9,219,499	156,472,730	9,222,870	169,797,443	9,223,884	9,302,080,000	8,585,999,000
Weighted average shares outstanding of Class B common stock - diluted (in shares)	195,869,537	195,537,601	116,530,963	9,229,781	9,222,214	9,219,499	156,472,730	9,222,870	169,797,443	9,223,884	9,302,080,000	8,585,999,000
Basic and diluted net income (loss) per share - basic (in dollars per share)	$ (0.13)	$ (0.14)	$ (0.58)	$ (3.47)	$ (2.77)	$ (2.85)	$ (0.60)	$ (5.63)	$ (0.70)	$ (9.10)	$ (12.37)	$ (9.72)
Basic and diluted net income (loss) per share - diluted (in dollars per share)	$ (0.13)	$ (0.14)	$ (0.58)	$ (3.47)	$ (2.77)	$ (2.85)	$ (0.60)	$ (5.63)	$ (0.70)	$ (9.10)	$ (12.37)	$ (9.72)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 6.B)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-10

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-11

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

+ Details

Summary of Significant Accounting Policies - Forward Purchase Agreement (Details) $ / shares in Units, $ in Thousands	Feb. 08, 2023 shares	Feb. 03, 2023 USD ($) tradingDay consecutiveTradingDay financial_instrument $ / shares shares	Mar. 08, 2022 USD ($)	Sep. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 07, 2022 $ / shares	Dec. 31, 2021 USD ($)
Derivative [Line Items]
Shares issued in transaction (in shares) \| shares	196,222,737
Sale of stock price (usd per share) \| $ / shares								$ 10.00
Purchase price			$ 1,800,000
Trigger share price (usd per share) \| $ / shares		$ 3.00
Additional paid-in capital				$ 939,868	$ 936,157	$ 927,641	$ 24,782		$ 21,710
Maturity Date Acceleration, Trading Days \| tradingDay		50
Maturity Date Acceleration, Consecutive Trading Days \| consecutiveTradingDay		60
Number of Freestanding Financial Instruments \| financial_instrument		3
FPA Put Option liability				38,092	26,743	44,593	$ 0
Adjustments
Derivative [Line Items]
Additional paid-in capital					(60,547)	(60,547)
FPA Put Option liability					$ 26,743	$ 44,593
Revision of Prior Period, Adjustment
Derivative [Line Items]
Additional paid-in capital				60,500
Derivative Asset, Noncurrent				60,500
FPA Put Option liability				$ 38,100
Forward Contracts
Derivative [Line Items]
Shares issued in transaction (in shares) \| shares		5,916,514
Sale of stock price (usd per share) \| $ / shares		$ 10.16
Purchase price		$ 60,096
Derivative term		3 years
Forward Contracts \| Maturity Consideration
Derivative [Line Items]
Maturity consideration, amount		$ 5,079
Maturity consideration (in shares) \| shares		500,000
Maturity consideration (usd per share) \| $ / shares		$ 2.00
Shares to issue (in shares) \| shares		7,500,000
Forward Contracts \| Fixed Maturity Consideration
Derivative [Line Items]
Shares issued in transaction (in shares) \| shares		5,916,513
Maturity consideration, amount		$ 3,167
Maturity consideration (usd per share) \| $ / shares		$ 2.00
Shares to issue (in shares) \| shares		7,500,000

Income Taxes - Reconciliation (Details) - USD ($)	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
Income Taxes - Reconciliation (Details) - USD ($)	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
Income tax (benefit) at the statutory federal income tax rate											$ (16,035,000)	$ (9,805,000)
Foreign tax rate differential											(72,000)	(605,000)
State and local taxes											(6,961,000)	(4,068,000)
Foreign exchange differences											0	(143,000)
Stock-based compensation											288,000	501,000
Interest income on receivable											0	882,000
Equity method investment											(701,000)	(443,000)
Non-deductible legal costs											0	1,291,000
Gain from redomiciliation of intellectual property											0	4,890,000
Valuation allowance											26,286,000	7,958,000
PPP loan forgiveness											0	(644,000)
Deferred True-Up											(2,836,000)	0
Other											31,000	186,000
Total income tax benefit	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Income tax (benefit) at the statutory federal income tax rate											21.00%	21.00%
Foreign tax rate differential											0.10%	1.30%
State and local taxes											9.10%	8.70%
Foreign exchange differences											0.00%	0.30%
Stock-based compensation											(0.40%)	(1.10%)
Interest income on receivable											0.00%	(1.90%)
Equity method investment											0.90%	0.90%
Non-deductible legal costs											0.00%	(2.80%)
Gain from redomiciliation of intellectual property											0.00%	(10.50%)
Valuation allowance											(34.40%)	(17.00%)
PPP loan forgiveness											0.00%	1.40%
Deferred True-Up											3.70%	0.00%
Other											0.00%	(0.30%)
Total income tax benefit	0.00%		0.00%	0.00%		0.00%	0.00%	0.00%			0.00%	0.00%

Warrants	3 Months Ended	6 Months Ended	9 Months Ended
Warrants	Mar. 31, 2023	Jun. 30, 2023	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Warrants	Warrants Warrants on preferred shares The Company had issued warrants to purchase its preferred shares representing 985,278 preferred shares. In connection with the closing of the Business Combination, all warrants were exercised on a cashless basis and are no longer outstanding. The warrants were exercised for 594,309 shares of preferred stock, which were converted at the closing of the Business Combination into shares of common stock. The exercise prices of the warrants ranged from $3.36 to $4.56 as of the closing of the Business Combination. The warrants were accounted for as liabilities in accordance with ASC 480, and were presented within warrants on the condensed consolidated balance sheet as of December 31, 2022. The warrant liabilities were measured at fair value at inception and on recurring basis, with changes in fair value presented within other expense, net on the condensed consolidated statements of operations and comprehensive loss. Immediately before the exercise of these warrants, the associated warrant liability was marked-to-market a final time to $5,890, which is equal to the number of shares issued multiplied by the share price of $9.91 on the date of exercise, February 8, 2023. AM SAFE warrant The warrant related to the AM SAFE (“AM SAFE warrant”) was accounted for as a liability in accordance with ASC 480 prior to the consummation of the Business Combination and was presented within warrants on the condensed consolidated balance sheet as of December 31, 2022. As a result of the Business Combination and issuance of the PIPE shares, the number of common shares available under the AM SAFE warrant equals 300,000. The exercise price of the AM SAFE warrant is $10.00 per share as of the Closing Date and March 31, 2023. The AM SAFE warrant expires at the earliest of (a) the fifth anniversary of the Business Combination, (b) the consummation of a dissolution event and (c) a change of control. Due to the AM SAFE warrant becoming exercisable for a fixed number of shares at a fixed exercise price, it no longer meets the criteria for liability accounting under ASC 480 and meets the criteria for equity classification under ASC 815-40. As a result, on the Closing Date, the AM SAFE warrant was marked-to-market a final time to $1,800 through other expense, net on the condensed consolidated statement of operations and comprehensive loss and reclassified to additional paid-in capital on the condensed consolidated balance sheet. Shortfall Warrants On March 27, 2023, the Company issued an aggregate of 2,073,486 warrants to ACM and 2,010,000 warrants to Vellar pursuant to the Forward Purchase Agreement (collectively, the “Shortfall Warrants”), as further described in Note 9 - Forward Purchase Agreement. Each Shortfall Warrant entitles the registered holder to purchase one share of common stock at a price of $10.00 per share, subject to adjustment in the event that the Company sells, grants or otherwise issues common stock or common stock equivalents at an effective price less than the then current exercise price of the Shortfall Warrants, at any time commencing on or after March 27, 2023. The Shortfall Warrants expire on the fifth anniversary of their issuance. As the Shortfall Warrants meet the definition of a derivative but do not qualify for the exception from derivative accounting under the indexation guidance, they meet the criteria for liability classification under ASC 815 and were presented within warrants on the condensed consolidated balance sheet. As a result, the Shortfall Warrants are measured at fair value at inception and on recurring basis, with changes in fair value presented within other expense, net on the condensed consolidated statements of operations and comprehensive loss. The fair value of the Shortfall Warrants as of March 31, 2023 was $5,104. On May 13, 2023, the Company amended the Shortfall Warrant agreement, which resulted in the reclassification of the Shortfall Warrants to equity on that date as the amended agreement met the requirements for equity classification in ASC 815-40. This reclassification will be reflected in the period ended June 30, 2023. Public Warrants and Private Placement Warrants As part of AMCI’s initial public offering (“IPO”), AMCI issued warrants to third party investors where each whole warrant entitles the holder to purchase one share of the Company’s common stock at an exercise price of $11.50 per share (the “Public Warrants”). Simultaneously with the closing of the IPO, AMCI completed the private sale of warrants where each warrant allows the holder to purchase one share of the Company’s common stock at $11.50 per share. Additionally, prior to the consummation of the Business Combination, AMCI issued warrants for the settlement of a working capital loan. The working capital warrants have the same terms as the private sale of warrants issued at the IPO. Warrants sold in the private sale at the IPO and the warrants issued to convert the working capital loan are collectively referred to as the “Private Placement Warrants”. On the Closing Date and as of March 31, 2023, 7,499,924 Public Warrants and 4,774,276 Private Placement Warrants remained outstanding. These warrants expire on the fifth anniversary of the Business Combination or earlier upon redemption or liquidation and are exercisable commencing 30 days after the Business Combination, provided that the Company has an effective registration statement under the Securities Act covering the shares of common stock issuable upon exercise of the warrants and a current prospectus relating to them is available (or the Company permits holders to exercise their warrants on a cashless basis under the circumstances specified in the warrant agreement) and registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder. Once the warrants become exercisable, the Company may redeem the outstanding warrants: a.in whole and not in part; b.at a price of $0.01 per warrant; c.upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and d.if, and only if, the closing price of the common stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending three trading days before we send the notice of redemption to the warrant holders. The Public Warrants and Private Placement Warrants are recognized as derivative liabilities in accordance with ASC 815. Accordingly, the Company recognizes the warrant instruments as liabilities at fair value as of the Closing Date, with an offsetting entry to additional paid-in capital and adjusts the carrying value of the instruments to fair value through other expense, net on the condensed consolidated statement of operations and comprehensive loss at each reporting period until they are exercised. As of March 31, 2023, the Public Warrants and Private Placement Warrants are presented within warrants on the condensed consolidated balance sheet.	Warrants Warrants on preferred shares The Company had issued warrants to purchase its preferred shares representing 985,278 preferred shares. In connection with the closing of the Business Combination, all warrants were exercised on a cashless basis and are no longer outstanding. The warrants were exercised for 594,309 shares of preferred stock, which were converted at the closing of the Business Combination into shares of common stock. The exercise prices of the warrants ranged from $3.36 to $4.56 as of the closing of the Business Combination. The warrants were accounted for as liabilities in accordance with ASC 480, and were presented within warrants on the condensed consolidated balance sheet as of December 31, 2022. The warrant liabilities were measured at fair value at inception and on recurring basis, with changes in fair value presented within other expense, net on the condensed consolidated statements of operations and comprehensive loss. Immediately before the exercise of these warrants, the associated warrant liability was marked-to-market a final time to $5,890, which is equal to the number of shares issued multiplied by the share price of $9.91 on the date of exercise, February 8, 2023. AM SAFE warrant The warrant related to the AM SAFE (“AM SAFE warrant”) was accounted for as a liability in accordance with ASC 480 prior to the consummation of the Business Combination and was presented within warrants on the condensed consolidated balance sheet as of December 31, 2022. As a result of the Business Combination and issuance of the PIPE shares, the number of common shares available under the AM SAFE warrant equals 300,000. The exercise price of the AM SAFE warrant is $10.00 per share as determined on the Closing Date and June 30, 2023. The AM SAFE warrant expires at the earliest of (a) the fifth anniversary of the Business Combination, (b) the consummation of a dissolution event and (c) a change of control. Due to the AM SAFE warrant becoming exercisable for a fixed number of shares at a fixed exercise price, it no longer meets the criteria for liability accounting under ASC 480 and meets the criteria for equity classification under ASC 815-40. As a result, on the Closing Date, the AM SAFE warrant was marked-to-market a final time to $1,800 through other expense, net on the condensed consolidated statement of operations and comprehensive loss and reclassified to additional paid-in capital on the condensed consolidated balance sheet. Shortfall Warrants On March 27, 2023, the Company issued an aggregate of 2,073,486 warrants to ACM and 2,010,000 warrants to Vellar pursuant to the Forward Purchase Agreement (collectively, the “Shortfall Warrants”), as further described in Note 9 - Forward Purchase Agreement. Each Shortfall Warrant entitles the registered holder to purchase one share of common stock at a price of $10.00 per share, subject to adjustment in the event that the Company sells, grants or otherwise issues common stock or common stock equivalents at an effective price less than the then current exercise price of the Shortfall Warrants, at any time commencing on or after March 27, 2023. The Shortfall Warrants expire on the fifth anniversary of their issuance. On the issuance date, the Shortfall Warrants met the definition of a derivative but did not qualify for the exception from derivative accounting under the indexation guidance and therefore met the criteria for liability classification under ASC 815. On May 13, 2023, the Company amended the Shortfall Warrant agreement. Under the amended agreement, the Shortfall Warrants meet the requirements for equity classification under ASC 815-40. Consequently, the Company recorded a gain of $2,042 in the three months ended June 30, 2023 to reflect the fair value of $3,063 at the date of the amendment through other expense, net on the condensed consolidated statements of operations and comprehensive loss and reclassified the Shortfall Warrants to additional paid-in capital on the condensed consolidated balance sheet as of the date of the amendment. Public Warrants and Private Placement Warrants As part of AMCI’s initial public offering (“IPO”), AMCI issued warrants to third-party investors where each whole warrant entitles the holder to purchase one share of the Company’s common stock at an exercise price of $11.50 per share (the “Public Warrants”). Simultaneously with the closing of the IPO, AMCI completed the private sale of warrants where each warrant allows the holder to purchase one share of the Company’s common stock at $11.50 per share. Additionally, prior to the consummation of the Business Combination, AMCI issued warrants for the settlement of a working capital loan. The working capital warrants have the same terms as the private sale of warrants issued at the IPO. Warrants sold in the private sale at the IPO and the warrants issued to convert the working capital loan are collectively referred to as the “Private Placement Warrants”. On the Closing Date and as of June 30, 2023, 7,499,924 Public Warrants and 4,774,276 Private Placement Warrants remained outstanding. These warrants expire on the fifth anniversary of the Business Combination or earlier upon redemption or liquidation and are exercisable commencing 30 days after the Business Combination, provided that the Company has an effective registration statement under the Securities Act covering the shares of common stock issuable upon exercise of the warrants and a current prospectus relating to them is available (or the Company permits holders to exercise their warrants on a cashless basis under the circumstances specified in the warrant agreement) and registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder. Once the warrants become exercisable, the Company may redeem the outstanding warrants: (a)in whole and not in part; (b)at a price of $0.01 per warrant; (c)upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and (d)if, and only if, the closing price of the common stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending three trading days before we send the notice of redemption to the warrant holders. The Public Warrants and Private Placement Warrants are recognized as derivative liabilities in accordance with ASC 815. Accordingly, the Company recognized the warrant instruments as liabilities at fair value as of the Closing Date, with an offsetting entry to additional paid-in capital and adjusts the carrying value of the instruments to fair value through other expense, net on the condensed consolidated statement of operations and comprehensive loss at each reporting period until they are exercised. As of June 30, 2023, the Public Warrants and Private Placement Warrants are presented within warrants on the condensed consolidated balance sheet.	Warrants Warrants on preferred shares The Company had issued warrants to purchase its preferred shares representing 985,278 preferred shares. In connection with the closing of the Business Combination, all warrants were exercised on a cashless basis and are no longer outstanding. The warrants were exercised for 594,309 shares of preferred stock, which were converted at the closing of the Business Combination into shares of common stock. The exercise prices of the warrants ranged from $3.36 to $4.56 as of the closing of the Business Combination. The warrants were accounted for as liabilities in accordance with ASC 480, and were presented within warrants on the condensed consolidated balance sheet as of December 31, 2022. The warrant liabilities were measured at fair value at inception and on a recurring basis, with changes in fair value presented within other expense, net on the condensed consolidated statements of operations and comprehensive loss. Immediately before the exercise of these warrants, the associated warrant liability was marked-to-market a final time to $5,890, which is equal to the number of shares issued multiplied by the share price of $9.91 on the date of exercise, February 8, 2023. AM SAFE warrant The warrant related to the AM SAFE (“AM SAFE warrant”) was accounted for as a liability in accordance with ASC 480 prior to the consummation of the Business Combination and was presented within warrants on the condensed consolidated balance sheet as of December 31, 2022. As a result of the Business Combination and issuance of the PIPE shares, the number of common shares available under the AM SAFE warrant equals 300,000. The exercise price of the AM SAFE warrant is $10.00 per share as determined on the Closing Date. The AM SAFE warrant expires at the earliest of (a) the fifth anniversary of the Business Combination, (b) the consummation of a dissolution event and (c) a change of control. Due to the AM SAFE warrant becoming exercisable for a fixed number of shares at a fixed exercise price, it no longer meets the criteria for liability accounting under ASC 480 and meets the criteria for equity classification under ASC 815-40. As a result, on the Closing Date, the AM SAFE warrant was marked-to-market a final time to $1,800 through other expense, net on the condensed consolidated statement of operations and comprehensive loss and reclassified to additional paid-in capital on the condensed consolidated balance sheet. Shortfall Warrants On March 27, 2023, the Company issued an aggregate of 2,073,486 warrants to ACM and 2,010,000 warrants to Vellar pursuant to the Forward Purchase Agreement (collectively, the “Shortfall Warrants”), as further described in Note 2 - Summary of Significant Accounting Policies. Each Shortfall Warrant entitles the registered holder to purchase one share of common stock at a price of $10.00 per share, subject to adjustment in the event that the Company sells, grants or otherwise issues common stock or common stock equivalents at an effective price less than the then current exercise price of the Shortfall Warrants, at any time commencing on or after March 27, 2023. The Shortfall Warrants expire on the fifth anniversary of their issuance. On the issuance date, the Shortfall Warrants met the definition of a derivative but did not qualify for the exception from derivative accounting under the indexation guidance and therefore met the criteria for liability classification under ASC 815. On May 13, 2023, the Company amended the Shortfall Warrant agreement. Under the amended agreement, the Shortfall Warrants meet the requirements for equity classification under ASC 815-40. Consequently, the Company recorded a gain of $2,042 as of the date of the amendment to reflect the fair value of $3,063 at the date of the amendment through other expense, net on the condensed consolidated statements of operations and comprehensive loss and reclassified the Shortfall Warrants to additional paid-in capital on the condensed consolidated balance sheet. Public Warrants and Private Placement Warrants As part of AMCI’s initial public offering (“IPO”), AMCI issued warrants to third-party investors where each whole warrant entitles the holder to purchase one share of the Company’s common stock at an exercise price of $11.50 per share (the “Public Warrants”). Simultaneously with the closing of the IPO, AMCI completed the private sale of warrants where each warrant allows the holder to purchase one share of the Company’s common stock at $11.50 per share. Additionally, prior to the consummation of the Business Combination, AMCI issued warrants for the settlement of a working capital loan. The working capital warrants have the same terms as the private sale of warrants issued at the IPO. Warrants sold in the private sale at the IPO and the warrants issued to convert the working capital loan are collectively referred to as the “Private Placement Warrants”. On the Closing Date and as of September 30, 2023, 7,499,924 Public Warrants and 4,774,276 Private Placement Warrants remained outstanding. These warrants expire on the fifth anniversary of the Business Combination or earlier upon redemption or liquidation and are exercisable commencing 30 days after the Business Combination, provided that the Company has an effective registration statement under the Securities Act covering the shares of common stock issuable upon exercise of the warrants and a current prospectus relating to them is available (or the Company permits holders to exercise their warrants on a cashless basis under the circumstances specified in the warrant agreement) and registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder. Once the warrants become exercisable, the Company may redeem the outstanding warrants: a.in whole and not in part; b.at a price of $0.01 per warrant; c.upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and d.if, and only if, the closing price of the common stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending three trading days before we send the notice of redemption to the warrant holders. The Public Warrants and Private Placement Warrants are recognized as derivative liabilities in accordance with ASC 815. Accordingly, the Company recognized the warrant instruments as liabilities at fair value as of the Closing Date, with an offsetting entry to additional paid-in capital and adjusts the carrying value of the instruments to fair value through other expense, net on the condensed consolidated statement of operations and comprehensive loss at each reporting period until they are exercised. As of September 30, 2023, the Public Warrants and Private Placement Warrants are presented within warrants on the condensed consolidated balance sheet.

Revenues

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Mar. 31, 2023

Jun. 30, 2023

Sep. 30, 2023

Dec. 31, 2022

Revenue from Contract with Customer [Abstract]

Revenues

Disaggregated Revenue

The following table presents disaggregated revenue in the following categories (in thousands):


	Three Months Ended March 31,
	2023		2022
Contract Types:
Licensing	$	553	$	540
Engineering and other services	5,801		4,308
Biorefining: carbon capture and transformation revenue	$	6,354	$	4,848

Joint development agreements	2,036		1,027
Contract research	1,256		1,242
Joint development and Contract research revenue	$	3,292	$	2,269

CarbonSmart (tangible product)	—		740

Total Revenue	$	9,646	$	7,857

Revenue from partners in collaborative arrangements, part of joint development and contract research revenue, in the amount of $1,088 and $0 for the three months ended March 31, 2023 and 2022, is included in the table above within joint development agreements. Revenue from related parties is included in licensing for $553 and $540 with the remaining revenue of $420 and $114 in Engineering and other services, for the three months ended March 31, 2023 and 2022, respectively.

The following table presents disaggregation of the Company’s revenues by customer location for the three months ended March 31, 2023 and 2022 (in thousands):


	Three Months Ended March 31,
	2023		2022
North America	$	4,232	$	4,039
Europe, Middle East, Africa (EMEA)	4,711		2,823
Asia	50		410
Australia	653		585
Total Revenue	$	9,646	$	7,857

Contract balances

The following table provides changes in contract assets and liabilities (in thousands):


	Current Contract Assets		Current Contract Liabilities		Non-current Contract Liabilities
Balance as of January 1, 2023	$	18,000	$	3,101	$	10,760
Additions to unbilled accounts receivable	11,241		—		—

Unbilled accounts receivable recognized in trade receivables	(10,833)		—		—
Increase on revaluation on currency	52		—		83
Reclassification from long-term to short-term	—		672		(672)
Reclassification to revenue as a result of performance obligations satisfied	—		(731)		—
Balance as of March 31, 2023	$	18,460	$	3,042	$	10,171

The increase in contract assets was mostly due to unbilled accounts receivable resulting from revenue recorded under contracts with customers where the Company performed engineering and other services, while the decrease in contract liabilities was primarily due to the recognition of revenue during the period related to advance payments previously received by the Company for engineering and other services contracts with customers. As of March 31, 2023 and December 31, 2022 the Company had $9,277 and $11,695, respectively, of billed accounts receivable, net of allowance.

The contract liability balance comprises unconditional payments received from the Company’s customers prior to the satisfaction of the related performance obligations. Such amounts are anticipated to be recorded as revenues when services are performed in subsequent periods. The Company expects to recognize the amounts classified as current contract liabilities in revenue within one year or less and those classified as non-current within two to three years.

Remaining performance obligations

Transaction price allocated to the remaining performance obligations represents contracted revenue that has not yet been recognized, which includes unearned revenue that will be recognized as revenue in future periods. Transaction price allocated to remaining performance obligations is influenced by several factors, including the length of the contract term compared to the research term and the existence of customer specific acceptance rights.

Remaining performance obligations consisted of the following (in thousands):


	As of
	March 31, 2023		December 31, 2022
Current	$	3,042	$	3,101
Non-current	10,171		10,760
Total	$	13,213	$	13,861

Revenues

Disaggregated Revenue

The following table presents disaggregated revenue in the following categories:


	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Contract Types:
Licensing	$	815	$	540	$	1,369	$	1,080
Engineering and other services	8,878		5,367		14,678		9,675
Biorefining revenue	$	9,693	$	5,907	$	16,047	$	10,755

Joint development agreements	1,080		1,420		3,116		2,447
Contract research	1,137		1,543		2,393		2,785
Joint development and contract research revenue	$	2,217	$	2,963	$	5,509	$	5,232

CarbonSmart (tangible product)	1,007		982		1,007		1,722

Total Revenue	$	12,917	$	9,852	$	22,563	$	17,709

The following table presents revenue from partners in collaborative arrangements, which is included in the table above within Joint development agreements.


	Three Months Ended June 30,			Six Months Ended June 30,
	2023	2022		2023	2022
Revenue from partners in collaborative agreements	462	$	973	1,550	973

The following table presents revenue from related parties, which is included in the table above within both Licensing and Engineering and other services.


	Three Months Ended June 30,		Six Months Ended June 30,
	2023	2022	2023	2022
Revenue from related parties, included within Licensing	815	540	1,369	1,080
Revenue from related parties, included within Engineering and other services	261	218	680	332

The following table presents disaggregation of the Company’s revenues by customer location for the three and six months ended June 30, 2023 and 2022 (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
North America	$	2,314	$	3,910	$	6,547	$	7,949
Europe, Middle East, Africa (EMEA)	9,646		3,784		14,356		6,607
Asia	418		1,853		468		2,263
Australia	539		305		1,192		890
Total Revenue	$	12,917	$	9,852	$	22,563	$	17,709

Contract balances

The following table provides changes in contract assets and liabilities (in thousands):


	Current Contract Assets		Current Contract Liabilities		Non-current Contract Liabilities
Balance as of January 1, 2023	$	18,000	$	3,101	$	10,760
Additions to unbilled accounts receivable	23,684		—		—
Increases due to cash received	—		515		—
Unbilled accounts receivable recognized in trade receivables	(20,016)		—		—
Increase on revaluation on currency	108		—		64
Reclassification from long-term to short-term	—		1,344		(1,344)
Reclassification to revenue as a result of performance obligations satisfied	—		(2,008)		—
Balance as of June 30, 2023	$	21,776	$	2,952	$	9,480

The increase in contract assets was mostly due to unbilled accounts receivable resulting from revenue recorded under contracts with customers where the Company performed engineering and other services, while the decrease in contract liabilities was primarily due to the recognition of revenue during the period related to advance payments previously received by the Company for engineering and other services contracts with customers. As of June 30, 2023 and December 31, 2022 the Company had $7,766 and $11,695, respectively, of billed accounts receivable, net of allowance.

Remaining performance obligations

Remaining performance obligations consisted of the following (in thousands):


	As of
	June 30, 2023		December 31, 2022
Current	$	2,952	$	3,101
Non-current	9,480		10,760
Total	$	12,432	$	13,861

Revenues

Disaggregated Revenue

The following table presents disaggregated revenue in the following categories (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Contract Types:
Licensing	$	1,515	$	540	$	2,902	$	1,620
Engineering and other services	10,912		2,955		25,572		12,630
Biorefining revenue	$	12,427	$	3,495	$	28,474	$	14,250

Joint development agreements	1,933		1,571		5,049		4,018
Contract research	2,987		1,315		5,380		4,100
Joint development and contract research revenue	$	4,920	$	2,886	$	10,429	$	8,118

CarbonSmart (tangible product)	2,258		1,691		3,265		3,413

Total Revenue	$	19,605	$	8,072	$	42,168	$	25,781

The following table presents revenue from partners in collaborative arrangements, which is included in the table above within Joint development agreements (in thousands).


	Three Months Ended September 30,			Nine Months Ended September 30,
	2023	2022		2023	2022
Revenue from partners in collaborative agreements	1,566	$	760	3,116	1,733

The following table presents disaggregation of the Company’s revenues by customer location for the three and nine months ended September 30, 2023 and 2022 (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
North America	$	4,847	$	4,412	$	11,309	$	12,361
Europe, Middle East, Africa (EMEA)	10,732		1,287		25,088		7,894
Asia	2,137		1,888		2,690		4,151
Australia	1,889		485		3,081		1,375
Total Revenue	$	19,605	$	8,072	$	42,168	$	25,781

Contract balances

The following table provides changes in contract assets and liabilities (in thousands):


	Current Contract Assets		Current Contract Liabilities		Non-current Contract Liabilities
Balance as of January 1, 2023	$	18,000	$	3,101	$	10,760
Additions to unbilled accounts receivable	43,901		—		—
Increases due to cash received	—		4,486		—
Unbilled accounts receivable recognized in trade receivables	(37,413)		—		—
Decrease on revaluation on currency	(175)		—		(73)
Reclassification from long-term to short-term	—		2,016		(2,016)
Reclassification to revenue as a result of performance obligations satisfied	—		(6,471)		—
Balance as of September 30, 2023	$	24,313	$	3,132	$	8,671

The increase in contract assets was mostly due to unbilled accounts receivable resulting from revenue recorded under contracts with customers where the Company performed engineering and other services, while the decrease in contract liabilities was primarily due to the recognition of revenue during the period related to advance payments previously received by the Company for engineering and other services contracts with customers. As of September 30, 2023 and December 31, 2022 the Company had $10,085 and $11,695, respectively, of billed accounts receivable, net of allowance.

Remaining performance obligations

Remaining performance obligations consisted of the following (in thousands):


	As of
	September 30, 2023		December 31, 2022
Current	$	3,132	$	3,101
Non-current	8,671		10,760
Total	$	11,803	$	13,861

Revenues

Disaggregated Revenue

The following table presents disaggregated revenue in the following categories (in thousands):


	Year Ended December 31,
	2022		2021
Contract Types:
Licensing	2,160		2,025
Engineering and other services	19,061		9,539
Carbon capture and utilization revenue	21,221		11,564

Joint development agreements	6,021		11,700
Other contract research	6,101		2,197
Research and development revenue	12,122		13,897

CarbonSmart (tangible product)	4,000		—

Total Revenue	$	37,343	$	25,461

Revenue from partners in collaborative arrangements of $2,575 and $3,337 for the years ended December 31, 2022 and 2021, is included in the table above within joint development agreements. Revenue from related parties is included in licensing for $2,160 and $2,025 with the remaining revenue of $810 and $1,228 in Engineering and other services, for the years ended December 31, 2022 and 2021, respectively.

The following table presents disaggregation of the Company’s revenues by customer location for the years ended December 31, 2022 and 2021 (in thousands):


	Year Ended December 31,
	2022		2021
North America	$	17,149	$	15,825
Europe, Middle East, Africa (EMEA)	11,500		7,522
Asia	5,752		1,477
Australia	2,942		637
Total Revenue	$	37,343	$	25,461

Contract balances

The following table provides changes in contract assets and liabilities (in thousands):


	Current Contract Assets		Current Contract Liabilities		Non-current Contract Liabilities
Balance as of January 1, 2021	$	6,186	$	5,480	$	11,291
Additions to unbilled accounts receivable	8,516		—		—
Increases due to cash received	—		20		5,690
Unbilled accounts receivable recognized in trade receivables	(3,002)		—		—
Reclassification from long-term to short-term	—		3,080		(3,080)
Reclassification to revenue as a result of performance obligations satisfied	—		(5,104)		—
Balance as of December 31, 2021	11,700		3,476		13,901
Additions to unbilled accounts receivable	30,308		—		—
Increases due to cash received	—		996		37
Unbilled accounts receivable recognized in trade receivables	(24,062)		—		—
Change on revaluation of currency	54		—		(341)
Reclassification from non-current to current contract liabilities	—		2,837		(2,837)
Reclassification to revenue as a result of performance obligations satisfied	—		(4,208)		—
Balance as of December 31, 2022	$	18,000	$	3,101	$	10,760

The increase in contract assets was mostly due to unbilled accounts receivable resulting from revenue recorded under contracts with customers where the Company performed engineering and other services, while the decrease in contract liabilities was primarily due to the recognition of revenue during the period related to advance payments previously received by the Company for engineering and other services contracts with customers. As of December 31, 2022 and December 31, 2021 the Company had $11,695 and $2,878, respectively, of billed accounts receivable, net of allowance.

Remaining performance obligations

Transaction price allocated to the remaining performance obligation represents contracted revenue that has not yet been recognized, which includes unearned revenue that will be recognized as revenue in future periods. Transaction price allocated to remaining performance obligations is influenced by several factors, including the length of the contract term compared to the research term and the existence of customer specific acceptance rights.

Remaining performance obligations consisted of the following (in thousands):


	As of
	December 31, 2022		December 31, 2021
Current	$	3,101	$	3,476
Non-current	10,760		13,901
Total	$	13,861	$	17,377

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org//606/tableOfContent

+ Details